The role of HOIL-1, HOIP and SHARPIN in immune signalling by Rieser, Eva
  
 
The role of HOIL-1, HOIP and 
SHARPIN in immune signalling 
 
 
 
 
 
 
A DISSERTATION 
SUBMITTED TO THE DEPARTMENT OF 
MEDICINE OF 
IMPERIAL COLLEGE LONDON 
IN FULFILMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
Eva Rieser 
 
January 2012 
Abstract 
ii 
 
Abstract 
Members of the tumour necrosis factor receptor (TNFR) superfamily, the interleukin-1 
Receptor (IL-1R), the Toll-like Receptor (TLR) and the NOD-like receptor (NLRs) families 
play crucial roles in the initiation of innate immune responses. Even though the stimulation of 
these different receptors is triggered by upstream signalling components which are largely 
receptor-specific, their signalling cascades generally converge in the activation of both 
mitogen-activated protein kinases (MAPKs)  and the inhibitor of nuclear factor–B (IB) 
kinases (IKKs). The activation of MAPKs and IKKs are crucial events in the signalling 
cascades of TNFR-, IL-1R-, TLR- and NLR family members and result in the activation of 
distinct transcription factors such as AP-1 and NF-B, respectively. In order to gain a more 
comprehensive picture of the signalling components associated with TNFR1 our group 
developed a modified tandem affinity purification (moTAP) strategy. This led to the 
identification of three novel components of the native TNFR1 signalling complex (TNF-
RSC): HOIL-1, HOIP and SHARPIN. Together, they form the “linear ubiquitin chain 
assembly complex” (LUBAC), a tripartite E3 ligase complex which generates linear ubiquitin 
chains. LUBAC activity is required for efficient TNF-mediated activation of NF-B and JNK 
by linearly ubiquitinating NEMO and RIP1 in the TNF-RSC. Mutation of the SHARPIN-
encoding gene in mice results in chronic proliferative dermatitis (cpdm). The cpdm phenotype 
is characterised by inflammatory skin lesions and defective lymphoid organogenesis.  
In this thesis it is shown that mouse embryonic fibroblasts (MEFs) and primary keratinocytes 
generated from cpdm mice showed impaired activation of the MAPK- and NF-B signalling 
pathways following stimulation by various TNF and IL-1 family members as well as by 
different TLR ligands. These alterations were also apparent in bone marrow-derived 
macrophages isolated from cpdm mice. Thereby, lack of SHARPIN exerted an inhibitory 
effect on gene-activatory signal transduction by these immune stimuli. Similar defects in NF-
B and MAPK signalling were also observed with a ligand for the NLR family member 
NOD2. Cells generated from mice conditionally deficient for the other LUBAC components 
exhibited similar alterations in diverse innate immune signalling pathways. These results 
imply that SHARPIN and HOIL-1 cannot substitute each other but instead cooperate with 
HOIP to generate linear ubiquitin chains in the signalling pathways that are activated by 
diverse immune receptors. In summary, the results of this thesis identify LUBAC and the 
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linear ubiquitin chains it generates as previously unrecognised components of various 
signalling pathways which are central to the induction of immunity and regulation of 
inflammation. 
 
Declaration 
iv 
 
Declaration 
 
 
I, Eva Rieser, declare that this PhD Thesis is my own work and has not been submitted in any 
form for another degree at any university or other institute of tertiary education. Information 
derived from the published and unpublished work of others has been acknowledged in the text 
and a list of references is given in the bibliography. 
 
London, 26.01.2012 
 
 
Eva Rieser 
Acknowledgements 
v 
 
Acknowledgements 
 
This thesis would not have been possible without the support of many people whom I would 
like to thank at this point: 
 Professor Gavin Screaton for his supervision and support throughout this thesis, 
 Professor Michael Martin and Professor Justin Mason for acting as examiners of this 
thesis, 
 Dr Stefanie Cordier, a helpful colleague, wonderful person and very special friend 
who left a big gap by leaving London, 
 Silvia Prieske for always cheering me up, making me laugh, motivating me and for her 
interest in my project, 
 Dr Björn Gerlach for all the nice chats and coffee breaks we had and for his positive 
personality, 
  The other LUBAC subgroup members, Anna Schmukle and Dr Christoph Emmerich, 
for their scientific support, 
 All former and present members of our laboratory, especially Dr Chahrazade Kantari, 
Dr Katharina Prieske, Julia Zinngrebe, Aida Sarr Daboh, Dr Johannes Lemke, Dr 
Mark Tuthill, Stefan Prieske, Torsten Hartwig, Pavanjit Raj, Sebastian Kupka, 
Maximilian Blanck and Frank Reichenbach for helpful discussions and technical 
support as well as for creating this very special atmosphere that characterises our 
laboratory,  
 My special thanks go to my my lovely sister Regine, my brother Götz and my 
wonderful parents who always believed in me and supported me in every possible 
way, but most of all for their unconditional love, 
 And Henning Walczak for his enthusiasm, his love, his never ending support and for 
being himself. 
 
  Table of Contents 
vi 
 
Table of Contents 
 
Abstract ii 
Declaration iv 
Acknowledgements .................................................................................................................... v 
Table of Contents ...................................................................................................................... vi 
1.  Introduction .......................................................................................................... 1 
1.1  The Immune System .................................................................................................... 1 
1.1.1  The innate immune system ................................................................................... 2 
1.1.1.1  Cells of the innate immune system ................................................................... 3 
1.1.1.2  Inflammation .................................................................................................... 5 
1.2  Pattern-Recognition Receptors .................................................................................... 6 
1.2.1  The CLR family ................................................................................................... 8 
1.2.2  The RLR family ................................................................................................... 8 
1.2.3  The NLR family ................................................................................................. 10 
1.2.3.1  The NOD2 signalling pathway ....................................................................... 11 
1.2.4  The TLR family .................................................................................................. 13 
1.2.4.1  The TLR4 signalling pathway ........................................................................ 15 
1.3  Pro-inflammatory Cytokines ..................................................................................... 17 
1.3.1  The IL-1 cytokine family ................................................................................... 18 
1.3.1.1  IL-1 signalling pathway .................................................................................. 19 
1.3.1.2  IL-33 signalling pathway ................................................................................ 22 
1.3.1.3  The role of IL-1 family members in immune-mediated diseases ................... 24 
1.3.2  TNF signalling .................................................................................................... 25 
1.4  NF-B and MAPK signalling .................................................................................... 27 
1.4.1  NF-B signalling ................................................................................................ 28 
1.4.1.1  Canonical NF-B signalling ........................................................................... 29 
1.4.1.2  Non-canonical NF-B signalling .................................................................... 30 
1.4.2  MAPK signalling ................................................................................................ 31 
1.4.2.1  MAP3Ks in innate immunity .......................................................................... 32 
1.4.2.2  The ERK1/2 module ....................................................................................... 34 
1.4.2.3  The JNK module ............................................................................................. 34 
1.4.2.4  The p38 MAPK module ................................................................................. 35 
1.5  The ubiquitin system ................................................................................................. 36 
1.5.1  Conjugation of ubiquitin: the formation of Ub-chains ....................................... 36 
1.5.2  Forms of ubiquitination and their physiological roles ....................................... 40 
1.5.3  Regulation of the ubiquitin system: Deubiquitination ....................................... 44 
1.5.4  Specific ubiquitin chain recognition: Ubiquitin binding domains ..................... 45 
1.6  Linear Ubiquitin Chain Assembly Complex (LUBAC) ............................................ 48 
1.6.1  Chronic proliferative dermatitis ......................................................................... 51 
1.7  Aims of the project .................................................................................................... 53 
2.  Materials and Methods ....................................................................................... 54 
2.1  Materials .................................................................................................................... 54 
2.1.1  Chemicals and reagents ...................................................................................... 54 
2.1.2  Specific inhibitors .............................................................................................. 54 
2.1.3  Buffers and solutions .......................................................................................... 54 
2.1.4  Biological agents ................................................................................................ 57 
  Table of Contents 
vii 
 
2.1.5  Antibodies .......................................................................................................... 58 
2.1.6  Cell culture media and additives ........................................................................ 60 
2.1.7  Beads for protein precipitation ........................................................................... 60 
2.1.8  Kits and Ready-to-Use Solutions ....................................................................... 60 
2.1.9  Additional material ............................................................................................. 61 
2.1.10  Instruments ......................................................................................................... 62 
2.1.11  Software ............................................................................................................. 63 
2.2  Methods of Cell Biology ........................................................................................... 64 
2.2.1  Cell lines ............................................................................................................. 64 
2.2.1.1  EL-4 cells ........................................................................................................ 64 
2.2.1.2  D6/76 cells ...................................................................................................... 64 
2.2.1.3  HEK293T cells ............................................................................................... 64 
2.2.1.4  HEK293RI cells .............................................................................................. 64 
2.2.1.5  HeLa cells ....................................................................................................... 65 
2.2.1.6  L929 ................................................................................................................ 65 
2.2.1.7  Mouse Embryonic Fibroblasts (MEFs) .......................................................... 65 
2.2.1.8  U937 ............................................................................................................... 65 
2.2.2  Cell culturing conditions .................................................................................... 65 
2.2.3  Freezing and thawing of eukaryotic cells ........................................................... 66 
2.2.4  Generation of primary keratinocytes .................................................................. 66 
2.2.5  Generation of primary bone marrow-derived macrophages .............................. 66 
2.2.6  Transfection of adherent cells ............................................................................ 66 
2.2.7  Lentiviral infection of eukaryotic cells .............................................................. 67 
2.2.7.1  Production of recombinant viruses ................................................................. 67 
2.2.7.2  Generation of stable knockdown, knockout or overexpressing cells ............. 67 
2.2.8  siRNA-mediated knock-down ............................................................................ 67 
2.3  Methods of Molecular Biology .................................................................................. 68 
2.3.1  DNA digestion and restriction analysis .............................................................. 68 
2.3.2  Agarose gel electrophoresis of nucleic acids ..................................................... 68 
2.3.3  Gel extraction of DNA fragments ...................................................................... 68 
2.3.4  Ligation of DNA fragments ............................................................................... 68 
2.3.5  Transformation of competent E. coli bacteria and Isolation of Plasmid DNA .. 68 
2.3.6  Polymerase Chain Reaction (PCR) .................................................................... 69 
2.4  Methods of Biochemistry .......................................................................................... 69 
2.4.1  Determination of protein content ....................................................................... 69 
2.4.2  Precipitation of Receptor Signalling Complexes and HOIP-IRAK1 complexes 69 
2.4.3  Protein interaction studies .................................................................................. 70 
2.4.4  Ubiquitin pull-down assay ................................................................................. 70 
2.4.5  SDS polyacrylamide gel electrophoresis (SDS-PAGE) ..................................... 70 
2.4.6  Western blotting ................................................................................................. 70 
2.4.7  Far western blotting ............................................................................................ 71 
2.4.8  Stripping of western blot membranes ................................................................. 71 
2.4.9  Enzyme-Linked Immuno Sorbent Assay (ELISA) ............................................ 71 
2.5  Animal work .............................................................................................................. 72 
2.5.1  Chronic proliferative dermatitis mice ................................................................ 72 
2.5.2  Conditional HOIL-1 mice .................................................................................. 72 
2.5.3  Enbrel administration ....................................................................................... 72 
3.  Results ................................................................................................................ 73 
3.1  Functional analysis of LUBAC’s role in IL-1 signalling .......................................... 73 
3.1.1  Stable knockdown of HOIL-1 attenuates IL-1-induced NF-B activation and 
phosphorylation of JNK ..................................................................................... 73 
  Table of Contents 
viii 
 
3.1.2  Overexpression of LUBAC components enhances IL-1-induced NF-B and 
MAPK signalling ............................................................................................... 74 
3.1.3  SHARPIN deficiency in cpdm MEFs gives contradictory results for IL-1 
signalling, yet primary cells reveal LUBAC contribution to IL-1-induced NF-B 
and JNK activation ............................................................................................. 75 
3.2  Functional analysis of potential LUBAC contribution to LPS-induced NF-κB 
activation and gene induction .................................................................................... 83 
3.2.1  Absence of SHARPIN and HOIL-1 has a negative regulatory effect on LPS-
induced NF-κB activation and gene induction ................................................... 83 
3.3  Functional analysis of LUBAC implication in NOD2 signalling .............................. 86 
3.3.1  NOD2 signalling requires LUBAC for proper NF-κB activation and MAPK 
signalling ............................................................................................................ 86 
3.4  Functional analysis of LUBAC involvement in IL-33 signalling ............................. 87 
3.4.1  IL-33 signalling does not depend on LUBAC activity ...................................... 88 
3.5  LUBAC’s role in noncanonical NF-B signalling and its influence in TWEAK-
induced canonical NF-B signalling ......................................................................... 90 
3.5.1  TWEAK-induced canonical and non-canonical NF-B signalling is impaired in 
HOIL-1-deficient cells ....................................................................................... 90 
3.6  Analysis of the IL-1 receptor signalling complex and other IL-1-induced complexes . 
  ................................................................................................................................... 92 
3.6.1  Production and characterisation of moTAP-IL-1 ............................................. 92 
3.6.2  HOIP forms part of the IL-1-RSC and interacts with IRAK1 ............................ 94 
3.7  Generation, characterisation and administration of tools specifically interacting with 
linear or K63-linked poly-ubiquitin chains ............................................................. 102 
3.7.1  Generation, purification and characterisation of GST-tagged 1x/2x UBAN- and 
1x/2x NZF domains .......................................................................................... 103 
3.7.1.1  The UBAN motif specifically detects linear tetra-ubiquitin chains in far 
western analyses whereas the NZF domain shows no preference for K63-linked 
tetra-ubiquitin chains ...................................................................................... 105 
3.7.1.2  The UBAN domain shows specific interaction with linear chains in pull-down 
assays whereas the NZF domain is not capable of precipitating ubiquitin chains
 .................................................................................................................108 
3.7.2  The GST-2xUBAN shows differences in its affinity for M1-linked ubiquitin 
chains of different lengths in far western analyses and pull-down assays ....... 109 
3.8  Employment of the GST-2xUBAN for the identification of new LUBAC targets . 112 
3.8.1  Identification of IRAK1 as a potential LUBAC target .................................... 112 
3.9  GST-2xUBAN precipitates the endogenous TNF-RSC .......................................... 117 
3.9.1  GST-2xUBAN is capable of precipitating the native TNF-RSC ..................... 117 
3.10  Summary .................................................................................................................. 119 
4.  Discussion ........................................................................................................ 120 
4.1  LUBAC’s implication in different innate immune signalling pathways ................. 120 
4.1.1  LUBAC contributes to IL-1-, LPS- and MDP-induced NF-B activation ...... 121 
4.1.2  LUBAC is dispensable for IL-33 signalling .................................................... 126 
4.1.3  Different roles for HOIL-1 and SHARPIN in TWEAK-induced non-canonical 
NF-B signalling .............................................................................................. 127 
4.2  HOIP is recruited to the IL-1-RSC possibly via interaction with IRAK1 ............... 128 
4.2.1  HOIP forms part of the IL-1-RSC .................................................................... 128 
4.2.2  IRAK1 and HOIP interact with each other possibly via N-and C-terminal 
domains of the latter ......................................................................................... 129 
  Table of Contents 
ix 
 
4.3  Linkage-specific Ubiquitin binding domains: Novel tools for detecting protein 
interactions and modifications .................................................................................... 131 
4.3.1  GST-2xUBAN is a specific tool for the detection of linear ubiquitin chains .. 131 
4.3.2  GST-2xNZF lacks binding of linkage-specific ubiquitin chains ..................... 133 
4.4  Identification of potential LUBAC targets in immune signalling pathways by means of 
linear-linkage specific GST-2xUBAN ....................................................................... 134 
4.4.1  IRAK1 is a potential LUBAC target ................................................................ 134 
4.5  Precipitation of the TNF-RSC utilising the GST-2xUBAN .................................... 138 
4.6  Summary and outlook .............................................................................................. 140 
5.  Appendix .......................................................................................................... 142 
5.1  Abbreviations ........................................................................................................... 142 
5.2  Figures ..................................................................................................................... 149 
5.3  Tables ....................................................................................................................... 151 
5.4  List of Publications .................................................................................................. 152 
6.  References ........................................................................................................ 153 
 
1. Introduction 
1 
 
1. Introduction 
1.1 The Immune System 
All living organisms are constantly challenged by a variety of pathogenic microorganisms and 
need to cope with their invasion into the body. To survive these challenges, multiple defence 
mechanisms evolved which recognise and neutralise pathogens. The collectivity of defence 
mechanisms and strategies of an organism is referred to as the immune system. Our current 
knowledge of the immune system can be attributed to a number of outstanding and visionary 
scientists whose work laid the foundations for the research field of immunology and medical 
treatments against infections.  
In 1796, Edward Jenner was the first to test the hypothesis that people infected with cowpox, 
were protected from the similar yet much more virulent smallpox, an often fatal disease. He 
was able to verify his hypothesis by successfully inoculating a series of 23 individuals with 
pus scraped form the blisters of a cowpox infected person, a procedure Jenner called 
vaccination (Hammarsten et al, 1979). Despite being successful, Jenner neither knew the 
exact reason for the disease nor the cause for protection, as infectious microorganisms were 
not known at the time. 
It was about one hundred years later that Robert Koch was the first to prove that infectious 
diseases were caused by pathogenic microorganisms and that every infectious disease was 
associated with a particular pathogen (Koch et al, 1884; Koch R, 1892). These new findings, 
together with Jenner’s effective cowpox vaccination strategy, inspired Louis Pasteur at the 
end of the 19th century to successfully develop vaccines against cholera and rabies (Pasteur et 
al., 1881). 
The identification of antibodies from vaccinated peoples’ serum by Emil von Behring and 
Shibasaburo Kitasato (von Behring & Kitasato, 1890), Paul Ehrlich’s studies on direct 
interaction between cell surface structures and toxins, summarised in his side-chain theory, 
and the discovery of the first phagocytic cell type by Elie Metchnikoff, which he called 
macrophages, were further milestones in the understanding of immunological processes and 
made clear that immunity is a very complex and tightly orchestrated system (Kaufmann, 
2008).  
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The vertebrate immune system can be broadly divided into adaptive, also called acquired, 
immunity and innate immunity. Adaptive immunity is mediated by T and B lymphocytes, 
both of which express a highly diverse set of antigen receptors generated by genetic 
recombination of antigen receptor gene segments and somatic hypermutation. These 
mechanisms allow a comparatively small number of genes and gene segments to generate a 
vast number of different antigen receptor specificities, capable of recognising virtually any 
chemical structure, thereby enabling T and B lymphocytes to respond to a wide range of 
potential antigens. Because DNA rearrangement is an irreversible event in each cell, every 
daughter cell emerging from an individual T and B lymphocyte after clonal expansion inherits 
the same antigen receptor specificity, including memory T and B cells which are the key 
components of long-living specific immunity. Hence, specificity and memory are the main 
characteristics of adaptive immunity resulting from this highly sophisticated system.  
The early concept of innate immunity in contrast was that its main role was to recognise and 
destroy pathogens in a non-specific manner and to present antigens to cells involved in the 
adaptive immune system. 
1.1.1 The innate immune system 
Innate immunity, the so called “first line of defence”, is thought to present an evolutionary 
older strategy of defence. It represents the dominant form of immunity not only in organisms 
such as plants, fungi, insects and other primitive multicellular organisms which lack the 
concept of acquired, adaptive immunity, but also in vertebrates. Most of the pathogenic 
microorganisms trying to invade the host’s body are successfully eliminated by components 
of the innate immune system before they can establish a local site of infection. However some 
pathogens succeed in bypassing or overwhelming the first barrier of defence represented by 
cells of the innate immune system and the induction of an immune response accomplished by 
the adaptive branch of the immune system is then required. Pathogens which are capable of 
evading innate host defences cause a weaker adaptive immune response, illustrating the 
importance of the two branches of the immune system to cooperate with each other in order to 
induce effective immunity. 
 The major functions of the innate immune system in vertebrates are to: 
1. Act as a physical and chemical barrier against infectious microbes: 
Gastrointestinal, respiratory, urogenital tracts as well as skin and mucosa are all 
body surfaces which are exposed to pathogens and are defended by epithelium 
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which forms a physical barrier between the host’s internal milieu and the external 
environment. Mucus secretion and ciliary movement are further physical defence 
mechanisms which characterise internal epithelia. The ciliary movement similar to 
the peristaltic movement of the gastrointestinal tract prevents microorganisms 
from adhering to the epithelium and helps to expel them in the flow of the mucus. 
Low pH levels, such as pH 1 in the stomach, the production of enzymes, such as 
lysozyme and pepsin, lipid acids and antibacterial peptides form a chemical barrier 
against pathogenic invasion. 
2. Identify and remove foreign structures in all tissues and blood:  Mono- and 
polymorphonuclear phagocytes located in the blood and all tissues are usually the 
first cells to encounter pathogens which have crossed the epithelial barrier. They 
play a crucial role in innate immunity as they recognise, phagocytose and destroy 
a large number of different microorganisms. Furthermore they release cytokines 
and other pro-inflammatory mediators to recruit additional types of cells of the 
innate immune system to the site of infection. 
3. Activate the complement system: The complement system is a biochemical cascade 
including a large number of plasma proteins which are responsible for 
complementing the ability of antibodies to either remove the pathogens or to mark 
them, a process called opsonisation, for clearance by other immune cells. 
4. Inform and activate the adaptive immune system by antigen presentation: Upon 
pathogen-encounter monocytes, dendritic cells and other cell types present 
pathogenic antigens to T and B lymphocytes via their MHC-molecules, thereby 
enabling them to initiate an adaptive immune response.  
A number of different cell types with distinct functions enables the innate immune system to 
accomplish the above mentioned defence strategies. 
1.1.1.1 Cells of the innate immune system 
Neutrophils, basophils and eosinophils belong to the group of polymorphonuclear phagocytes. 
They were named on the basis of their morphological feature of lobed nuclei and their ability 
to phagocytose. They are also referred to as granulocytes due to the presence of cytoplasmic 
granules. Neutrophils represent the most abundant cells of the innate immune system and are 
normaly found in the bood stream. During the beginning phase of inflammation they are 
recruited to the site of infection by chemotaxis. Their strategies to attack a pathogen are 
phagocytosis and degranulation. These granules contain highly toxic substances which are 
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mainly targeted against bacteria and fungi. Granules of basophils contain mainly histamines 
for shaping the inflammatory milieu. In contrast, eosinophilic granules enclose highly toxic 
proteins to attack larger parasites. Both cell types are also involved in allergic reactions 
(Bochner, 2000). 
Mast cells function in a similar role as basophils as their granules are rich in histamine, 
heparin, chemokines and chemotactic cytokines. Establishing an inflammatory milieu, mast 
cells are also important mediators of allergic reactions (Theoharides & Kalogeromitros, 
2006).  
Natural killer (NK) cells belong to the group of lymphoid cells but due to a lack of antigen 
receptors they are categorised as innate immune cells. They circulate in the blood and are able 
to detect and kill abnormal cells, such as tumour and virus-infected cells lacking expression of 
classical MHC class I molecules, by employing their cytotoxic granules. Due to their 
capability to produce IFN- in the early stage of infection and due to their expression of a 
number of pattern-recognition receptors, NK cells constitute an important component of the 
innate immune defence against intracellular pathogens (Biron & Brossay, 2001). 
The group of mononuclear phagocytes comprises macrophages and the closely related 
dendritic cells (DCs), both of monocytic origin. DCs act at the interface between innate and 
adaptive immunity and are the essential gatekeepers that determine whether and in which way 
the immune system reacts towards a pathogenic invasion (Steinman & Hemmi, 2006). 
Immature dendritic cells are long-lived cells which reside in most tissues and express 
receptors which recognise common pathogenic structures. Upon binding such structures, DCs 
phagocytose these pathogens and degrade them intracellularly. The pathogen encounter 
activates DCs, turning them into professional antigen-presenting cells (APCs) which 
contribute to the innate immune response by secreting cytokines and to the adaptive immune 
response by activating pathogen-specific lymphocytes in the lymph node (Steinman & 
Hemmi, 2006).  
Macrophages are distributed throughout the body of the host and are the most efficient 
phagocytes. They are capable of recognising, engulfing and killing substantial numbers of 
bacteria or microbes, which results in their activation, yet their other important functions are 
more supervisory. Subsequently, production of a variety of chemokines and chemotactic 
cytokines results in recruitment of other myeloid cells, particularly granulocytes to the site of 
infection thereby initiating a process called inflammation (Palmblad, 1984). 
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1.1.1.2 Inflammation 
Inflammation is a stereotypic and immediate response to pathogens and tissue injuries. 
Moreover, it is a protective response of the innate immune system to assure the removal of 
harmful stimuli and the healing process of injured tissue (Medzhitov, 2008). Inflammation 
can be categorised into either acute and local or chronic and systemic inflammation. While 
acute inflammation occurs in the very early phase of an immune response, includes mainly 
macrophages and polymorphonuclear cells and only lasts for a few days, chronic 
inflammation is a prolonged inflammatory process which leads to a progressive shift of the 
cell types present at the site of inflammation including lymphocytes and B plasma cells. 
Chronic inflammation is often associated with auto-immunity or cancer (Trinchieri, 2011). 
The four cardinal signs of an acute inflammation are defined by the Latin words rubor, calor, 
tumor and dolor, meaning redness, heat, swelling and pain. The main initiators of 
inflammation are usually resident macrophages which use their surface receptors to recognise 
and engulf the foreign microorganism. This results in their activation, the release of 
inflammatory mediators such as cytokines and chemokines and the production of 
prostaglandins and leukotrienes. Prostaglandins and leukotrienes induce vascular dilatation 
leading to an increased local blood flow which in turn causes redness (rubor) and increased 
heat (calor). The increased permeability of blood vessels also leads to swelling (tumor) as it 
causes leakage of plasma proteins, fluid and further immune cells into the affected tissue. Pro-
inflammatory cytokines also affect the adhesive properties of the blood vessel endothelium. 
This facilitates the trans-migration of mainly neutrophils following the chemotactic gradient 
from the blood vessel into the affected tissue. The release of chemicals such as prostaglandin 
E2 and histamin leads to stimulation of nerve endings and cause pain (dolor). Acute 
inflammation requires a constant stimulation to be sustained and is rapidly terminated once 
the stimulus has been removed and damaged tissue is repaired.  
Despite the tightly regulated and effective mechanisms of the innate immune system which 
are responsible for the elimination of most of the pathogens trying to invade or bypass the 
physical barriers of our bodies every day, it has been regarded as a crude and unspecific 
system until recently. Macrophages, the main players of the innate immune system were 
thought to unspecifically recognise pathogenic structures and to encounter them in a generic 
rather than specific way, which was so far thought to be reserved for the adaptive immune 
system only. However, in 1989 Charles Janeway challenged this view by postulating that the 
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innate immune system should be capable of detecting pathogens in a specific manner via so-
called germline-encoded pattern-recognition receptors (PRRs) which should recognise highly 
conserved pathogenic structures, thereby resulting in the induction of a rapid and potent 
immune response (Janeway, 1989a; Janeway, 1989b).  
The discovery of Toll-like receptors (TLRs) in the mid-1990s confirmed Janeway’s theory 
and left no doubt that the innate immune system shows a greater degree of specificity than 
previously thought. Using TLRs and other PRRs that have evolved for detecting components 
derived from foreign pathogens, referred to as pathogen-associated molecular patterns 
(PAMPs) (Akira et al, 2001; Janeway & Medzhitov, 2002), the innate immune system is 
highly advanced in its ability to discriminate between pathogens and self (Aderem & 
Ulevitch, 2000; Hoffmann et al, 1999; Janeway & Medzhitov, 2002; Medzhitov & Janeway, 
1997). The far-sightedness of Janeway and Medzhitov and the discovery made by Jules 
Hoffmann and colleagues in 1996, who showed that the Drosophila protein Toll (dToll), 
formerly known only for its developmental function (Anderson et al, 1985), was required for 
an effective immune response to the fungus Aspergillus fumigatus in the adult fly (Lemaitre et 
al, 1996), led to a renaissance of research into innate immunity. Their hypotheses and 
discoveries enabled a rapid progress in our understanding of innate immune recognition of 
pathogenic components and its decisive role in host defence against infection which lasts to 
date. For his discovery of Toll and its impact on our understanding concerning the activation 
of innate immunity, Jules Hoffmann was awarded the 2011 Nobel Prize in medicine, along 
with Bruce Beutler for his work on TLR4 and the late Ralph Steinman for his discovery of 
dendritic cells and their role in immunity. 
1.2 Pattern-Recognition Receptors 
The theory of PRRs proposed by Janeway in 1989 and the discovery of their founding 
member Toll in 1996 revolutionised the picture of the so-called non-specific character of 
innate immunity and revealed that this branch of the immune system is not completely non-
specific. PRRs are highly conserved among species, from plants to Drosophila to mammals 
and are germline-encoded, non-clonal receptors of limited number. PRRs are expressed by 
cells of the innate immune systems, including macrophages and dendritic cells. PRR 
expression enables immune cells to recognise a variety of different microorganisms by 
sensing PAMPs, molecular structures which are conserved within a class of microbes. Yet, 
PRRs are not restricted to recognise microbial structures but are also capable of sensing 
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endogenous molecules released from damaged cells as a result of tissue injury or necrosis 
(e.g. after burns or trauma). Although it has been noticed before that so-called “danger 
signals” associated with tissue damage were able to initiate an inflammatory response, 
Matzinger was the first to describe and refer to them as damage-associated molecular patterns 
(DAMPs) (Matzinger, 1994; Seong & Matzinger, 2004). Most DAMPs are intracellular 
proteins such as heat-shock proteins (Panayi et al, 2004) or high-mobility group box 1 
(HMGB1) (Scaffidi et al, 2002), which are released by cells or exposed on their surface upon 
tissue damage or necrotic cell death. Non-protein DAMPs include DNA (Farkas et al, 2007), 
uric acid (Shi et al, 2003), adenosine-tri-phosphate (ATP) (Boeynaems & Communi, 2006; 
Bours et al, 2006) and heparin sulphate. Similar to PAMPs, DAMPs initiate and perpetuate 
inflammatory responses upon binding to their respective PRRs. 
All so far known PRRs share two characteristics which are responsible for their effectiveness. 
First, they recognise pathogenic structures which are essential for survival of the 
microorganism and are therefore difficult for it to alter. Second, PRRs are constitutively 
expressed on or in the cells of the innate immune system and are able to recognise pathogens 
regardless of their life-cycle stage. The interaction between PAMPs or DAMPs and their 
respective PRRs upregulates the transcription of certain genes which encode pro-
inflammatory proteins such as cytokines, chemokines, type I interferons (IFNs), antimicrobial 
proteins, PRR signalling proteins and a number of other so far non-characterised proteins. 
The PRRs which have been identified to date can be categorised into four classes of PRR 
families. The first class comprises all members of the TLR family, the second class consists of 
the Nucleotide Oligomerization Domain (NOD)-like receptor (NLR) family, the third class 
represents all members of the C-type lectin receptor (CLR) family and the fourth class 
comprises the Retinoic acid-inducible gene (RIG)-I-like receptor (RLR) family. While all 
members of the RLR and NLR families are located in the cytoplasm, TLR and CLR family 
members are transmembrane proteins. 
Due to the aims formulated in this thesis, CLR and RLR families will be described only 
briefly in the following two paragraphs, whereas more emphasis will be put on the TLR 
family, with particular focus on TLR4, and on the NLR family, discussing the NOD2 
signalling in more detail. 
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1.2.1 The C-type lectin receptor family 
 The CLRs represent an important family of PRRs as they take part in the induction of 
specific gene expression profiles either by modulating TLR signalling or by directly inducing 
gene expression, thereby tailoring the appropriate immune response to the specific pathogen 
(Gringhuis et al, 2009; Gringhuis et al, 2007; Meyer-Wentrup et al, 2009; Rogers et al, 2005). 
All members of the CLR family that function as PRRs are transmembrane proteins which 
share at least one carbohydrate recognition domain that contains conserved residue motifs and 
determines the carbohydrate specificity of each CLR. Due to their specificity towards 
PAMPs, CLRs can be subdived into two groups. While group I includes CLRs which belong 
to the mannose receptor family, group II comprises those CLRs which are part of the 
asialoglycoprotein receptor family including the DC-associated C-type lectin 1 (dectin 1) and 
DC immunoreceptor (DCIR) subfamilies. CLRs are mainly expressed on DCs and 
macrophages, yet some are also expressed on neutrophils and B cells. They interact with 
pathogens primarily by recognising mannose, fucose and glucan carbohydrate patterns, 
whereby they detect most classes of human pathogens. Their specificity towards mannose 
enables them to recognise viruses, fungi and mycobacteria. Furthermore, glucan structures are 
expressed by certain fungi and mycobacteria, thereby enabling CLRs to specifically recognise 
these pathogens (Rothfuchs et al, 2007; van Kooyk & Rabinovich, 2008). Their ability to 
specifically bind fucose allows recognition of certain bacteria and helminths. Binding of the 
diverse PAMPs to the respective CLRs leads to an internalisation of the pathogen, its 
degradation and subsequent antigen presentation by macrophages and DCs (van Kooyk & 
Rabinovich, 2008). Signal transduction induced by the different CLRs leads to the production 
of pro-inflammatory cytokines and seems to be mainly a result of NF-B (nuclear factor-
kappa B) activation, yet also the activation of mitogen-activated protein kinases (MAPKs) and 
the transcription factor nuclear factor of activated T cells (NF-AT) have been reported to 
occur upon CLR stimulation. The regulation of further transcription factors by CLRs is not 
well studied and it therefore cannot be excluded that CLRs exert additional functions which 
have not been determined so far. 
1.2.2 The RIG-I-like receptor family 
Members of the RLR family are specialised in recognising RNA viruses and are essential for 
initiating and modulating antiviral immune responses by evoking the production of type I 
IFNs and pro-inflammatory cytokines. The family comprises three members, namely retinoic 
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acid-inducible gene-I (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and 
laboratory of genetics and physiology 2 (LGP2) which are encoded in three genes of the 
mouse and human genome. While RIG-I and MDA5 are characterised by a regulatory domain 
located in the C-terminus, a central DEAD box helicase/ATPase domain and two N-terminal 
caspase recruitment domains (CARDs), LGP2 features only the regulatory and helicase 
domain but lacks the CARD homology. RLRs sense viral RNA via their helicase domain and 
need the CARD domain to transmit the signal downstream. As LGP2 lacks a CARD, it was 
thought to function as a negative regulator by interfering with the recognition of viral RNA by 
RIG-I and MDA5 (Yoneyama et al, 2005). However, recent findings contrast with this view 
and describe LGP2 as a positive regulator of RIG-I- and MDA5-mediated anti-viral responses 
by facilitating the accessibility to viral RNA, thereby ensuring a robust immune response 
(Satoh et al, 2010). While the exact functions of LGP2 and especially its ligands are still 
discussed controversially, the specificity towards different RNA viruses of RIG-I and MDA5 
are well studied. While both receptors redundantly recognise Dengue virus, West Nile virus as 
well as reovirus (Kato et al, 2006; Loo et al, 2008; Sumpter et al, 2005) each of them is 
responsible for the detection of further specific viral RNAs and they cannot substitute each 
other. RIG-I specifically binds RNAs of Newcastle disease, Sendai, vesicular stromatitis, 
respiratory syncytial and Japanese encephalitis virus and is responsible for defending the host 
against influenza, Ebola and hepatitis C (Kumar et al, 2011; Schlee & Hartmann, 2010). The 
spectrum of ligands detected by MDA5 seems to be more restricted as it only detects 
mengovirus as well as encephalomyocarditis and Theiler’s virus (Kumar et al, 2011). 
Interestingly however, whilst both receptors share the ability to bind 
Polyinosinic:polycytidylic acid  (poly (I:C)), the synthetic equivalent of double-stranded 
RNA, RIG-I binds specifically only to short- length poly (I:C) whereas MDA5 only 
recognises long-length of the RNA equivalent.  
The RLR signalling cascade involves a number of downstream molecules including E3 
ubiquitin ligases which mediate activatory K63-linked poly-ubiquitination (Gack et al, 2007; 
Pichlmair et al, 2009) as well as inhibitory K48-type poly-ubiquitination (Arimoto et al, 2007) 
of RIG-I.  Recent publications also propose an inhibitory involvement of linear ubiquitin 
chains in RLR signalling (Inn et al, ; Oshiumi et al, 2011). The central component of the RLR 
signalling pathway is the N-terminal CARD-containing adaptor IFN--promoter stimulator 1 
(IPS-1) (also known as MAVS, CARDIF, or VISA) which interacts with RIG-I and MDA5 
through homophilic interactions between the CARD domains (Kawai & Akira, 2006). Upon 
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interaction IPS-1 activates downstream signalling cascades leading, on the one hand, to the 
expression of type I IFN genes via the transcription factors interferon regulatory factor 3 and 
7 (IRF3 and 7) and on the other, to the expression of genes encoding pro-inflammatory 
cytokines by activating the transcription factor NF-B.  
1.2.3 The NLR family 
The NLRs are a cytoplasmic protein family that senses a wide range of PAMPs within the 
cytoplasm of cells. So far, at least 23 human and about 34 murine genes encoding NLRs have 
been identified (Kumar et al, 2011); however, the physiological role of most of them is still 
poorly understood. All members share three common structural features: The C-terminal 
domain consists of several leucine-rich repeats (LRRs) and is responsible for recognition of 
the PAMPs. The central nucleotide-binding domain (NBD, also called NACHT) is required 
for ligand-induced self-oligomerisation and has ATPase activity. The composition of protein-
binding motifs in the N-terminal effector domain shows the highest variation in all members 
of the NLR family. The N-terminus can harbour CARDs, a pyrin domain, a baculovirus 
inhibitor of apoptosis protein repeat (BIR) domain or an acidic transactivation domain. 
Depending on their N-terminal structures, NLRs can be categorised in five subfamilies 
including the acidic transactivation domain containing NLRA subfamily, the NLRB 
subfamily which is characterised by its BIR domain, the NLRP subfamily comprising a pyrin 
domain and the CARD-containing NLRC subfamily. NLRs which contain an unknown 
domain in their N-terminus belong to the NLRX subfamily. Upon binding of PAMPs, NLRs 
either induce NF-B and MAPK activation for the production of pro-inflammatory cytokines, 
or they activate a multiprotein-complex called “inflammasome”. NLRs that feature an N-
terminal pyrin or BIR domain do not directly contribute to the transcriptional activation of 
inflammatory mediators but are components of the inflammasome, which either initiates the 
proteolytic cleavage of various caspases resulting in the maturation and production of pro-
inflammatory cytokines, such as interleukin 1(IL-1) and IL-18, or initiates cell death. The 
NLR members nucleotide-binding oligomerisation domain 1 (NOD1) and NOD2 recognise 
peptidoglycans (PGN), major components of bacterial cell walls. While NOD1 specifically 
binds to -D-glutamyl-meso-diaminopimelic acid (iE-DAP) (Chamaillard et al, 2003), NOD2 
recognises muramyl dipeptide (MDP) (Girardin et al, 2003; Inohara et al, 2003; McDonald et 
al, 2005). As certain members of the TLR family are also capable of binding bacterial cell 
wall components, TLRs and NODs synergistically activate the production of pro-
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inflammatory cytokines and thus enhance the induction of an immune response to efficiently 
remove the pathogen. Recent publications suggest an involvement of NOD2 also in 5’-
triphosphate RNA-induced type I IFN production and in host defence against single-stranded 
RNA-viruses which cause respiratory tract infections (Sabbah et al, 2009). 
1.2.3.1 The NOD2 signalling pathway 
NOD2, also known as CARD15, comprises a number of C-terminal LRRs, an intermediate 
oligomerisation domain and two CARDs in its N-terminus.  NOD2 is mainly located in the 
cytosol of cells (Inohara & Nunez, 2003), however expression on the plasma membrane has 
also been reported (Barnich et al, 2005). As NOD2 binds peptides which are derived from cell 
wall components of Gram-positive and Gram-negative bacteria it is not surprising that NOD2 
is mainly expressed by APCs such as macrophages and DCs and is therefore an essential 
regulator of both innate and adaptive immunity (Tattoli et al, 2007). Among all primary 
epithelial cells it seems as if NOD2 expression is restricted to Paneth cells, which are located 
at the base of the intestinal crypt (Ogura et al, 2003). The expression of NOD2 can be induced 
by tumour necrosis factor (TNF) and further increased by IFN- (Rosenstiel et al, 2003). 
Once MDP has been released into the cytosol, it is thought to interact with the C-terminal 
LRRs of NOD2. However, evidence for a direct interaction is still lacking. The postulated 
interaction has been proposed to initiate the activation of NOD2 by a conformational change 
of the MDP/NOD2-complex which leads to self-oligomerisation via its NBD (Inohara et al, 
2000; Tanabe et al, 2004). Subsequently, Receptor interacting protein 2 (RIP2, also known as 
RICK, CARDIAK or RIPK2) is recruited to the MDP/NOD2-complex and is conjugated with 
K63-linked ubiquitin chains (Yang et al, 2007). Poly-ubiquitination of RIP2 allows binding of 
the downstream signalling component TGF- activated kinase 1 (TAK1), which leads to the 
activation of the MAPK and NF-B pathways and the production of cytokines, chemokines 
and anti-microbial peptides (Hasegawa et al, 2008; Park et al, 2007). The ubiquitin-
conjugating enzymes E2 N (Ubc13) and E2 variant 1 (Uev1a) have been described to form the 
E2 complex responsible for the attachment of K63-linked ubiquitin chains to RIP2 (Hasegawa 
et al, 2008; Park et al, 2007) and a recent study by Bertrand et al. suggested the cellular 
inhibitor of apoptosis proteins (cIAPs) 1 and 2 acting as respective E3 ligases in this crucial 
event (Bertrand et al, 2009). The current model of NOD2 signalling suggests a cIAP1- and 
cIAP2-dependent recruitment of RIP2 to the NOD2 receptor upon stimulation and a K63-
ubiquitin dependent interaction of RIP2 with the downstream molecule TAK1, which is 
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required to initiate NF-B and MAPK signalling. Bertrand et al. suggest a conjugation of 
RIP2 with both K63- and K48-linked chains by cIAP1/ 2, whereas K63-linked chains are 
responsible for signal transduction and K48-linked chains for termination of the signalling 
cascade. The current model of NOD2 signalling and its diverse outcomes are illustrated in 
Figure 1.       
 
 
 
 
 
 
 
 
 
 
Polymorphisms of NOD2 are associated with chronic inflammation of the intestine and a high 
susceptibility to Crohn’s disease (Hugot et al, 2001; Ogura et al, 2001). Furthermore, MDP 
administration was shown to have a protective effect in mice suffering from experimental 
(dextran sodium sulphate-induced) colitis (Watanabe et al, 2008). Hence, these results 
indicate that NOD2 signalling does not only induce protective immunity but also exerts 
protective functions by downregulation of certain TLR-driven immune responses. The inter-
relationship between NOD2 and TLRs, especially TLR2, is due to the fact that intact PGN is 
postulated to signal through TLR2 whereas MDP, which is a component of PGN and released 
Figure 1: The NOD2 signalling pathway. Detection of bacterially derived MDP by NOD2 results in cIAP1/2
binding to RIP2. cIAP1/2 function as E3 ligases, conjugating K63-linked poly-ubiquitin chains to RIP2. This
modification precedes binding and activation of TAK1, which subsequently initiates NF-B and MAPK
signalling. 
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into the cytosol after PGN uptake, stimulates NOD2. Thereby two different molecular forms 
of the same microbial component stimulate two different pathways and modify each other’s 
function. While NOD2 stimulation with MDP leads to the transcription of pro-inflammatory 
genes by transducing the above described signalling cascade, it at the same time also 
negatively cross-regulates the TLR2/PGN-mediated NF-B activation, thereby keeping the 
immune response in check and preventing an overproduction of cytokines (cytokine storm) by 
immune cells (Strober et al, 2006). Hence, NOD2 functions in a bidirectional way by, on the 
one hand, inducing immune responses and, on the other, fine-tuning the outcome of innate 
immunity through dampening TLR signalling.        
1.2.4 The TLR family 
The TLR family is probably the best-characterised PRR family and its members are 
considered to be the primary sensors of pathogens. TLRs can be expressed on the cell surface 
where they are responsible for the recognition of invading pathogens that are still outside of 
the cell. However, they can also be expressed in intracellular vesicles such as the 
endoplasmatic reticulum (ER), endosomes, lysosomes and endolysosomes, thereby sensing 
pathogens inside of cells (Akira et al, 2006). So far, ten functional TLRs have been identified 
in humans and twelve in mice, with TLR1-TLR9 being conserved in both species. Mouse 
TLR10 is not functional because of a stop codon in the murine TLR10 gene and TLR11, 
TLR12 and TLR13 are only expressed in mice but have been lost from the human genome. 
Whereas TLR1, 2, 4, 5 and 6 are primarily expressed on the cell surface and are responsible 
for the detection of bacteria, protozoa and fungi, TLR3, 7, 8 and 9 are primarily intracellular 
sentinels located in endocytic compartments responsible for the recognition of PAMPs 
derived from various viruses and bacteria (Kawai & Akira, 2010; Kumar et al, 2009; 
Takeuchi & Akira, 2010).  Table 1 summarises all so far known members of the TLR family 
and specifies their cellular localisation, ligands and the origin of each of their ligands 
identified to date.  
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TLRs are type I trans-membrane glycoproteins characterised by N-terminal LRRs which 
mediate the specific recognition of PAMPs and a transmembrane domain followed by an 
intracellular Toll/IL-1 receptor (TIR) domain which is crucial for downstream signal 
transduction. TLR signalling is primarily mediated via interaction between the TLR receptor 
and a respective adaptor molecule. Upon TLR stimulation, TIR domain-containing adaptor 
molecules such as myeloid differentiation primary response gene 88 (MyD88) (Kawai et al, 
1999), TIR domain-containing adaptor inducing IFN- (TRIF, also known as  TICAM-1) 
(Yamamoto et al, 2003), TIR domain-containing adaptor protein (TIRAP also termed Mal) 
(Fitzgerald et al, 2001), and TRIF-related adaptor molecule (TRAM also referred to as 
TICAM-2) (Bin et al, 2003) are recruited to the TIR domains of the different TLRs, thereby 
enabling downstream signal transduction. 
 The specific recruitment of one adaptor molecule or a combination of two different adaptor 
molecules to individual TLRs or TLR heterodimers triggers a specific biological response, 
which is characterised by the production of either mainly type I IFNs or pro-inflammatory 
Table 1: TLRs and their ligands. Summary of all so far known TLRs, their localisation, ligands and the
pathogenic origin of their ligands. 
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cytokines or a combination of both depending on the pathogen. MyD88 was the first member 
of the TIR family to be identified and it is recruited by all TLRs except TLR3. The 
recruitment of MyD88 leads to the activation of NF-B and MAPKs and hence the production 
of pro-inflammatory cytokines by macrophages and DCs (Akira et al, 2006).  Recruitment of 
TRIF by TLR3 and TLR4 induces alternative pathways which induce the production of type I 
IFN by activating the transcription factors IRF3 and IRF7 and the production of pro-
inflammatory cytokines and a specific set of chemokines by late-phase activation of NF-B in 
the case of TLR4. Due to these different transcriptional outcomes depending on the 
combination of employed adaptor molecules, TLR signalling can be roughly divided into two 
distinct pathways, the MyD88-dependent signalling pathway and the TRIF-dependent 
signalling pathway. TIRAP and TRAM in contrast only act as bridging adaptors allowing the 
activation of either the MyD88- or TRIF-dependent signalling pathway. However, in some 
cases MyD88 and TRIF do not need either of the bridging adaptors but can also directly 
interact with the TIR domain of some TLRs. 
1.2.4.1 The TLR4 signalling pathway 
TLR4 is a founding member of the TLR family and activates both, MyD88- and TRIF-
dependent signalling via recruitment of all four adaptor molecules. TLR4 is therefore an 
excellent example demonstrating the variety of mediators which can be produced by the 
employment of four different adaptor molecules. The specific ligand for TLR4 is bacterial 
lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative bacteria 
which is known to cause septic shock (Akira et al, 2006). TLR4 in complex with myeloid 
differention factor 2 (MD2) engages LPS on the cell surface (Akashi-Takamura & Miyake, 
2008). The crystal structure of the complex comprising TLR4, MD2 and LPS revealed that 
five of the six lipid chains of LPS bind the hydrophobic pocket of MD2 and the remaining 
sixth lipid chain which is exposed to the surface on MD2 associates with TLR4 (Kawai & 
Akira, 2010). The study further showed that two copies of the TLR4-MD2-LPS complex 
interact symmetrically to form a TLR4 homodimer which initiates signal transduction by 
recruitment of the respective intracellular adaptor molecules (Kim et al, 2007a; Park et al, 
2009). Additional proteins involved in the binding of LPS to the TLR4-MD2 complex are the 
LPS-binding protein (LBP) and the glycosylphosphatidylinositol-linked, leucine-rich repeat-
containing protein CD14 that binds LBP and delivers LPS-LBP to the TLR4-MD2 complex 
on the cell surface. Formation of the TLR4-MD2-LPS homodimer leads to the recruitment of 
TIRAP, which then facilitates the association with MyD88 and the formation of a receptor-
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associated complex to initiate the so-called first- or early-phase of NF-B and MAPK 
activation. This receptor-associated complex comprises IL-1R-associated kinases (IRAKs), 
TNFR-associated factor 6 (TRAF6) and the TAK1 complex, and initiates the production of 
pro-inflammatory cytokines. Subsequently, the TLR4-MD2-LPS complex is internalised and 
translocates to endosomes in which it triggers another signal transduction cascade by 
recruiting the bridging adaptor TRAM and the adaptor molecule TRIF. The TRIF-dependent 
signalling pathway then leads to the activation of the transcription factor IRF3 resulting in the 
induction of type I IFNs and the induction of the so-called late-phase NF-B activation for 
further cytokine production (Kagan et al, 2008). First- and second-phase of NF-B activation 
are both required for the expression of pro-inflammatory cytokines via TLR4. The signalling 
pathway of TLR4 is summarised and illustrated in Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The TLR4 signalling pathway. TLR4/MD2 complexes bind to LPS which leads to recruitment of
MyD88 and TIRAP. Subsequent complex-formation of TRAF6 and IRAKs initiates E3 activity of TRAF6.
TRAF6-mediated K63-linked poly-ubiquitination activates the TAB/TAK complex, resulting in IKK-complex
and subsequent early phase NF-B activation on the one hand and in activation of the MAPKs p38 and JNK on
the other hand. Furthermore, LPS induces translocation of TLR4 and TRAM to the endosome where they
activate TRIF-dependent signalling, which activates late phase NF-B and IRF3. 
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At this point it should be noted that although all TLRs are important sensors of the innate 
immune system and are essential for protective immunity against a variety of pathogen-
induced infections, inappropriate or excessive TLR responses contribute to often fatal acute 
and chronic inflammation as well as to systemic autoimmune diseases. There is increasing 
evidence that under certain pathological conditions, such as necrosis, cells produce and 
release endogeneous molecules which stimulate TLRs. This can result in the development or 
acceleration of systemic, acute or chronic auto-inflammatory diseases (Takeuchi & Akira, 
2010). 
1.3 Pro-inflammatory Cytokines 
Cytokines are mediators of the immune system with various and often contrary activities 
which are extensively used in intercellular communication. Depending on their activity 
spectrum, cytokines can be divided into functional classes. Pro-inflammatory and anti-
inflammatory cytokines represent two such functional classes and are both regulators of host 
responses to infection, immune responses, inflammation and trauma. Whereas pro-
inflammatory cytokines promote inflammation, anti-inflammatory cytokines reduce 
inflammation, promote healing and thereby antagonise the activities driven by pro-
inflammatory cytokines (Dinarello, 2007). A balance between the effects exerted by both 
types of cytokines is thought to determine the outcome of disease. An imbalance in each 
direction can cause severe consequences for the host’s immune status. A shift of the cytokine 
balance in the direction favouring anti-inflammatory cytokine production can result in 
immuno-suppression, whereas an excess of pro-inflammatory cytokines can cause chronic 
inflammatory diseases. In the case of pro-inflammatory cytokine-favouring imbalances anti-
cytokine therapies have been developed and successfully applied to treat autoimmune diseases 
such as rheumatoid arthritis, Crohn’s disease (CD) and psoriasis (Maini & Taylor, 2000; 
Nograles & Krueger, 2011; Pizarro & Cominelli, 2007b; van den Berg, 2001). 
The human genome encodes a large number of pro-inflammatory cytokines to guarantee the 
induction of effective immune responses, inflammation, and thus to fight infection. Due to the 
objectives underlying this thesis the following paragraphs will focus on the three pro-
inflammatory cytokines IL-1, IL-33 and TNF. 
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1.3.1 The IL-1 cytokine family 
The IL-1 family of cytokines comprises eleven members which are encoded on eleven distinct 
genes in humans and mice. The founding members of this family are IL-1also referred to as 
IL-1F1, IL-1 also known as IL-1F2 and IL-1 receptor antagonist (IL-1RA), which has been 
renamed IL-1F3. In the last few years, the family was expanded by the addition of eight other 
members, IL-1F4 to IL-1F11. While IL-1F4, also referred to as IL-18, has already been 
known for some years and has been subject of intense study since its discovery (Nakamura et 
al, 1989; Okamura et al, 1995), IL-1F11, also known as IL-33, is the most recently discovered 
member of the IL-1 cytokine family (Schmitz et al, 2005) and we are still only beginning to 
unravel its biological functions. All genes encoding IL-1 cytokine family members, except 
those encoding IL-18 and IL-33, are clustered in one region on human chromosome 2 
(Nicklin et al, 2002; Taylor et al, 2002). Although all family members exert their function as 
extracellular molecules, only IL-1RA features a signal peptide which enables its translocation 
from the cytoplasm into the lumen of the endoplasmatic reticulum. The secretion mechanisms 
of all other IL-1 family members remain unknown. 
All members of the IL-1 cytokine family play central roles in the regulation of immune and 
inflammatory responses to infection and tissue injury by PAMPs and DAMPs. Hence, IL-1 
cytokines are major mediators in innate immunity and their actions need to be tightly 
regulated to protect the host from auto-inflammatory diseases. The pro-inflammatory potential 
of IL-1 and IL-1 is therefore restricted at three major levels: (i) expression of IL-1 and 
IL-1 is low under normal conditions and their synthesis is controlled at the transcriptional as 
well as the translational level (Dinarello, 1996; Dinarello, 2009). Further restriction at this 
level applies to the release of IL-1 which is controlled by a multiprotein complex, called 
NACHT, LRR and PYD domains-containing protein 3 (NALP3)-inflammasome, which keeps 
the maturation of IL-1 to its biologically active form under surveillance by controlling the 
activity of the IL-1-processing protease caspase-1 (formerly known as IL-1-converting 
enzyme (ICE)) (Martinon et al, 2002; Martinon et al, 2009; Netea et al, 2009); (ii) regulation 
at the level of membrane receptors restricts the amount of IL-1 and IL-1that binds to their 
signal-transducing receptors by expressing the transmembrane decoy-receptor type II IL-1 
receptor (IL-1RII) (Colotta et al, 1993), soluble forms of IL-1 binding receptors (Arend et al, 
2008), regulatory receptors (e.g. single immunoglobulin IL-1R-related molecule (SIGIRR)) 
(Polentarutti et al, 2003; Wald et al, 2003) and competing receptor antagonists (IL-1RA), 
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respectively (Dinarello, 2005); (iii) regulatory mechanisms at the level downstream of 
activated receptors are manifold and include a number of regulatory proteins which either 
compete with signalling molecules at different steps of the cascade for binding to adaptor 
domains or enzymatically modify, and thereby inactivate,  downstream signal transducers. 
These negative-feedback mechanisms do not only apply to IL-1 and IL-1 but instead this 
concept, in the same or slightly different occurrences, applies to all members of the IL-1 
cytokine family. 
Members of the IL-1 cytokine family signal through a group of closely related receptors 
which contain extracellular immunoglobulin-like domains and a cytoplasmic TIR domain. 
The cytokine response is initiated when the ligand binds to its primary receptor unit, which in 
the case of IL- and IL-1is the ubiquitously expressed type I IL-1 receptor (IL-1R1). The 
IL-1 receptor accessory protein (IL-1RAcP) serves as co-receptor for IL- and 
IL-1(Greenfeder et al, 1995; Wesche et al, 1996), stabilises the IL-1 receptor complex 
(Wesche et al, 1998) and is required for signal transduction. Formation of the receptor 
heterodimer enables the rapid recruitment of the adaptor protein MyD88 (Brikos et al, 2007), 
IRAK4 (Li et al, 2002), IRAK1 (Cao et al, 1996a), TRAF6 (Cao et al, 1996b) and other 
downstream signalling components. The subsequent biological responses typically emanate 
from NF-B and MAPK pathway activation. 
1.3.1.1 IL-1 signalling pathway 
IL- and IL-1 share only24% amino acid sequence identity and differ in several ways. 
Whereas IL-1 is secreted and acts systemically, IL-1 is mainly associated with the plasma 
membrane of the producing cell and is therefore restricted to acting locally (Dinarello, 2009; 
Kurt-Jones et al, 1985). Expression of IL-1is generally limited to monocytes and 
macrophages whereas IL-1 can be produced by a variety of cells and is highly expressed by 
keratinocytes and endothelial cells (Dinarello, 1996; Dinarello, 2009). In addition, IL-1 
comprises a nuclear localisation sequence and is a pro-inflammatory activator of transcription 
influencing gene expression patterns as well as cell survival (Buryskova et al, 2004; Werman 
et al, 2004).  
Despite the numerous differences, both cytokines have largely identical biological functions 
(Auron et al, 1984; Pizarro & Cominelli, 2007a) and signal through the same receptor 
complex. Extensive studies on the IL-1 signalling pathway in the recent years have revealed 
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new mechanistic details on IL-1-induced NF-B- and MAPK activation and a four-step 
process as been proposed (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The IL-1 signalling pathway. (1) Binding of IL-1 to IL-1R/IL-1RAcP results in rapid recruitment of
MyD88, IRAK4, IRAK1 and probably IRAK2 to the receptor. (2) Multiple phosphorylation events of IRAKs lead
to their dissociation from MyD88 and the receptor. IRAK1 phosphorylates the E3 Pellino. (3) Activated Pellino
conjugates K63-linked ubiquitin chains to IRAK1. Recruitment of TRAF6 to the IRAK complex results in its
activation and auto-ubiquitination, thus TRAF6 serves as a recruitment-platform for TAB/TAK and IKK complex,
respectively. This leads to activation of NF-B and MAPKs. (4) A second mechanism to activate NF-B requires
Pellino-induced ubiquitin chains on IRAK1, which serves in this second mechanism as the IKK complex
recruitment platform, thereby putting the TAB/TAK and IKK complex into close proximity, resulting in IKK
activation, following NF-B activation. 
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The initial step in IL-1 signal transduction is the binding of IL-1 to IL-1R1 which induces a 
conformational change in IL-1R1 facilitating the recruitment of the co-receptor IL-1RAcP. 
The cytosolic TIR domains of the IL-1R1/IL-1RAcP complex then serve as a scaffold for the 
recruitment of the adaptor protein MyD88 via its TIR domain (Brikos et al, 2007), which in 
turn and via its death domain (DD) enables the recruitment of IRAK1, IRAK4 and probably 
IRAK2 via their respective DDs (Figure 3, picture 1). Auto-phosphorylation of IRAK4 and 
subsequent phosphorylation of IRAK1 and IRAK2 is an early event in this signalling pathway 
which is accompanied by their dissociation as a stable complex from the membrane-
associated MyD88/IL-1R1/IL-1RAcP complex (Figure 3, picture 2). Attachment of phosphate 
groups to all IRAKs are crucial events as these modifications mediate the recruitment of E3-
ligases. The Pelle-interacting proteins Pellino-1 and Pellino-3b bind to and are phosphorylated 
(thereby activated) by IRAK1 and IRAK4 and subsequently cause K63-linked poly-
ubiquitination of IRAK1 (Butler et al, 2007; Ordureau et al, 2008; Yu et al, 2002). TRAF6 is 
is a second E3 ligase which was shown to interact with the IRAK-complex (Cao et al, 1996b). 
Upon recruitment, TRAF6 is thought to trimerise (Baud et al, 1999) and, by employing the 
ubiquitin-conjugating enzymes Ubc13 and Uev1a, to auto-ubiquitinate, attaching K63-linked 
poly-ubiquitin chains to itself. Ubiquitinated TRAF6 then recruits TAK1 (Ninomiya-Tsuji et 
al, 1999) which stably interacts with TAK1-binding proteins 1 (TAB1) and TAB2 and/or 
TAB3 in a pre-formed TAB/TAK complex. The recruitment of this cytoplasmic pre-formed 
complex is mediated by the Npl4 zinc finger (NZF) domains of TAB2 and TAB3 which 
specifically interact with K63-linked ubiquitin chains (Ishitani et al, 2003; Kanayama et al, 
2004; Komander et al, 2009; Takaesu et al, 2000). The mechanisms of subsequent TAK1 
activation have been enigmatic for a long time and still are not completely resolved. Yet, 
recent studies suggest a TRAF6-mediated ubiquitination of TAK1 which induces its 
activation (Yamazaki et al, 2009). Activated TAK1 then interacts with the inhibitor of NF-B 
(IB) kinase (IKK) complex, which consists of the NF-B essential modulator (NEMO or 
IKK), IKK1 (also known as IKK) and IKK2 (also referred to as IKK), the kinase 
responsible for IB phosphorylation. TAK1 at the same time also couples to upstream 
MAPKs for activation of c-Jun N-terminal kinase (JNK) and p38 pathways (Huang et al, 
2004; Shim et al, 2005) (Figure 3, picture 3). However, it appears that there is a second 
mechanism to activate the IKK complex and to induce NF-B activation. This second 
mechanism requires Pellino-activity as modified IRAK1 is proposed to recruit the IKK 
complex via NEMO binding to K63-ubiquitinated IRAK1. The recruitment of the IKK 
complex to IRAK1 and the recruitment of the TAB/TAK complex to TRAF6 are two events 
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which put TAK1 into close proximity to IKKs allowing for their activation (Figure 3, picture 
4). Although the exact order of signalling events is not yet fully resolved, it seems as if the 
p38 and JNK pathways as well as both NF-B- activating mechanisms are necessary to 
guarantee an effective transcription of IL-1-responsive genes such as the ones encoding IB, 
IL-6 (Saccani et al, 2002), IL-8 (Hoffmann et al, 2002), monocyte chemoattractant protein 1 
(MCP1) or cyclo-oxigenase 2 (COX2) (Nakao et al, 2000). 
1.3.1.2 IL-33 signalling pathway 
IL-33 is expressed as a 30 kDa protein in the cytoplasm and its nuclear trans-localisation is 
mediated by its N-terminal domain which contains a chromatin-binding motif, suggesting 
localisation of IL-33 to heterochromatin (Carriere et al, 2007; Moussion et al, 2008; Roussel 
et al, 2008). Constitutive expression of IL-33 has been reported in several cell types such as 
endothelial and epithelial cells as well as in fibroblasts (Carriere et al, 2007; Kuchler et al, 
2008; Moussion et al, 2008). Its expression is induced in resident cells as well as in infiltrate 
inflammatory cells of inflamed tissue (Kobori et al, 2010; Palmer et al, 2009; Pastorelli et al, 
2010; Prefontaine et al, 2009; Prefontaine et al, 2010; Sponheim et al, 2010). IL-33 has been 
shown not to require any cleavage for its secretion or activation as originally thought (Ali et 
al, 2010; Luthi et al, 2009; Ohno et al, 2009; Talabot-Ayer et al, 2009), but that its C-terminal 
cleavage by apoptotic caspases, including caspase-3 and caspase-10, rather exerts the reverse 
effect by inactivating the cytokine (Ali et al, 2010; Cayrol & Girard, 2009; Luthi et al, 2009). 
The secretion mechanism of IL-33 is still not resolved and the release of the cytokine was so 
far only observed in the context of pathological necrotic cell death (Cayrol & Girard, 2009; 
Luthi et al, 2009; Matsuyama et al, 2009; Nile et al, 2010). Thus, these studies indicate that 
IL-33 seems to act intracellularly in two ways: (i) by exerting functions in the cell nucleus and 
(ii) as an endogenous danger signal (alarmin) that activates the innate immune system during 
the early phase of infection or tissue injury when released in the pathological context of 
necrosis (Haraldsen et al, 2009; Moussion et al, 2008). Hence, IL-33 seems to be a dual-
function cytokine similar to IL-1 which administrates distinct biological activities in the cell 
nucleus and on the cell-surface upon receptor-binding. IL-33 was discovered only five years 
ago and the signalling pathway which results from its receptor-binding is still largely 
unknown. What is known so far is that IL-33 binds to ST2L, the long isoform of ST2 which 
corresponds to the signal-transducing transmembrane form of the receptor with the same 
affinity as to sST2, the soluble isoform of ST2 which lacks transmembrane and intracellular 
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domains and functions as a decoy-receptor for IL-33. IL-1RAcP has been shown to function 
as co-receptor for ST2L and is required for IL-33-mediated signal transduction (Ali et al, 
2007; Chackerian et al, 2007; Palmer et al, 2008). IL-33-binding to ST2L and IL-1RAcP 
induces the IL-1 family-type-like recruitment of MyD88 via the TIR domains inducing the 
activation of NF-B and a variety of MAPK pathways including p38, JNK and extracellular 
signal-regulated-kinases (ERK) (Schmitz et al, 2005). Involvement of TRAF6 in IL-33-
mediated activation of NF-B, p38 and JNK has been reported, yet the activation of the 
MAPK pathway ERK was shown to be TRAF6-independent (Funakoshi-Tago et al, 2008). 
The same group showed that IL-33-mediated NF-B activation also requires activity of Janus 
kinase 2 (JAK2) which  is however dispensable for p38, JNK and ERK activation (Funakoshi-
Tago et al, 2010). Furthermore, crosstalk of IL-33 with c-kit signalling (Drube et al, 2010) 
and immunoreceptor tyrosine-based activation motif (ITAM)-bearing receptors (Mun et al, 
2010) have been reported recently. Figure 4 summarises our so far still rather restricted 
knowledge about IL-33 signalling. 
 
 
 
 
 
 
 
 
 
Figure 4: The IL-33 signalling pathway. 
Binding of IL-33 to ST2 and IL-1RAcP activates intracellular signalling pathways which employ the adaptor
molecule MyD88 and the signalling proteins TRAF6 and IRAKs. This results in TRAF6-dependent activation
of NF-B, p38 and JNK, as well as MyD88-dependent, TRAF6-independent activation of the MAPK ERK.
JAK2 has also been shown to be involved in IL-33-induced NF-B activation, yet the exact mechanisms of its
activation and interaction with other IL-33 signalling molecules still needs to be resolved. 
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1.3.1.3 The role of IL-1 family members in immune-mediated diseases 
Numerous inflammatory diseases are caused by excessive or immoderate immune responses 
triggered by dysregulated activity of cytokines. The inflammation which characterises these 
destructive disorders originally may have formed part of an appropriate immune response to 
infection or trauma, yet became pathological as the response failed to terminate. Members of 
the IL-1 family are key mediators in regulating the immune system and inflammatory 
processes and are therefore important contributors to these immune-mediated diseases such as 
psoriasis, rheumatoid arthritis (RA), CD and gout.  
Psoriasis is a common disease characterised by excessive growth and aberrant differentiation 
of keratinocytes leading to redness and scaling of the skin. Th1 and Th17 cells were shown to 
contribute to the disease and high amounts of IL-1, IL-18, IL-1F6 and IL-1F9 in skin lesions 
of patients have been reported (Blumberg et al, 2007; Naik et al, 1999; Zhou et al, 2003). 
Treatment of patients with soluble TNFR2-Fc (Etanercept or Enbrel®), and narrow-band 
UVB light led to clinical improvement and significant decrease in epidermal IL-1 and IL-18 
expression (Gottlieb et al, 2005; Piskin et al, 2004). Very recent studies however provided 
convincing data that the IL-1F family members IL-1F5, IL-1F6, IL-1F8 and IL-1F9 are the 
main drivers in psoriasis (Blumberg et al, 2010; Johnston et al, 2011).  
Studies applying the collagen-induced arthritis mouse model which closely resembles RA in 
humans suggested a crucial role for IL-1 and IL-17 in this autoimmune disease (Nakae et al, 
2003). Anti-IL-1 treatment of these mice prevented further disease progression and even 
reversed already established disease whereas blockade of TNF only ameliorated joint 
inflammation (Joosten et al, 1999). However, treatment of patients with the recombinant form 
of IL-1RA (Anakinra or Kineret®), revealed that anti-IL-1 treatment was only a modestly 
efficacious biologic therapy for RA (Mertens & Singh, 2009). The IL-1 family members 
IL-18 and IL-33 have also been detected in blood, inflamed joints and RA synovium of 
patients (Boissier, 2010; Cayrol & Girard, 2009), yet the clinical effect of their inhibition has 
so far not been investigated.  
Elevated expression levels of IL-18, IL-1 and IL-1 have been reported in inflamed 
intestinal mucosa of patients suffering from the inflammatory bowel disease CD which is 
characterised by destructive granulomatous inflammation of the gasterointestinal tract. An 
elevated concentration of these cytokines correlated with disease severity (Casini-Raggi et al, 
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1995; Kanai et al, 2000), yet IL-1RA did not nearly reach these levels. Hence, a mucosal 
imbalance of IL-1 and IL-1RA has been suggested to drive the inflammation (Casini-Raggi et 
al, 1995).  
IL-1 family cytokines can directly activate innate immune cells, which designates them as 
endogenous activators of innate inflammatory responses. This capacity has implications in 
diverse settings of chronic pathological inflammation. However, chronic inflammatory 
diseases may not always be associated with infection or antigen-induced immune responses, 
but can also emerge from pathological cell death. One example for an immune-mediated 
disease which is initiated by cell death is gout. Cell death causes the release of crystallised 
uric acid in the intestinal fluid. These crystals have been shown to activate the inflammasome, 
resulting in the processing and release of IL-1 which then induces inflammation despite lack 
of infection (Martinon et al, 2006). IL-1 and IL-33 are both associated with chronic 
inflammatory diseases and do not require proteolysis to become active. Being released during 
necrosis, they can contribute to or induce a sterile inflammatory response which, if it persists, 
can result in a chronic inflammatory disorder. 
1.3.2 TNF signalling 
TNF is another key cytokine involved in the initiation of innate immune responses against 
infection or tissue damage by activating NF-B and MAPK pathways. Its dysregulated 
activity is associated with auto-immune diseases such as RA or CD (Feldmann et al, 1991; 
Van Deventer, 1997) and therapeutic use of TNF-neutralising antibodies 
(Infliximab/Remicade® and Adalimumab/Humira®) or the before-mentioned TNFR2-Fc 
fusion protein (Etanercept/Enbrel®) has yielded great benefit for patients suffering from these 
inflammatory disorders (Taylor & Feldmann, 2009). Binding of PAMPs or DAMPs to the 
respective PRRs leads to TNF-production and release by monocytes, macrophages, DCs and 
other non-immune cell types such as keratinocytes. Subsequent TNF-signalling contributes to 
the initiation of host defence mechanisms as it induces the production of additional pro-
inflammatory cytokines and chemokines, thereby enhancing phagocytic activity of 
macrophages at the site of infection (Bekker et al, 2001) and establishing an inflammatory 
milieu (Roach et al, 2002). Mice lacking TNF or its receptors are therefore more susceptible 
to a variety of infections and show resistance to LPS-induced septic shock as a consequence 
of severely impaired host defence mechanisms (Aggarwal, 2003; Pfeffer et al, 1993).  TNF 
can bind two receptors, TNFR1 and TNFR2. TNFR1 is expressed in most tissues, can be fully 
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activated by both, the membrane-bound and the soluble form of TNF (Grell et al, 1998; 
Wajant et al, 2003) and can also induce cell death due to its intracellular DD. In contrast, 
TNFR2 expression is restricted to cells of the immune system and endothelium, can only 
respond to the membrane-bound form of TNF (Grell, 1995; Grell et al, 1995) and comprises 
exclusively pro-survival activity as it lacks an intracellular DD.  Binding of trimeric TNF to 
TNFR1 results in receptor-trimerisation and causes a conformational change in the receptor 
trimer. This conformational change allows for the subsequent recruitment of the adaptor 
protein TNFR associated death domain (TRADD) via its death domain (Hsu et al, 1995) 
which then serves as platform for subsequent protein binding (Figure 5).  The first protein to 
be recruited to TRADD is TRAF2 (and possibly TRAF5) (Hsu et al, 1996; Tsao et al, 2000). 
TRAF2 in turn was shown to form complexes with cIAP1 and cIAP2 (Zheng et al, 2010) and 
is responsible for their subsequent recruitment to the TNFR1 signalling complex (TNF-RSC). 
The E3 ligase activity of cIAPs is indispensable for TNF-induced activation of NF-B- and 
MAPK pathways as cIAP-generated ubiquitin chains are needed for  modification of RIP1 
and for further recruitment of the linear ubiquitin chain assembly complex (LUBAC) (Haas et 
al, 2009) to the TNF-RSC. The recruitment of RIP1 to the TNF-RSC was originally thought 
to be mediated by TRADD (Hsu et al, 1996), yet later studies suggested a TRADD-
independent recruitment of RIP1 to the TNF-RSC (Zheng et al, 2006) possibly via interaction 
of its own DD with the DD of TNFR1. Modification of RIP1 with linear ubiquitin chains 
mediated by LUBAC (Gerlach et al, 2011) then allows for further recruitment of the IKK 
complex via its regulatory subunit NEMO, which was shown to selectively bind to linear 
ubiquitin chains (Rahighi et al, 2009). LUBAC-mediated modification of NEMO with linear 
ubiquitin chains (Gerlach et al, 2011) might result in IKK-complex oligomerisation or 
increased IKK-complex recruitment thereby amplifying the downstream effects which leads 
to NF-B activation. Recent studies have markedly expanded our knowledge about the 
TNFR1 signalling but they have also revealed that its complexity is of much higher degree 
than originally thought.  Fig.5 represents a revised model of the TNF-RSC including all new 
aspects. 
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1.4 NF-B and MAPK signalling 
Inflammation is induced by the action of PAMPs, DAMPs and pro-inflammatory cytokines, 
including members of the IL-1 cytokine family and TNF. These cytokines and microbial or 
cellular products each act through binding to distinct receptors as described in the previous 
chapters (1.2. and 1.3.) and trigger four major intracellular signal transduction pathways, 
which represent cascades of protein kinases. These four signalling cascades include the three 
MAPK pathways ERK1/2, JNK and p38 as well as the pathway leading to activation of 
NF-B. They directly activate and induce the expression of a distinct set of transcription 
factors which promote the transcription of inflammatory response genes, thereby initiating 
Figure 5: Triggering of gene activation by TNFR1. Binding of TNF to TNFR1 leads to recruitment of the
adaptor molecule TRADD and further recruitment of the E3 ligases TRAF2, TRAF5, cIAP1 and cIAP2, and the
kinase RIP1 to the receptor complex. cIAP1/2-induced ubiquitination of receptor-associated signalling proteins
leads to recruitment of the TAB/TAK and IKK complex and of LUBAC, which linearly ubiquitinates RIP1 and
NEMO and possibly other receptor components. Activation of the TAB/TAK and IKK complex results in
NF-B and MAPK activation, respectively.  
Signalling towards cell death, triggered from complex II, is not depicted. 
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inflammation. The following paragraphs will focus on the different mechanisms leading to the 
activation of these pathways. 
1.4.1 NF-B signalling 
The NF-B family of transcription factors comprises five members: NF-B1 (p50 and its 
precursor p105), NF-B2 (p52 and its precursor p100), p65 (also called RelA), c-Rel, and 
RelB, and are encoded by NFB1, NFB2, RELA, REL, and RELB, respectively. All 
members are characterised by the presence of an N-terminal Rel homology domain (RHD), 
which is responsible for homo- and heterodimerisation, for nuclear translocation and DNA 
binding. RelB, c-Rel and p65 additionally share a C-terminal transcription activation domain 
(TAD), which is necessary for positive regulation of gene expression. As they lack TADs, p50 
and p52 subunits rely on interactions with other factors to positively regulate gene 
transcription (Hayden & Ghosh, 2008). Crystal structures of NF-B dimers have been 
analysed and revealed that the RHD consists of two immunoglobulin-like domains; one is 
responsible for recognition of B sites within the promoters of target genes, while the other 
provides the dimerisation interface between NF-B subunits (Hoffmann et al, 2006). Small 
differences in these dimer interfaces determine preferences for certain binding partners. RelB 
for instance heterodimerises with p50 (Saccani et al, 2003) and p52 (Dejardin et al, 2002; 
Saccani et al, 2003; Senftleben et al, 2001), whereas p65 and c-Rel preferentially form 
heterodimers with p50 (Grumont et al, 2001; Kunsch & Rosen, 1993; Libermann & 
Baltimore, 1990; Sanjabi et al, 2000; Schreck & Baeuerle, 1990). Posttranslational 
modifications such as phosphorylation and acetylation at certain parts of RHD and TAD 
domains further modulate transcriptional activity as well as DNA binding affinity of the NF-
B dimers (Hoffmann et al, 2006). In non-stimulated cells, NF-B dimers are associated with 
IB proteins, which restrain NF-B dimers from nuclear translocation by binding to the latter 
via ankyrin repeats. The IB protein family consists of the three classical members, IB, 
IB and IB and the two atypical members, IκB and Bcl-3. Although structurally related 
to the classical IB proteins, the atypical IB proteins differ from them in functional aspects 
as well as in localisation. They can reside in the nucleus, where they have been shown to 
function as co-activators once NF-B heterodimers are liberated and translocated to the 
nucleus (Bours et al, 1993; Kitamura et al, 2000). However other reports have indicated that 
IκB and Bcl-3 may also be capable of selectively inhibiting specific NF-B dimers 
(Carmody et al, 2007; Motoyama et al, 2005; Yamamoto et al, 2004) and further studies will 
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be necessary to better comprehend their seemingly contradictory functions and regulatory 
mechanisms.  
NF-B signalling can be generally sub-divided into the canonical or classical NF-B pathway 
and the non-canonical or alternative NF-B pathway. Both pathways play important yet 
distinct roles in the immune system and are activated by different stimuli, require activities of 
different kinases and involve diverse proteins and NF-B dimers.  
1.4.1.1 Canonical NF-B signalling 
The canonical NF-B signalling pathway is mainly responsible for initiating and regulating 
inflammation and is involved in the control of proliferation of lymphoid cells during an 
immune response. Canonical NF-B signalling is a fast acting process which is initiated 
rapidly after ligand-receptor interaction. Due to the presence of various negative feedback 
mechanisms, canonical NF-B signalling is a reversible process. Loss of regulatory 
mechanisms can result in constitutive NF-B activity and can be causative for chronic 
inflammatory diseases. As mentioned earlier, IL-1 cytokine family members, DAMPs, 
PAMPs and TNF are all strong inducers of canonical NF-B activity in a variety of different 
cells. The Rel heterodimers p50/p65 and p50/c-Rel are primarily activated by these stimuli 
(Basak & Hoffmann, 2008). Both heterodimers are present in non-stimulated cells, however, 
as mentioned before, association with IB proteins inhibits their nuclear translocation and 
DNA-binding activity, thus keeping them in an inactive state. Upon inflammatory stimulation, 
the IKK complex, consisting of the two catalytic subunits IKK1, which is dispensable for 
canonical NF-B signalling and IKK2, which is indispensable for canonical NF-B 
signalling, and the regulatory subunit NEMO, is activated by a still unknown mechanism. 
Several studies suggest a TAK1-dependent IKK complex activation for the canonical NF-B 
pathway (Sato et al, 2005; Shim et al, 2005) and RIP-mediated oligomerisation of NEMO has 
been discussed as a further IKK-activatory mechanism (Inohara et al, 2000; Poyet et al, 2000), 
yet additional studies will be required to fully understand this crucial step in NF-B 
signalling. Following IKK complex activation, IKK2 phosphorylates IBproteins on two 
specific N-terminal serines (Brown et al, 1995; DiDonato et al, 1996). This modification on 
IB leads to recognition by the -TRCP F-box-containing component of a Skp1-Cullin-F-box 
(SCF)-type E3 ubiquitin ligase complex, called SCF-TRCP, which attaches K48-linked 
ubiquitin chains to IB lysine residues K21 and K22, thereby marking IB for proteasomal 
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degradation. Proteolysis of the IB protein does not affect the integrity of the bound NF-B 
dimer, but instead leads to its liberation and translocation into the nucleus. Post-translational 
modifications of the RHD and TAD of both NF-B dimer components in the nucleus affect 
NF-B transcriptional activity as well as its binding to specific B sites within target gene 
promoters and allow for induction of cell type-, context- and stimulus-specific responses. One 
early NF-B-responsive promoter which is induced almost immediately upon cell stimulation 
is that of IB, thereby promoting a strong negative feedback loop, which leads to post-
induction inhibition of NF-activity upon stimulus removal (Scott et al, 1993; Sun et al, 
1993). Further negative regulatory target genes of NF-B are those encoding deubiquitinating 
enzymes (DUBs) such as A20, Cezanne and CYLD, which mainly accomplish their 
regulatory function by targeting receptor proximal events (Enesa et al, 2008; Kovalenko et al, 
2003; Trompouki et al, 2003; Wertz et al, 2004). 
1.4.1.2 Non-canonical NF-B signalling 
The non-canonical NF-B signalling pathway is induced by a subset of TNF superfamily 
ligands, including CD40 ligand (CD40L), receptor activator of NF-B ligand (RANKL), 
lymphotoxin (LT), B cell-activating factor (BAFF) and TNF-related weak inducer of 
apoptosis (TWEAK) (Claudio et al, 2002; Coope et al, 2002; Dejardin et al, 2002; Novack et 
al, 2003; Saitoh et al, 2003; Wicovsky et al, 2009) and is involved in cellular differentiation, 
survival and organogenesis. Non-canonical NF-B signalling is a rather slow process, yet 
yields long-lasting NF-B activity that is regulated differently from the canonical pathway. 
The NF-B-inducing kinase (NIK) has been identified to play a central role in this alternative 
pathway as it phosphorylates and thereby activates IKK1, the major IKK protein required for 
non-canonical NF-B signalling (Senftleben et al, 2001; Xiao et al, 2001). Activated IKK1 in 
turn phosphorylates p100 at specific C-terminal serine residues in the ankyrin repeat domain, 
leading to p100 recognition by the E3 ligase complex SCFIB resulting in its K48-poly-
ubiquitination and partial proteasomal degradation (Amir et al, 2004; Liang et al, 2006). This 
leads to the release of a p52 fragment which, together with RelB, forms the primary NF-B 
heterodimer in non-canonical NF-B signalling. 
In contrast to canonical NF-B signalling, the alternative pathway seems to lack the powerful 
negative regulatory mechanism of IB induction. One explanation for this observation might 
be the fact that RelB-containing dimers in general show low affinities for canonical 
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IBproteins and therefore do not require their highly dynamic regulation. Regulatory 
mechanisms in non-canonical NF-B signalling mainly target NIK, the central kinase in this 
pathway. A number of proteins such as TRAF2, TRAF3 and cIAP1/2 have been identified to 
interact with NIK in a cytoplasmic complex and to negatively regulate this kinase by K48-
linked poly-ubiquitination, thereby inducing its proteasomal degradation (Vallabhapurapu et 
al, 2008; Zarnegar et al, 2008). Upon cellular stimulation, TRAFs and cIAPs are recruited to 
the respective receptor signalling complexes, followed by their own degradation which then 
allows NIK stabilisation and subsequent activation of RelB/p52. 
1.4.2 MAPK signalling 
MAPKs are Ser/Thr-specific protein kinases which respond to a large number of extracellular 
stimuli and convert these signals into a wide range of distinct cellular responses. So far 14 
mammalian MAPKs have been characterised and divided into conventional and atypical 
kinases. Conventional MAPKs are ERK1/2, JNK1/2/3, p38 isoforms (, ,  and ) and 
ERK5. Atypical MAPKs comprise ERK3/4, ERK7 and Nemo-like kinase (NLK). The latter 
are characterised by nonconforming features and will not be discussed in any further detail in 
this thesis.  
Although every MAPK has unique characteristics, a number of structural features and aspects 
regarding activation and cascade regulation are shared. The structural characteristic shared by 
every MAPK is the Ser/Thr kinase domain flanked by N-and C-terminal regions of different 
lengths (Cargnello & Roux, 2011). The kinase domains of all conventional MAPKs contain a 
Thr-X-Tyr motif located in their activation loop which is crucial for their enzymatic activities. 
Every MAPK signalling cascade comprises a set of at least three sequentially acting protein 
kinases: a MAPK, a MAPK kinase (MAPKK or MAP2K) and a MAPKK kinase (MAPKKK 
or MAP3K). MAP3Ks are usually activated through phosphorylation at a membrane 
associated receptor complex and/or as a result of their interaction with small Guanosine-
triphosphate (GTP)-binding proteins of the Ras/Rho family in response to extracellular stimuli 
(Cargnello & Roux, 2011). Activated MAP3Ks then phosphorylate and activate their 
downstream MAP2Ks which in turn leads to subsequent activation of the respective MAPK 
through dual phosphorylation on Thr and Tyr residues within the conserved Thr-X-Tyr motif. 
Due to their consensus phosphorylation motifs, MAPKs can only phosphorylate their target 
substrates on Ser or Thr residues which are followed by a Pro residue, hence, they are called 
Pro-directed kinases. Further substrate specificity and selectivity is achieved by interaction or 
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docking domains within substrates as well as by scaffolding or linker proteins involved in 
certain MAPK pathways. Docking domains are required for high-affinity interactions with the 
MAPKs and scaffolding proteins can simultaneously bind different components thereby 
organising the kinase cascade in specific complexes. Members of the MAPK family are 
specifically dephosphorylated and inactivated by MAP kinase phosphatases (MKPs). MKPs 
are dual-specificity phosphatases because they are able to remove phosphates from Ser/Thr- 
as well as from Tyr-residues and are important regulators of MAPK signalling as they 
terminate the pathway once the stimulus has been removed (Chen et al, 2001). 
1.4.2.1 MAP3Ks in innate immunity 
Pro-inflammatory cytokines and microbial components are key mediators for initiation and 
regulation of innate immune responses. Their respective receptors activate the three main 
MAPK families ERK, JNK, and p38 which control a wide range of cellular activities in 
immune responses including the regulation of cytokine gene expression and programmed cell 
death. Activation of innate immunoreceptors such as IL-1R, TLR4, and TNFR1 triggers 
MAPK pathways as it leads to phosphorylation and activation of specific MAP3Ks.  So far, 
21 MAP3Ks have been identified to activate various MAPKs by phosphorylating and 
activating the respective MAP2Ks. The presence of such a large number of MAP3Ks suggests 
that multiple MAP3Ks might be required for each stimulus. Indeed, analyses of cells derived 
from MAP3K-deficient mice showed impaired TNF-induced JNK activation in those lacking 
the MAP3Ks Tpl-2 (tumor progression locus 2), ASK1 (apoptosis signal-regulating kinase 1), 
TAK1, MLK3 (mixed-lineage kinase 3), MEKK1 (MAPK/ERK kinase kinase 1) or MEKK3 
(Symons et al, 2006). MAP3Ks and MAP2Ks involved in innate immunoreceptor-mediated 
activation of the diverse MAPK pathways are shown in fig. 6.    
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Figure 6: Schematic overview of immune stimuli-induced MAPK signalling. Following receptor stimulation, 
numerous MAP3Ks are activated and subsequently phosphorylate down-stream MAP2Ks. MKK1/2 then activate 
the MAPKs ER1/2, whereas MKK4/7 are rather associated with JNK1/2/3 activation. MKK3/6 lead to activation 
of the different p38 isoforms. 
 
TAK1 is the most widely utilised MAP3K in innate immunity and its key role in initiating 
innate immune responses was first demonstrated in Drosophila (Silverman et al, 2003; Vidal 
et al, 2001). TAK1 null mutants exhibited defective NF-B and IKK activation, resulting in 
high susceptibility to Gram-negative bacterial infection. The analysis of murine embryonic 
fibroblasts (MEFs) lacking TAK1 revealed that this MAP3K is also a central component in 
the mammalian innate immune system and that it transduces signals from a variety of 
receptors leading to the activation of JNK, p38 but also NF-B, respectively (Sato et al, 2005; 
Shim et al, 2005).  These results further imply that NF-B activation depends on TAK1. 
TAK1 is a unique member of the MAP3K family considering that its activation requires 
complex formation with TAB proteins (Adhikari et al, 2007). TAB proteins are characterised 
by a ubiquitin-binding domain which allows them to interact with ubiquitinated signalling 
proteins. Mutations in this domain which inhibit the interaction of the TAB/TAK complex 
with ubiquitinated signalling proteins abrogate their ability to activate TAK1. This 
demonstrates the importance of the ubiquitin system in TAK1 activation in particular and in 
immune signalling pathways in general (Kanayama et al, 2004). Members of the TRAF 
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family are E3 ligases and form part of the different innate immune receptor complexes 
forming upon ligand binding. The family members TRAF2 and possibly TRAF5 are involved 
in TNFR1 signalling (see 1.3.2.), whereas TRAF6 forms part of the signalling cascades 
triggered by IL-1 cytokine family members (see 1.3.1.) and diverse TLRs (see 1.2.4. and 
1.2.4.1.). TRAFs have been implicated in the recruitment of TAB/TAK complexes to 
membrane-associated or intracellular signalling complexes and in the activation of TAK1 
(Kanayama et al, 2004). The mechanism how ubiquitination affects MAPK cascades is still 
not completely understood, yet it is clear that this process has an important role in the 
activation of TAK1 and hence also of the NF-B pathway. 
1.4.2.2 The ERK1/2 module  
ERK1 and ERK2 share 83% amino acid identity and are expressed to varying extent in all 
tissues. ERK1 was cloned in the early 1990s as the first mammalian MAPK and was found to 
be phosphorylated in response to growth factors (Boulton et al, 1990). However, depending 
on the cell type, a variety of other stimuli like G protein-coupled receptors (GPCRs), osmotic 
stress, pro-inflammatory cytokines and PAMPs can strongly activate the ERK1/2 pathway 
(Raman et al, 2007). The ERK1/2 module in mammalians comprises the MAP3Ks A-Raf, B-
RAF and Raf-1, the MAP2Ks MEK1 and MEK2, and the MAPKs ERK1 and ERK2. The 
protein kinases MEKK1 and Tpl2 function as additional MAP3Ks; they are however, utilised 
in a more restricted manner that depends on cell type and stimulus (Shaul & Seger, 2007). In 
non-stimulated cells, all ERK1/2 pathway components are located in the cytoplasm. Yet, upon 
cell stimulation ERK1/2 accumulates in the nucleus (Chen et al, 1992; Lenormand et al, 1993) 
in which it phosphorylates and activates the transcription factor ETS-like transcription factor 
1 (Elk-1). Elk-1 induces immediate expression of c-Fos (Gille et al, 1995) which is stabilised 
via ERK1/2-mediated phosphorylation (Murphy et al, 2002), thereby allowing c-Fos to 
heterodimerise with c-Jun to form transcriptionally active AP-1 complexes (Whitmarsh & 
Davis, 1996). AP-1 then induces transcription of a variety of target genes, thus initiating 
stimuli-dependent cellular responses. 
1.4.2.3 The JNK module 
The JNK family consists of three family members, JNK1, JNK2 and JNK3 which share more 
than 85% amino acid identity and are encoded by three distinct genes giving rise to a large 
number of spliced variants (Derijard et al, 1994; Gupta et al, 1996; Kyriakis et al, 1994). 
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While JNK1 and JNK2 are broadly expressed in most tissues, JNK3 expression is restricted to 
neuronal tissue, testis, and cardiac myocytes (Bode & Dong, 2007). All JNK family members 
can be activated by a variety of stress signals, including PAMPs, DAMPs and pro-
inflammatory cytokines, which all stimulate dual-phosphorylation on Thr and Tyr residues 
within their conserved Thr-Pro-Tyr motif located in the kinase domain activation loop. The 
first phosphorylation event in the JNK kinase cascade can emanate from several upstream 
MAP3Ks, including MEKK1-4, MLK1-3, Tpl-2, ASK1/2 and TAK1. The main MAP2Ks in 
the JNK cascade are MKK4 and MKK7 which are responsible for phosphorylation and 
activation of the JNKs. Although both MAP2Ks were found to be activated upon IL-1 
stimulation, Inoue et al. have shown that only MKK7 was essential for IL-1-induced JNK 
activation, suggesting that MKK7 might be considered a target in the treatment of chronic 
inflammation (Inoue et al, 2006). Upon stimulation activated JNKs have been reported to 
redistribute from cytoplasm to the nucleus where they activate a considerable number of 
transcription factors including c-Jun, one of the best studied nuclear substrates of JNKs. 
Activation of c-Jun promotes AP-1 complex formation and the transcription of AP-1 binding 
site-containing genes which contribute to the stimulus-specific cellular response.  
1.4.2.4 The p38 MAPK module 
The p38 MAPK family consists of four members, p38, p38, p38, and p38.  p38 was the 
first isoform to be found in 1994 (Han et al, 1994) and is the best characterised member of 
this family of MAPKs. Whereas p38 and p38 are ubiquitously expressed in all tissues, 
p38 and p38 seem to be more restricted regarding their expression and might exert 
specialised functions. All p38 MAPKs are strongly activated upon environmental stress and 
by numerous inflammatory mediators including cytokines, PAMPs and DAMPs. Activation 
of p38 isoforms requires phosphorylation on Thr and Tyr residues within the conserved Thr-
Gly-Tyr motif in their activation loop. The major MAP2Ks which catalyse their activation are 
MKK3 and MKK6 (Derijard et al, 1995; Han et al, 1996; Stein et al, 1996), yet also MKK4 
has been shown to induce p38 activation (Meier et al, 1996). MKK3/6 are activated and 
phosphorylated by several MAP3Ks, including MEKK1-3, MLK2/3, ASK1, Tpl2 and TAK1 
(Cuadrado & Nebreda, 2010). In non-stimulated cells, p38 isoforms are localised in the 
cytoplasm as well as in the nucleus. Yet, following stimulation a proportion of p38 isoforms 
seem to accumulate in the nucleus where they catalyse activation of a large number of 
substrates, including Elk-1 and ATF1/2/6. Cytoplasmic substrates for p38 isoforms include 
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Bax, MNK1/2, MK2/3 and cytosolic phospholipase A2 (cPLA2). The p38 kinase cascade 
plays a major role in inflammatory responses and is responsible for the production of pro-
inflammatory cytokines via mRNA stabilisation and/or NF-B modulation. The main isoform 
involved in these processes seems to be p38as its deletion was found to reduce pro-
inflammatory gene expression (Kim et al, 2008). 
1.5 The ubiquitin system 
Post-translational modifications of proteins and the domains capable of recognising these 
modifications play a central role in cell signalling. Protein modification by covalent 
attachment of the short modifier protein ubiquitin (Ub) is called ubiquitination and is involved 
in a large variety of biological processes, including protein stability, cell-cycle progression, 
gene transcription, receptor transport and immune responses (Haglund & Dikic, 2005). 
Ubiquitination was first described in the late 1970’ by Ciechanover et al. as an ATP-
dependent proteolytic process present in cellular extracts. Ubiquitin, at that time referred to as 
ATP-dependent proteolysis factor 1 (APF-1), was shown to be covalently attached to lysine 
residues of target proteins in an ATP-dependent mechanism (Ciechanover et al, 1978) which 
led to their proteasomal degradation and the release of free ubiquitin (Ciechanover et al, 
1980a; Ciechanover et al, 1980b; Hershko et al, 1980; Wilkinson et al, 1980).  The in vivo 
proof for the concept of ubiquitin-mediated protein degradation was published in 1984 
(Ciechanover et al, 1984) and for almost twenty years ubiquitination was thought to be simply 
a regulatory mechanism leading to protein degradation. However, the work by Spence et al. in 
1995 suggested a further, non-proteolytic function for ubiquitin and thereby promoted a 
change of mindset overcoming the concept that ubiquitin’s function is restricted to protein 
degradation (Spence et al, 1995). Since then, extensive research has led to the identification of 
different types of ubiquitin-linked chains with distinct functions and a large number of 
proteins being involved in ubiquitination. Today the ubiquitin system is found to be a highly 
versatile mechanism controlling signal integration and cellular responses.  
1.5.1 Conjugation of ubiquitin: the formation of Ub-chains 
Ubiquitin is a highly conserved, small protein of 76 amino acids and a molecular mass of 
about 8.5 kDa. It is expressed in all eukaryotic cells from plants to mammals and performs its 
highly versatile function through conjugation to lysine residues of target proteins thereby 
regulating a myriad of cellular processes. Ubiquitin comprises seven internal lysine residues 
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(K6, K11, K27, K29, K33, K48 and K63) of which all can be utilised for ubiquitin chain 
assembly.  The N-terminal methionine (M1) of ubiquitin has recently been shown to function 
as an additional acceptor for the C-terminal Glycine of another ubiquitin protein thereby 
generating M1-linked linear ubiquitin chains (Kirisako et al, 2006). 
The process of ubiquitin chain assembly is called ubiquitination and is a three-step cascade 
requiring Ub-activating (E1), Ub-conjugating (E2) and Ub-ligating (E3) enzyme activities 
(Figure 7).  
 
 
Figure 7: Schematic of ubiquitin chain formation. ATP-dependent activation of ubiquitin by an E1 leads to its 
transfer to the reactive cysteine residue of an E2 conjugating enzyme. Subsequently, ubiquitin gets either 
transferred to the reactive cysteine of a HECT E3 enzyme, which then facilitates ubiquitin transfer from the E2 
to the target substrate via a thioester intermediate on the E3, or the E2 interacts with a RING-box E3 which 
confers target selectivity and the E2 directly attaches ubiquitin to the target substrate. 
 
 
The first step in this process is the activation of ubiquitin by the E1. In this ATP-dependent 
step the terminal carboxyl group of ubiquitin is attached to the sulfhydryl group of a key 
cysteine residue in E1, thereby forming a thioester bond.  Activated ubiquitin is then 
transferred to a sulfhydryl group of a catalytic cysteine residue within the E2. In the final step, 
the Ub-ligating enzyme E3 catalyses the ubiquitin-transfer from E2 to the target protein by 
facilitating the formation of an isopeptide bond between the C-terminal glycine residue of 
ubiquitin and the -amino group of a lysine residue within the target protein. To date, two E1 
enzymes (Uba1 and Uba6), about 50 E2s and more than 600 E3 ligases have been described 
for the human ubiquitin system. The sheer number of E2 and E3 enzymes identified so far is 
an indication for the importance of the ubiquitin system in cellular signalling and its versatile 
character. 
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E2 enzymes are the central players in the ubiquitin transfer process as they must interact with 
both, E1 enzymes and a variety of E3 enzymes. They are characterised by a compact structure 
and their evolutionarily conserved ubiquitin-conjugating catalytic (Ubc) domain consisting of 
150-200 amino acids serves as a binding platform for E1s, E3s and the activated ubiquitin. E2 
enzymes can be subdivided into four classes. Class I E2s consist only of the catalytic domain, 
other E2s are characterised by additional N-or C-terminal extensions (class II and III, 
respectively). Class IV E2s comprise both, N- and C-terminal extensions. These highly 
variable extensions (length varies from ~50 to more than 4000 residues in class IV E2s) are 
responsible for functional differences between E2s. They are involved in stabilisation of the 
interaction with E1 enzymes, in modulating the E3 activity and in determining sub-cellular 
localisation (van Wijk & Timmers, 2009). Extensive research on E2 enzymes has further 
revealed that they must perform multiple functions and play an important role in dictating the 
character of the final ubiquitin chain regarding the length of the chain and its linkage type 
(Christensen et al, 2007; Rodrigo-Brenni & Morgan, 2007; Windheim et al, 2008a).  
E3s form the largest and most diverse family of enzymes involved in ubiquitination. All E3 
family members are characterised by one of several defining motifs that determine structure 
and function of each ligase and that were used to divide the heterogeneous E3 family into 
three subgroups: homologous to E6-associated protein C-terminus (HECT), really interesting 
new gene (RING), and U-box (a modified RING motif without the full complement of Zn2+-
binding ligands) E3s (Ardley & Robinson, 2005; Christensen & Klevit, 2009). HECT E3s 
exert a direct role in catalysis during ubiquitination as they possess highly conserved cysteine 
residues which enable them to accept the ubiquitin from E2s and subsequently transfer it to 
lysine residues in target proteins or to lysine residues within ubiquitins of a growing chain 
(Kee & Huibregtse, 2007). In contrast, RING and U-box E3s lack enzymatic activity and 
rather act as adaptor proteins as they bring an activated E2-Ub and the target protein into 
sufficiently close proximity thereby promoting the ubiquitin transfer from the catalytically 
competent E2 directly to the substrate (Deshaies & Joazeiro, 2009). Although some RING 
E3s, such as TRAFs or cIAPs can apparently act alone, others are found as components of 
larger multi-protein complexes, such as the SCF-TRCP E3 ligase complex involved in K48-
ubiquitination of IB. The RING E3s are the most common type of ubiquitin ligases with 
hundreds of members encoded in the human genome (Christensen & Klevit, 2009). Due to 
their structure and sequence similarity, RING E3s can be divided into several subgroups. One 
such subgroup is the family of RING-in-between-RING (RBR) E3s, characterised by an N-
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terminal canonical RING1 domain with a C3HC4-signature of conserved cysteine and 
histidine residues, followed by the in-between-RING domain which consists of two 
consecutive zinc-binding domains (Beasley et al, 2007), and the RING2 domain (Marin et al, 
2004). For certain members of the RBR E3 subfamily it has recently been shown that they 
catalyse a novel form of ubiquitin transfer mechanism which combines RING and HECT 
characteristics. Hence, such RBR E3s have been termed RING/HECT hybrid E3s by Wenzel 
et al (Wenzel et al, 2011). This study shows that the RING1 mediates binding between the 
RBR E3 and the E2, whereas the RING2 catalyses the ubiquitin shuttle by first accepting 
ubiquitin from the E2 by forming an obligate thioester bond and subsequently transferring it 
to the substrate by employing the catalytic activity of an internal conserved cysteine residue.  
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1.5.2 Forms of ubiquitination and their physiological roles 
The ubiquitin system exhibits a highly dynamic character as it utilises a vast number of 
enzymes specialised to either attach the modification or to remove it. The fact that ubiquitin 
itself contains seven lysine residues of which all can serve as acceptors for further ubiquitin 
molecules thereby generating ubiquitin polymers, renders this system even more complex. 
Thus, proteins can be modified by the ubiquitin system in different ways. The attachment of a 
single ubiquitin to a single lysine residue is called mono-ubiquitination and the conjugation of 
mono-ubiquitins on multiple lysine residues is referred to as multi-mono-ubiquitination 
(Figure 8).  
Multi-mono-ubiquitination is linked to a number of cellular events such as DNA repair (Alpi 
et al, 2008; Sigismund et al, 2004), internalisation and degradation of cell-surface receptors 
Figure 8: Forms of ubiquitination. (A) Target proteins can be modified with mono-, multi- or poly-
ubiquitination. (B) Homotypic poly-ubiquitination is characterised by the presence of a single linkage type.
Depending on the linkage type, distinct ubiquitin chain structures may form. K48- and K63-linked/linear chains
show different conformations. (C) Heterotypic poly-ubiquitination is characterised by either alternating linkage
types in one chain (mixed linkages) or by extension of a single ubiquitin at two or more lysine residues
(branched linkages). 
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(Haglund et al, 2003a; Haglund et al, 2003b) or gene silencing (Pickart & Fushman, 2004). In 
addition, mono-ubiquitination is considered to be an important “priming” event for 
subsequent poly-ubiquitin chain assembly (Petroski et al, 2007; Rodrigo-Brenni & Morgan, 
2007; Windheim et al, 2008a). The first homotypic poly-ubiquitination (Figure 8) was 
described by Ciechanover and colleagues and it was characterised by K48-type linkages (see 
1.5). For more than ten years this type of poly-ubiquitin chain was thought to be the only one 
and the ubiquitin system was believed to be functionally limited to protein degradation. 
However, the discovery of K63-linked poly-ubiquitin chains which are functionally different 
from K48-linked chains as being non-degradative (Chen & Sun, 2009; Deng et al, 2000; 
Hofmann & Pickart, 1999) changed this view. It became clear that all seven ubiquitin lysine 
residues might be capable of serving as ubiquitin acceptors. By now, all possible homotypic 
poly-ubiquitin chains including M1-linked chains have been shown to exist in variable lengths 
and different abundances in cells (Xu et al, 2009).  Structural analyses of differently linked 
poly-ubiquitin chains have revealed that the localisation of each lysine residue in the ubiquitin 
molecule dictates the conformation of the poly-ubiquitin chain. Since all seven lysine residues 
of ubiquitin reside on different surfaces of the molecule, each type of ubiquitin chain is 
structurally different from the others and defines a distinct conformation likely exerting a 
linkage-type specific set of cellular functions. So far, the structures of five differently linked 
ubiquitin chains have been described, namely those of K48-, K11-, K6-, K63- and M1-linked 
chains. In K48-linked chains all ubiquitin molecules interact with each other and therefore the 
chain displays a quite compact globular structure (Cook et al, 1994; Varadan et al, 2002). 
Also K11- and K6-linked chains adopt compact conformations (Bremm et al, 2010; Virdee et 
al, 2011). In contrast, K63-linked ubiquitin chains adopt an open conformation in which 
individual ubiquitin molecules do not interact with each other (Tenno et al, 2004; Varadan et 
al, 2004). Due to the spatial proximity of the N-terminal methionine amino group (M1) to the 
lysine residue K63, linearly linked ubiquitin chains display a similar open conformation to 
K63-linked ubiquitin chains (Komander et al, 2009). However, whilst linear ubiquitin chains 
are linked by peptide bonds, K63-linked chains and all other linkage types are linked by 
isopeptide bonds.  
It remains to be seen whether the remaining four chain types will also adopt distinct 
conformations and their structural analysis will hopefully help to extend our sparse 
knowledge regarding their physiological functions. K48-linkages are the most abundant 
ubiquitin chain type accounting for 29% of all ubiquitin linkages in yeast (Xu et al, 2009). 
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K48-linked poly-ubiquitin chains can be degraded within minutes by the proteasomal 
machinery and tetramers linked via K48-residues have been shown to display the minimal 
recognition motif for this process (Thrower et al, 2000). For a long time proteasomal 
degradation of proteins was associated only with K48-linkages, yet early work and more 
recent studies have implicated an important role of K11-linkages in proteasomal degradation 
(Baboshina & Haas, 1996; Jin et al, 2008; Xu et al, 2009). K11 ubiquitin linkages represent 
the second most abundant linkage type in cells and recent studies have implicated them in 
diverse cellular processes such as cell division (Jin et al, 2008; Wickliffe et al, 2011) and TNF 
signalling (Dynek et al, 2010; Gerlach et al, 2011). These findings suggest that K11-linkages 
and their functional role in cellular processes have been underestimated for a long time. 
Together, K6-, K27-, K29- and K33-linked chains account for about 26% of all ubiquitin 
linkages in the cell and their physiological roles are currently still unclear (Xu et al, 2009). 
K6-linked poly-ubiquitin chains were suggested to be conjugated via a heteromeric RING E3 
ligase complex consisting of the breast cancer-susceptibility protein BRCA1 and BARD1, 
which is recruited to sites of DNA damage via K6- and K63-linked ubiquitin chains (Morris 
& Solomon, 2004; Nishikawa et al, 2004; Wu-Baer et al, 2003). These studies therefore 
suggest a role for K6-linkages in DNA repair. The cellular role of K27-linked poly-ubiquitin 
chains has recently been described in two publications. Arimoto et al report that K27-linked 
ubiquitin chains on NEMO by TRIM23 are critical in anti-viral defence, whereas Peng et al 
suggest that K27-linked ubiquitination of TIEG1 (TGFbeta Inducible Early Gene-1) regulates 
Foxp3 (forkhead box P3) expression and tumour growth (Arimoto et al, 2010; Peng et al, 
2011). However, the knowledge concerning the physiological roles of K29- and K33-linked 
ubiquitin chains is still very limited. K29-linked ubiquitin chain formation was suggested to 
be catalysed by HECT E3s, yet these results were obtained only from in vitro experiments 
(You & Pickart, 2001). More recent work suggests that K29-linked chains might target 
proteins for lysosomal instead of proteasomal degradation and that Itch, a HECT E3 ligase 
involved in Notch signalling, catalyses K29-linked chain formation (Chastagner et al, 2006; 
Chastagner et al, 2008). K29- as well as K33-linked poly-ubiquitin chains were shown to be 
attached to several members of the AMP-activated protein kinase-related family of protein 
kinases thereby inhibiting their kinase activity. Two DUBs, USP9X and TRABID, were 
shown to counter-regulate this inhibitory effect by removing K29- and K33-linked chains (Al-
Hakim et al, 2008; Licchesi et al). The E3 ligase responsible for their initial attachment 
however still needs to be determined.  
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K63-linkages correspond to 17% of all ubiquitin chains in cells (Xu et al, 2009) and extensive 
research on this linkage type has revealed important non-degradative roles for K63 poly-
ubiquitin chains in DNA repair (Hofmann & Pickart, 1999) and cell signalling events. Deng et 
al. were the first to show that the E2 complex consisting of Ubc13 and Uev1A together with 
the E3 ligase TRAF6 specifically utilised K63 lysine residues to elongate ubiquitin chains and 
that this ubiquitination event was required for activation of the IKK complex in a cell-free 
system (Deng et al, 2000). Later studies showed that also other TRAFs are capable of 
functioning as E3s in K63-linked poly-ubiquitination events and that cytokine signalling in 
general as well as signalling cascades induced by a large variety of stimuli including certain 
PAMPs such as LPS and MDP require the presence of K63-linked poly-ubiquitin chains. 
Since then many components of diverse receptor and intracellular complexes such as IRAKs 
and RIPs have been identified as targets for K63-poly-ubiquitination (Ea et al, 2006; 
Ordureau et al, 2008). Knockout of TRAF6 and Ubc13 abolished IKK and MAPK activation 
in signalling pathways triggered by a large number of stimuli, including IL-1, LPS, NOD2, 
RANKL and Epstein-Barr virus latent membrane protein 1 (LMP1), underlining the 
importance of K63-linked ubiquitin chains in these signalling cascades (Conze et al, 2008; 
Lamothe et al, 2007; Lamothe et al, 2008; Luftig et al, 2003; Walsh et al, 2008; Yang et al, 
2007). The first hint that other so far underestimated ubiquitin linkage types could be involved 
in cell signalling and could potentially be as important as K63 linkages was provided by Xu et 
al. in 2009. Employing a ubiquitin replacement strategy in which endogeneous ubiquitin was 
knocked down and replaced by mutant ubiquitin lacking the K63 residue, this study showed 
that IL-1 signalling was completely dependent on K63-linked ubiquitin chains whereas TNF 
signalling did not require this chain type for the induction of NF-B activation (Xu et al, 
2009).  
Recent publications on linear ubiquitin chains and their role in TNF-induced NF-B and 
MAPK activation (Gerlach et al, 2011; Haas et al, 2009; Ikeda et al, 2011; Tokunaga et al, 
2011; Tokunaga et al, 2009) demonstrated that the complexity of cellular signalling requires 
more ubiquitin linkage types than just K63 and K48 and that attention should also be paid to 
other ubiquitin linkages so far referred to as atypical ubiquitin chains.  Linear ubiquitin chains 
are assembled in a “head-to-tail” manner by conjugation of C- and N-termini of ubiquitins. 
The first ubiquitin attached to the substrate is conjugated to the -amino group of a distinct 
lysine residue within the substrate (acceptor lysine) forming an isopeptide bond. Yet, the next 
incoming ubiquitin is attached by a peptide bond formed between the carboxyl group of the 
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C-terminal glycine (G76) and the -amino group of the N-terminal methionine residue (M1) 
of the preceding, target-attached ubiquitin molecule. Consequently, the linear poly-ubiquitin 
chain is linked by peptide bonds and not by isopeptide bonds as all other linkage types. 
Hence, although linear chains adopt a similar open conformation as K63-linked ubiquitin 
chains, due to the different chemistry of their linkages they are conformationally more 
restrained and less flexible than the lysine-linked K63 poly-ubiquitin chains.  
Finally, in-vitro generated data suggested additional forms of atypical ubiquitination. Highly 
promiscuous E3s together with non-specific E2s assembled mixed poly-ubiquitin chains 
(heterotypic chains) which are characterised by alternating linkage types in the same ubiquitin 
chain, and branched ubiquitin chains in which more than one lysine residue of a single 
ubiquitin molecule is conjugated with other ubiquitins (Figure 8) (Kim et al, 2007b). 
However, their existence in vivo, as well as their physiological relevance, remains to be 
established. 
1.5.3 Regulation of the ubiquitin system: Deubiquitination 
Like all other types of protein modification, ubiquitination is a tightly regulated mechanism 
which can be reversed by a special set of enzymes called deubiquitinases (DUBs). However, 
the role of DUBs is not only restricted to antagonising ubiquitination of target proteins but 
also includes the processing of ubiquitin gene products and the recycling of monoubiquitin 
(Reyes-Turcu et al, 2009). The human genome encodes nearly 100 DUBs. Based on their 
structural motifs they can be classified in five families. Four families are cysteine proteases: 
(i) ubiquitin C-terminal hydrolases (UCH), (ii) ubiquitin specific proteases (USP), (iii) 
ovarian tumour proteases (OTU) and (iv) josephin domain (MJD) families. The fifth family 
consists of only metalloproteases and is called the JAB1/MPN/Mov34 metalloenzymes 
(JAMMs) family. More than 50 DUBs encoded by the human genome belong to the USP 
family, making this class of DUBs the largest.  
A20 belongs to the OTU family whereas CYLD is a member of the USP family. Yet, both 
DUBs have been associated with inhibition and downregulation of NF-B signalling. TNF-
induced expression of A20 serves as a negative feedback loop and is crucial for terminating 
the inflammatory signalling pathway. Overexpression of A20 leads to inhibition of TNF- 
mediated cell death and NF-B activation (Cooper et al, 1996; Heyninck & Beyaert, 2005), 
underlining the regulatory function of A20 in TNF signalling. Mice deficient for A20 die pre-
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maturely due to multi-organ inflammation and cachexia resulting from excessive, 
uncontrolled NF-κB signalling (Lee et al, 2000). Concomitant MyD88 deficiency however 
prevents premature lethality and cachexia in A20-/- mice, indicating that the regulatory effect 
of A20 is not restricted to the TNF pathway but is also crucial for regulating IL-1/TLR 
signalling (Turer et al, 2008). Further studies revealed a large number of A20 target proteins 
such as ubiquitinated NEMO, RIPs and TRAFs, demonstrating that A20 is involved in 
negative regulation of NF-B signalling induced by a variety of stimuli (Boone et al, 2004; 
Heyninck & Beyaert, 1999; Ning & Pagano, 2010; Stilo et al, 2008).  
CYLD was originally identified as a tumour suppressor whose mutation causes a benign 
tumour syndrome called cylindromatosis. Yet, later studies identified an additional role for 
CYLD and showed that its DUB activity negatively regulated NF-B activation by processing 
K63-linked poly-ubiquitin chains on TRAF2, which are required for activation of the IKK 
complex (Kovalenko et al, 2003; Trompouki et al, 2003). Further CYLD substrates such as 
TRAF6, TRAF7 and NEMO have been elucidated since then (Saito et al, 2004; Yoshida et al, 
2005) and similar to A20, CYLD has been shown to form part of the NF-B-regulating 
negative feedback loop as its gene expression is upregulated by NF-B (Jono et al, 2004). 
Recent studies have reported that CYLD and A20 show different specificities for ubiquitin 
linkages. Whilst A20 preferentially cleaves K48-linked ubiquitin chains in vitro, CYLD 
specifically hydrolyses linear and, albeit at reduced activity, K63-linked ubiquitin chains in 
vitro (Komander et al, 2008; Komander et al, 2009; Lin et al, 2008). Furthermore, in-vivo 
studies by Wertz et al. provided evidence that A20 removes K63-linked ubiquitin chains on 
RIP1, thereby downregulating NF-B activity (Wertz et al, 2004). 
1.5.4 Specific ubiquitin chain recognition: Ubiquitin binding domains 
Ubiquitin chain recognition is mediated by at least 20 types of ubiquitin binding domains 
(UBDs). So far, approximately 200 proteins have been identified to contain one or several 
UBDs. Consisting of less than 100 amino acids, these domains are generally small and bind 
non-covalently to the protein modifier ubiquitin. UBD-ubiquitin interactions are functionally 
important events as they control a variety of physiological processes such as protein stability, 
DNA repair, receptor trafficking, cell cycle progression and inflammatory pathways 
(Hofmann, 2009; Raiborg & Stenmark, 2009; Wickliffe et al, 2009; Winget & Mayor, 2010). 
The preference of UBDs to bind to ubiquitin chains of specific linkage type and length is 
caused by multimeric interactions between the UBD, multiple ubiquitin molecules and 
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specific regions that link ubiquitin molecules into a polymer (Dikic et al, 2009). UBDs can be 
structurally subdivided into five classes, those which fold into (i) -helical structures, (ii) zinc 
fingers (ZnFs), (iii) ubiquitin-conjugating (UBC) domains or (iv) pleckstrin homology (PH) 
folds and those (v) which do not share any of these structures. Most UBDs use -helical 
structures to interact with a solvent-exposed hydrophobic patch within in the -sheet of 
ubiquitin. However, the amino acids surrounding this preferentially targeted hydrophobic 
patch are chemically diverse and the distinct conformation of each chain depending on its 
linkage-type determines their alignment and accessibility, thus conferring a certain layer of 
specificity.  
Recognition of linkage-specific poly-ubiquitin chains contributes to the multiple set of 
physiological outcomes associated with ubiquitination. Yet, for a long time it was unclear 
whether UBDs were able to provide the capability of linkage-specific recognition. Cecile 
Pickart and colleagues were the first to show linkage-dependent ubiquitin chain recognition 
preferences for 30 different ubiquitin-associated domains (UBAs), a subfamily of the -helix 
class of UBDs (Raasi et al, 2005). This study revealed that some UBAs functioned as linkage-
selective poly-ubiquitin binders, whereas others were more promiscuous, binding different 
chains and mono-ubiquitins in a non-discriminatory manner, and still others were not capable 
of binding any ubiquitin ligand surveyed. Later studies by Husnjak et al. expanded the group 
of UBDs capable of selectively binding ubiquitin chains of certain linkages. This study 
revealed preferential binding of the proteasome receptor Rpn13 via its PH-domain to K48-
linked di-ubiquitin, demonstrating that also other UBDs structurally different from UBAs 
show ubiquitin chain recognition preferences (Husnjak et al, 2008). 
More recent work on crystal structures of the TAB2 Npl4-type zinc finger (NZF) domain 
bound to K63-linked di- and tri-ubiquitin revealed that TAB2 binds adjacent ubiquitin 
moieties via two distinct binding sites thereby imposing conformational constraints on K63-
linked dimers which cannot be adopted by the linear linkage due to its more restrained 
character as explained above. These studies therefore suggest a K63-dependent recruitment of 
the TAB/TAK complex to different receptor-associated or intracellular complexes forming 
upon various stimuli (Komander et al, 2009; Kulathu et al, 2009). 
NEMO, ABINs (A20-binding inhibitor of NF-B proteins) and optineurin are all important 
regulators of NF-B signalling and share a ubiquitin binding motif called UBAN domain 
(ubiquitin binding domain found in ABIN and NEMO). Several studies using different 
1. Introduction 
47 
 
approaches have identified the UBAN domain of NEMO to specifically bind linearly linked 
ubiquitin chains (Ivins et al, 2009; Komander et al, 2009; Lo et al, 2009; Rahighi et al, 2009). 
NEMO was originally described to specifically bind K63-linked ubiquitin chains (Ea et al, 
2006; Wu et al, 2006). However biophysical evidence provided by three independent reports 
showed that the affinity of the UBAN motif of NEMO for K63-linked chains is 100-fold 
weaker than for linear chains (Ivins et al, 2009; Lo et al, 2009; Rahighi et al, 2009) and 
competition experiments revealed that the UBAN of NEMO will exclusively bind linear 
chains from a mixture of linear, K63- and K48-linked chains (Komander et al, 2009), 
manifesting NEMOs selectivity for linear chains. Crystal structure analyses of the UBAN 
domain of NEMO in complex with linear di-ubiquitin have revealed that the UBAN domain 
forms a hetero-tetrameric complex with two linear di-ubiquitins on either side of the parallel 
symmetric UBAN coiled-coil dimer. The linear di-ubiquitin is kinked along its linker, and 
NEMO contacts the residues involved in the linkage directly, which explains the specificity of 
NEMO for linear chains, despite the fact that K63- and linear ubiquitin chains adopt similar 
overall conformations (Rahighi et al, 2009).  NEMO also contains an NZF domain in its C-
terminus, which has been shown to bind K63-, K48- and linearly linked chains with similar 
affinity (Bloor et al, 2008; Cordier et al, 2009). Yet, a fusion protein consisting of both, NZF 
and UBAN domain showed higher affinity for K63-linked chains in vitro (Cordier et al, 
2009). 
These results suggest that NEMO might be able to use both chain types, K63- and linear 
chains and possibly other types such as K11-linked chains (Dynek et al, 2010) to be recruited 
to specific signalling platforms and that absence of one chain type or mutation in either the 
UBAN or NZF domains of NEMO therefore only attenuates NF-B activation instead of 
completely abrogating it.  
ABIN1 and ABIN2 have also been shown to preferentially bind to linearly linked ubiquitin 
chains (Komander et al, 2009; Rahighi et al, 2009) and ABIN1 was suggested to act as a 
negative regulator in NF-B signalling (Wagner et al, 2008) required to prevent auto-
immunity (Nanda et al, 2011). However, cells derived from ABIN1-deficient mice did not 
show any defect in TNF-induced NF-B activation, possibly due to redundancy with 
ABIN2/3. In contrast, these cells rather showed high susceptibility for TNF-induced apoptotic 
cell death. Hence, these data suggest an additional role for ABIN1 as an anti-apoptotic 
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ubiquitin sensor for linearly linked ubiquitin chains that is required for sustained embryonic 
development (Oshima et al, 2009). 
1.6 Linear Ubiquitin Chain Assembly Complex (LUBAC) 
The linear ubiquitin chain assembly complex called LUBAC is so far the only E3 ligase 
complex known to catalyse the formation of linearly linked poly-ubiquitin chains in cells. 
LUBAC was initially identified by gel filtration analyses as a ~ 600 kDa complex consisting 
of two RING-IBR-RING proteins referred to as HOIL-1 (heme-oxidised iron-regulatory 
protein 2 ubiquitin ligase-1; also called RBCK1) and HOIP (HOIL-1 interacting protein; also 
known as RNF31), which have molecular masses of 58 kDa and 120 kDa, respectively 
(Kirisako et al, 2006). Importantly, we and others recently identified a third component of the 
LUBAC complex, referred to as SHARPIN (SHANK-associated RH domain-interacting 
protein; 45 kDa) (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 2011). Although 
SHARPIN lacks the RBR domain and thus enzymatic activity (Lim et al, 2001), it shares high 
sequence similarity with HOIL-1, and it has been suggested that the HOIL-1 gene might have 
emerged by fusion of a SHARPIN-like gene with an RBR family gene (Marin & Ferrus, 
2002). All three LUBAC components possess multiple domains which are important for 
LUBAC activity, their complex formation and for interaction with ubiquitinated proteins. A 
schematic overview is depicted in Figure 9.  
 
 
Figure 9: Schematic illustration of HOIL-1, HOIP and SHARPIN domain structures. N-termini of HOIL-1 
and HOIP and C-terminus of SHARPIN are implicated in Ubiquitin binding, stars (*) indicate the domains 
binding to ubiquitin. Errors indicate mutual interactions. ZF= zinc finger; NZF= Npl4-type zinc finger; UBA= 
ubiquitin-associated domain; UBL= ubiquitin-like domain; RBR= RING-between-RING; cc= coiled-coil 
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The first NZF (NZF1) of HOIP and each NZF domain of SHARPIN and HOIL-1 confer 
binding capacity to ubiquitin. The other domains are important for LUBAC formation and the 
current model suggests HOIP as the central component of the complex as it binds via its UBA 
domain to the UBL domain of HOIL-1 and via its NZF2 to the UBL domain of SHARPIN 
(Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 2011) (Figure 9). Tokunaga et al. 
provided evidence for the presence of multiple HOIP molecules in the 600 kDa complex 
(Tokunaga et al, 2009) and variable numbers of SHARPIN and HOIL-1 molecules forming 
part of the LUBAC complex have been discussed, yet the actual stoichiometry of this 
complex remains to be resolved. Furthermore, it has been suggested that HOIP functions as 
the central catalytically active component with HOIL-1 and/or SHARPIN as promoters of its 
linear ubiquitin-chain-forming activity (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 
2011). This model allows the presumption that HOIP-HOIL-1 and HOIP-SHARPIN 
complexes may function independently under certain circumstances and might even exert 
different functions (Gerlach et al, 2011). However, studies with cells derived from either 
HOIL-1 knockout mice or SHARPIN-mutant mice revealed that absence of one of the 
LUBAC components negatively affects the stability of the other two complex components 
(Tokunaga et al, 2011; Gerlach et al, 2011; and own observation) suggesting that a 
considerable proportion of all HOIL-1, HOIP and SHARPIN molecules are part of LUBAC 
complexes in the cell.  
Although both, HOIP and HOIL-1 contain RBR domains, studies with mutant forms of 
HOIL-1 and HOIP have shown that the catalytic activity of LUBAC solely depends on the 
RBR domain of HOIP whereas the RBR domain of HOIL-1 is not directly involved in linear 
ubiquitin chain formation (Haas et al, 2009; Tokunaga et al, 2009). 
Like other RBR family members, LUBAC might utilise the RING-HECT hybrid mechanism 
described in chapter 1.5.1. (Wenzel et al, 2011). This mechanism is characterised by E3-
mediated linkage specific chain formation, i.e. the specificity for linear ubiquitin chain 
formation catalysed by LUBAC would be independent of the E2s used in LUBAC-charging 
reactions but might be controlled by elements within and flanking the RBR of HOIP. In line 
with this hypothesis, it was shown that LUBAC failed to generate poly-ubiquitin chains with 
a version of ubiquitin in which the N-terminus was blocked (Kirisako et al, 2006).  
Although HOIL-1 activity has been shown to be dispensable for LUBAC-mediated chain 
formation (Haas et al, 2009; Tokunaga et al, 2009), it should be noted that HOIL-1 was shown 
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to mediate K48-ubiquitination of a number of proteins such as iron-regulatory protein 2 
(IRP2), the transcription factor Bach1, IRF3, TAB2 and TAB3 (Ishikawa et al, 2005; Tian et 
al, 2007; Yamanaka et al, 2003; Zenke-Kawasaki et al, 2007). Tian et al. therefore suggested 
a LUBAC-independent negative regulatory role for HOIL-1 in TNF-and IL-1-induced NF-B 
activation (Tian et al, 2007). However, considering that HOIL-1-deficient cells show reduced 
TNF-induced NF-B and MAPK activation, a physiological function of HOIL-1 as negative 
regulator of TAB2/3 is rather unlikely. More recent studies suggested an inhibitory function 
for LUBAC in RIG-I-induced INF production by targeting TRIM25 for proteasomal 
degradation and by competing with TRIM25 for the interaction with RIG-I, thereby 
suppressing the anti-viral activity of this pathway (Inn et al), 2011). These data support the 
first studies on LUBAC by Kirisako et al. in 2006 which implied linear ubiquitination in 
protein degradation (Kirisako et al, 2006).  
However, most recent work by our group and others provided evidence for LUBAC-mediated 
linear ubiquitin chain formation as required for proper NF-B and MAPK activation in TNF- 
and CD40 signalling (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 2011). 
Given the clear roles for K48- and K63-linked ubiquitin chains in TNF-induced NF-B 
signalling, the initial indication by Xu et al. that other forms of ubiquitin chains might be 
involved in TNF signalling came as a surprise (Xu et al, 2009). The data obtained by 
replacing endogenous ubiquitin with a ubiquitin-K63R mutant suggested that TNF-induced 
NF-B activation did not require K63-poly-ubiquitin chains (Xu et al, 2009). These results 
were in line with the concurrent findings of our group and others which clearly showed that 
LUBAC and linear ubiquitin chains are involved in TNF-induced NF-B activation (Gerlach 
et al, 2011; Haas et al, 2009; Ikeda et al, 2011; Tokunaga et al, 2011; Tokunaga et al, 2009). 
Furthermore, our group showed recruitment of all three LUBAC components to the TNF- and 
CD40-RSCs in a signal-dependent manner, which leads in the case of TNFR1 to stabilisation 
of the receptor complex  (Haas et al, 2009; Gerlach et al, 2011). Due to the presence of 
numerous ubiquitinated proteins in the TNF-RSC, recruitment of LUBAC is most likely 
facilitated by the NZF ubiquitin binding domains, present in each one of the three LUBAC 
components. Once recruited to the TNF-RSC, LUBAC was shown to attach linear poly-
ubiquitin chains to RIP1 and NEMO, which is required for NF-B activation (Gerlach et al, 
2011). Modification of RIP1 and NEMO with linear ubiquitin chains causes TNFR1 complex 
stabilisation as it serves as a binding platform for more NEMO molecules (and thus IKK 
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complexes) (Haas et al, 2009) which are specifically recruited to linear chains within the 
complex via their UBAN domain (Rahighi et al, 2009). This receptor stabilisation and the 
high number of IKK complexes attached to it might be necessary to ensure potent NF-B 
activation and efficient TNF-induced gene induction. Given the fact that the LUBAC target 
NEMO is a central component of NF-B signalling induced by various pro-inflammatory 
stimuli raises the question whether other signalling pathways also require LUBAC activity 
and linear ubiquitin chains to promote an efficient immune response. 
The role of LUBAC and linear ubiquitin chains in TNF-induced MAPK signalling has been 
studied in less detail and is currently still controversial, especially for JNK and ERK. 
Furthermore, its role in MAPK signalling triggered by other stimuli remains to be resolved. 
The identification of possible other LUBAC targets besides NEMO may contribute to the 
clarification of these aspects. 
1.6.1 Chronic proliferative dermatitis  
Mice carrying a homozygous loss of function mutation in the SHARPIN gene develop a 
severe, chronic, inflammatory skin disease termed chronic proliferative dermatitis (cpdm) 
beginning at about four to six weeks of age. A single base pair deletion in the 3’ end of exon 1 
encoding the coiled coil domain of SHARPIN, creates a frame shift in the open reading frame 
predicted to cause a pre-mature stop codon at position 624, resulting in the generation of a 
non-functional protein (Seymour et al, 2007). The strong macroscopic skin phenotype is 
characterised by epidermal hyperplasia, hyperkeratosis, and perakeratosis and is associated 
with infiltration of immune cells such as macrophages, mast cells and granulocytes, resulting 
in vascular dilatation (Gijbels et al, 1995; Gijbels et al, 1996). In addition, similar lesions have 
been observed in other epithelia of cpdm mice, including oesophagus and forestomach. 
Furthermore, inflammation is also present in lung, liver and several joints. Weight loss, 
formation of self-inflicted wounds and growth retardation are typical for this disease entity. A 
recent publication by Xia et al suggested a role for SHARPIN in bone metabolism, explaining 
the growth retardation observed in cpdm mice (Xia et al, 2010). 
Apart from inflammatory lesions, cpdm mice also exhibit developmental abnormalities 
regarding lymphoid architecture in so far as they are completely devoid of Peyer’s patches, 
lymph nodes and nasal-associated lymphoid tissue. Furthermore, they lack well-formed B cell 
follicles, germinal centres and follicular dendritic cells in secondary lymphoid organs 
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(HogenEsch et al, 1999). These defects in lymphoid tissue organisation causes impaired B cell 
development in cpdm mice which results in diminished numbers of serum immunoglobulins 
and a decreased production of antigen-specific antibodies of all isotypes upon antigenic 
challenge, indicating a function of SHARPIN in humoral immune responses. In addition, 
cpdm mice exhibit defects in TH1 cytokine production and show increased numbers of 
eosinophils which infiltrate the red and white pulp of the spleen causing splenomegaly.  
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1.7 Aims of the project 
Our group recently showed that the linear ubiquitin chain assembly complex (LUBAC) plays 
an important role in TNF-stimulated gene induction and that the absence of one of the 
LUBAC components and thus reduction of linear ubiquitination attenuates the activation of 
the transcription factor NF-B. By employing a novel highly sensitive modified tandem 
affinity purification (moTAP) method we were able to show that all three LUBAC 
components, HOIL-1, HOIP and SHARPIN form part of the native TNF-RSC and CD40-
RSC, respectively (Gerlach et al, 2011; Haas et al, 2009). Furthermore, ubiquitin-targeted 
mass spectrometric analysis of the native TNF-RSC revealed that RIP1 and NEMO are 
linearly ubiquitinated when forming part of this complex. 
Given these new findings with respect to LUBAC and its implication in TNF and CD40 
signalling, the aim of this thesis is to elucidate several aspects concerning the detailed role of 
LUBAC and intends to answer the following questions: 
1. Do signalling pathways stimulated by members of the IL-1 family or PAMPs require 
LUBAC for activation of canonical NF-B- and/or MAPK cascades? 
2. Does LUBAC play a role in non-canonical NF-B-signalling pathways? 
3. Both, SHARPIN and HOIL-1 do not contribute to the catalytic activity of LUBAC. 
Are they able to substitute for each other, or is there a difference between cells lacking 
SHARPIN and cells lacking HOIL-1? 
4. Does LUBAC form part of other receptor signalling complexes induced by pro-
inflammatory signals, and if so, are there other LUBAC targets apart from NEMO and 
RIP1? 
5. Is it possible to create a biochemical tool to specifically detect linear poly-ubiquitin 
chains? 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
All reagents used in this thesis were purchased from the following companies unless stated 
otherwise: Amersham Biosciences, AppliChem, Becton Dickinson, Gerba, Merck 
(Calbiochem), Invitrogen, Pierce, Roche, Roth and Sigma/Aldrich (Fluka). All chemicals were 
purchased in pA quality unless indicated otherwise. 
 
2.1.2 Specific inhibitors 
COMPLETE Protease Inhibitor Cocktail  Roche 
Phosphatase Inhibitor Cocktail   Sigma/Aldrich 
TNFR2-Fc (Enbrel)     Pfizer 
 
2.1.3 Buffers and solutions 
Bacteria lysis buffer     1 x PBS 
       70 μM serine protease inhibitor AEBSF 
       5 μM E-64 
       1.2 μg/ml Aprotinin 
       1 μM Pepstatin 
       1 mM DTT 
 
Blocking Buffer     5 % milk powder 
       0.05 % Tween-20 in PBS 
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Carbonate Coating Buffer (pH = 9.5)  8.4 g NaHCO3 
       3.56 g Na2CO3   
 
Citrate Buffer      0.025 M citric acid (pH = 4.5) 
 
Coomassie staining solution    2.5g Coomassie Brilliant Blue R-250 
       450 ml methanol 
       100 ml acetic acid  
       ad 1L with H2O 
 
ELISA Assay Buffer     0.5 % BSA 
       0.05 % Tween-20 in PBS  
 
ELISA Substrate Solution    10 ml Citrat Buffer 
 10 µl H2O2 
       10 mg OPD  
 
Freezing medium (for cells)    90 % FCS (v/v) 
       10 % DMSO (v/v) 
 
HBS (2x, pH = 7.0)     50 mM HEPES 
       280 mM NaCl 
       1.5 mM Na2HPO4 x 2 H2O 
 
IP-lysis Buffer 1/2     30 mM Tris-Base (pH 7.4) 
       120 mM NaCl 
       2 mM EDTA 
       2 mM KCl 
       10 % Glycerol (v/v) 
       1 % Triton X-100 (v/v) (IP-LB1) 
       or 1% NP-40 (v/v) (IP-LB2)  
       COMPLETE protease-inhibitor cocktail  
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IP-lysis Buffer 3     50 mM HEPES (pH 7.9) 
       25 mM NaCl 
       20 mM β-Glycerophosphate 
       5 mM Na2-4-Nitrophenylphosphate-6xH2O 
       1 mM Na2EDTA-2xH2O 
       10 % Glycerol (v/v) 
       0.5 % IGEPAL 
 
Macrophage medium     500 ml DMEM 
       5 ml Pen/Strep 
5 ml L-glutamine 
500 μl  mercaptoethanol 
40 ml  FCS 
40 ml   L929 supernatant (M-CSF)  
 
Maintenance Buffer     50 mM Trizma Base 
       100 mM NaCl 
       0.02 % Tween 20 (v/v) 
       2 mM DTT 
       0.5 M L-Arginin 
 
MOPS Running Buffer (pH = 7.7)   50 mM MOPS 
       50 mM Tris-Base 
       3.5 mM SDS 
       1.0 mM EDTA 
 
PBS (pH = 7.4)     137 mM NaCl 
       8.1 mM Na2HPO4 
       2.7 mM KCl 
       1.5 mM KH2PO4 
 
PBS/Tween      137 mM NaCl 
       8.1 mM Na2HPO4 
       2.7 mM KCl 
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       1.5 mM KH2PO4 
       0.05 % Tween-20 in PBS (v/v) 
 
Stripping Buffer (pH = 2.3)    50 mM Glycin in H2O  
 
TAE buffer (10x)     400 mM Tris/HCl 
       200 mM Acetic Acid 
       10 mM EDTA 
 
TB buffer      10 mM Pipes 
       55 mM MnCl2 
       15 mM CaCl2 
       250 mM KCl 
  
Transfer Buffer     192 mM Glycin 
       25 mM Tris-Base 
       0.01 % EDTA 
       20% Methanol (v/v) 
 
Wash Buffer      0.05% Tween-20 in PBS (1x) 
 
 
 
2.1.4 Biological agents  
 
Table 2.1: Commercial biological agents 
Agent Source 
murine IFN-γ Invivogen 
human IL-1β Enzo Life Sciences 
murine M-CSF R&D Systems 
L18-MDP Invivogen 
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2.1.5 Antibodies 
Table 2.2: Unconjugated primary antibodies (WB: Western blotting; IP: immunoprecipitation) 
Antibody Isotype Source Application 
Actin (A5441) mIgG1 Sigma WB 
cIAP1/2 Pan (MAB3400) mIgG2a R&D Systems WB 
FLAG (M2) mIgG1 Sigma WB, IP 
GST goat Cell Signaling WB, IP 
HA (3F10) mIgG1 Roche Applied Science WB 
His (BMG-His-1) mIgG1 Roche Applied Science WB 
HOIL-1 mIgG2a Walczak lab WB 
HOIP rabbit Eurogentec WB,IP 
IL-1RI rabbit Abcam WB 
IRAK1 (F-4) mIgG1 Santa Cruz WB 
IRAK4 rabbit Gift by M.U.Martin WB 
IB (44D4) rabbit Cell signalling WB 
JNK (56G8) rabbit Cell Signalling WB 
Myc (9E10) mIgG1 Abcam WB 
pIkBα (5A5) mIgG1 Cell Signaling WB 
pJNK (98F2) rabbit Cell Signalling WB 
p38 (7D6) rabbit Cell signalling WB 
p65 (A) rabbit Santa Cruz WB 
p100/p52 (4882) rabbit Cell signalling WB 
pp38 (3D7) rabbit Cell signalling WB 
RIP1 (#610459) mIgG2a BD WB 
SHARPIN rabbit Gift by I. Dikic WB 
TNFR1 (ab19139) rabbit Abcam WB 
Ubiquitin (FK1) mIgM Biomol WB 
Ubiquitin (FK2) mIgG1 Biomol WB 
Ubiquitin (#07-375) rabbit Millipore WB 
Ubiquitin (HWA4C4) 
(K63-linkage-specific) mIgG2a Biomol WB 
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Antibody Isotype Source Application 
Ubiquitin (D9D5) 
(K48-linkage-specific) rabbit Cell signaling WB 
V5 (V5-10) mIgG1 Sigma WB 
 
Table 2.3: Conjugated antibodies 
Antibody Source Application 
Goat-anti-mIgG1-HRP Southern Biotech WB 
Goat-anti-mIgG2a-HRP Southern Biotech WB 
Goat-anti-mIgM-HRP Southern Biotech WB 
Goat-anti-rabbit-IgG-HRP Southern Biotech WB 
 
Table 2.4: Bacteria strains 
Strain Application 
Top10F’ plasmid amplification 
BL21 expression of GST fusion proteins 
AVB 101 moTAP-IL1β production 
 
Table 2.4: Oligonucleotides 
Name Sequence (5’-3’) 
UBAN_1_fwd_BamHI atat ggatcc gag gcc gag cag cac aag 
UBAN_1_rev_linker tag ttc ctg ctt ttc ttc gac atg ccg ctt cct cat g 
UBAN_2_fwd_linker gaa gaa aag cag gaa cta cac aag att gtg atg gag 
UBAN_2_rev_NotI atat gcggccgc ctg gga gac ctc gac atg 
TAB2_1_fwd_BamHI atat ggatcc gac aca gaa gat gat gag 
TAB2_1_rev_linker tag ttc ctg ctt ttc ttc gaa atg cct tgg cat ctc 
TAB2_2_fwd_linker gaa gaa aag cag gaa cta gat gag gga gct cag tgg 
TAB2_2_rev_NotI atat gcggccgc cca ttt ggc tca gaa atg 
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2.1.6 Cell culture media and additives 
Dulbecco’s Modified Eagle Medium Invitrogen, Karlsruhe; Germany 
Dulbecco’s PBS    Invitrogen, Karlsruhe; Germany 
RPMI 1640     Invitrogen, Karlsruhe; Germany  
Opti-MEM® Reduced Serum Medium Invitrogen, Karlsruhe; Germany 
Keratinocyte Serum Free Media (KSFM) Invitrogen, Karlsruhe; Germany  
Ampicillin     Roth, Karlsruhe; Germany 
Penicillin/Streptomycin (Pen/Strep)  Invitrogen, Auckland; New Zealand 
Gentamycine     Cambrex Bio Whittaker, Verviers; Belgium 
Hygromycin B    Boehringer Mannheim, Mannheim; Germany 
G418 (Geneticin®)    Invitrogen, Karlsruhe; Germany 
Zeocin      Invitrogen, Karlsruhe; Germany 
Sodium Pyruvate    Invitrogen, Karlsruhe; Germany 
Hypoxanthine Thymidine (HAT)  Invitrogen, Karlsruhe; Germany 
Trypsin/EDTA solution   Invitrogen, Karlsruhe; Germany 
β-mercaptoethanol    Invitrogen, Karlsruhe; Germany 
 
2.1.7 Beads for protein precipitation 
FLAG M2 affinity Gel   Sigma-Aldrich, Munich; Germany  
Glutathione sepharose   GE Healthcare, Munich; Germany 
Protein G Sepharose    GE Healthcare, Munich; Germany 
 
2.1.8 Kits and Ready-to-Use Solutions 
BCA Protein assay    Perkin Elmer, Wellesley; United States 
ECL Western Blotting Detection  GE Healthcare 
ECL Western Blotting Detection Plus GE Healthcare 
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Chemoluminescent Substrate   Pierce 
SuperSignal West Dura 
Chemoluminescent Substrate   Pierce 
SuperSignal West Femto 
IL-6 ELISA      eBioscience, Frankfurt; Germany 
IL-8 ELISA     Biolegend 
Perhydrol® 30 % H2O2   Merck, Darmstadt; Germany 
QIAprep Maxi Kit    Qiagen, Hilden; Germany 
QIAprep Spin Mini Kit   Qiagen, Hilden; Germany 
QIAquick Gel Extraction Kit   Qiagen, Hilden; Germany 
TrypanBlue     Serva, Heidelberg; Germany 
 
2.1.9 Additional material 
Cell Culture Petri dishes   TPP, Trasadingen; Switzerland 
Cell Culture Test Plates (6-, 12-, 24-well) TPP, Trasadingen; Switzerland  
Cell Sieve (70 µm pore size)   Becton Dickinson, Heidelberg; Germany  
Cryogenic vials    Nunc, Wiesbaden; Germany  
Cuvette     Greiner Bio-One, Flacht; Germany  
Dialysis membrane    KMF; Germany 
F96 MaxiSorp Plates for ELISA  Nunc, Wiesbaden; Germany 
Conical tubes (15 ml and 50 ml)  TPP, Trasadingen; Switzerland  
Glassware     Schott, Mainz; Germany  
GSTrap FF     Amersham Pharmacia 
HisTrap     Amersham Pharmacia 
Hybond ECL Nitrocellulose Membrane Amersham Bioscience, Buckinghamshire; UK 
NuPAGE® 4-12% Bis-Tris Gels  Invitrogen, Karlsruhe; Germany  
PCR Tubes     StarLab, Ahrensburg; Germany 
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Pipette tips (0.1-10, 1-200, 101-1000 µl) StarLab, Ahrensburg, Germany 
Plastic pipettes (5 ml, 10 ml and 15 ml) Becton Dickinson, Heidelberg; Germany 
Polypropylene round bottom tube (5 ml) Becton Dickinson, Heidelberg; Germany 
Round and flat bottom 96-well test plates TPP, Trasadingen; Switzerland  
Safe-Lock Reaction Tubes (1,5ml, 2 ml) Eppendorf, Hamburg; Germany 
SeeBlueTM Plus2 Pre-Stained Standards Invitrogen 
SDS-Sample buffer    Invitrogen 
Single-Use Syringe (5 ml, 30 ml, 50 ml) Terumo, Eschborn; Germany 
Single-Use Syringe (1 ml, 2 ml)  Becton Dickinson, Heidelberg; Germany 
Single-Use Scalpel    Feather, Osaka; Japan 
Single-Use Needles    Becton Dickinson, Heidelberg; Germany  
SmartLadder DNA Standards  Eurogentec 
Sterile filter (0.22 µm and    Millipore, Billerica; United States 
0.45 µm pore size)   
Tissue Culture flasks (25, 75, 150 cm2) TPP, Trasadingen; Switzerland  
Ubiquitin chains of different lengths  
and linkages     Enzo Life Sciences   
Vivaspin Concentrator MWCO 10000 Sartorius, Goettingen; Germany 
Whatman paper    Schleicher&Schuell, Maidstone; United Kingdom 
X-Ray film HyperfilmTM ECL  Amersham, Freiburg; Germany 
 
2.1.10 Instruments 
Multiskan Ascent    Thermo Labsystems, Vantaa; Finnland 
Hyper Processor X-Ray film Developer Amersham Bioscience, Buckinghamshire; UK 
Blotting equipment X cell IITM  Novex, Bergisch Gladbach; Germany 
NanoDrop Spectrophotometer ND-1000 NanoDrop Technologies, Wilmington; USA 
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Photometer Ultrospec 3100 pro  Amersham, Freiburg; Germany  
Steri-Cult Cell culture bench   HERA Safe, Berlin; Germany 
Incubator Stericult 2000   Forma Scientific, Scotia; United States 
Millipore Super-Q water installation  Millipore, Billerica; United States 
Ice machine     Scotsman, Vernon Hills; United States 
Microwave     AEG, Nuremberg; Germany 
Table Centrifuge Biofuge   Heraeus, Hanau, Germany 
Varifuge 3O-R    Heraeus, Hanau, Germany 
Multifuge 3S-R    Heraeus, Hanau, Germany 
Biofuge Stratos    Heraeus, Hanau, Germany 
Gene Amplification PCR system 9700 Applied Bioscience, Mumbai; India 
Power Supply for agarose gels  BioRad, Hercules; United States 
Light Microscope    Zeiss, Oberkochen; Germany 
Vortex      Heidolph, Schwabach; Germany 
Cryo 1°C Freezing container   Nalgene Labware, Neerijse; Belgium 
pH Meter     Mettler, Giessen; Germany 
Thermomixer compact   Eppendorf, Hamburg; Germany 
Freezer -20° C    Liebherr, Biberach; Germany 
Freezer -80° C    Forma Scientific, Marietta; United States 
GelSystem Flexi 4040   Biostep, Jahnsdorf; Germany  
Digital Camera    Olympus, Hamburg; Germany 
Pipettes (10 µl, 100 µl, 200 µl, 1 ml) Gilson, Bad Camber; Germany 
Pipetboy     Integra Bioscience, Fernwald; Germany 
Multichannel pipettes    Micronic Systems, McMurray; United States 
2.1.11 Software 
Vector NTI     Invitrogen, Karlsruhe; Germany 
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Microsoft® Excel 2003   Microsoft, Redmont; United States 
Microsoft® Powerpoint 2003   Microsoft, Redmont; United States 
Microsoft® Word 2003   Microsoft, Redmont; United States 
Sequencing     Imperial College London, London, UK 
ND1000 V3.3.0    NanoDrop Technology; Wilmington; USA  
Ascent Software Version 2.6   Thermo Labsystems, Vantaa; Finnland  
 
2.2 Methods of Cell Biology 
2.2.1 Cell lines 
2.2.1.1 EL-4 cells 
EL-4 cells were generated from a carcinogen-induced murine thymoma. EL-4 cells are 
suspension cells which express high levels of type I IL-1R and are therefore IL-1-responsive.  
These cells were kindly provided by M.U. Martin (University of Giessen, Germany). 
2.2.1.2 D6/76 cells 
D6/76 cells are a subline of the IL-1 responder EL-4. D6/76 cells lack IL-1RAcP-expression 
and are therefore non-responsive towards IL-1. These cells were kindly provided by M.U. 
Martin (University of Giessen, Germany). 
2.2.1.3 HEK293T cells 
HEK293T cells were generated by transformation of human embryonic kidney (HEK) cell 
cultures with sheared adenovirus 5 DNA (Graham et al, 1977). HEK293T cells are adherent 
cells which are highly transfectable due to expression of the SV40 large T-antigen, and they 
support the extra chromosomal replication of plasmids bearing the SV40 origin of replication. 
2.2.1.4 HEK293RI cells 
HEK293RI cells were kindly provided by M.U. Martin (University of Giessen, Germany). 
These human embryonic kidney cells stably overexpress the type I IL-1R and are therefore 
highly responsive towards IL-1 stimulation. 
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2.2.1.5 HeLa cells 
The HeLa cell line originated from an adenocarcinoma of the cervix in 1952. It is the first 
human epithelial cancer cell line established in long-term cell culture (Scherer et al, 1953). 
HeLa cells have a hypertriploid chromosome number (3n+), 20 clonally abnormal 
chromosomes and contain multiple copies of HPV type 18 (HPV18), integrated at specific sites 
(Chen, 1988; Popescu et al, 1987). 
2.2.1.6 L929 
L929 cells were originately generated from mouse connective tissue in 1948 . The parental L 
strain was one of the first cell strains to be established in continuous culture, and clone 929 was 
the first cloned strain developed. (Sanford et al, 1948). L929 cells are adherent cells which 
produce murine M-CSF. Thus, macrophage medium can be complemented with 10% L929 
supernatant as a source of murine M-CSF. 
2.2.1.7 Mouse Embryonic Fibroblasts (MEFs) 
MEFs were generated from E15 embryos in accordance with standard procedures and were 
infected with SV40 large T antigen-expressing lentivirus. For the generation of HOIL-1-
deficient MEFs, cells were additionally infected with Cre-expressing lentivirus and selected by 
addition of 2 µg/ml puromycin. 
2.2.1.8 U937 
The human hematopoetic cell line U937 was derived from a patient with generalised histiocytic 
lymphoma and was first described in 1976 by Sundstrom and Nilsson (Sundstrom & Nilsson, 
1976). 
2.2.2 Cell culturing conditions 
All adherent cell lines were cultured in a 10% CO2-humidified atmosphere at 37 °C. HEK293T, 
HeLa and MEF cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 5% foetal bovine serum. Cells were detached with a 1 x PBS/trypsin 
(Invitrogen) solution before they reached confluence. 
All suspension cell lines were maintained in RPMI supplemented with 10% FBS at 5% CO2 
(37 °C) at a density of ~ 1x106 cells/mL. Cell density was determined with a Neubauer 
chamber slide.  
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2.2.3 Freezing and thawing of eukaryotic cells 
For freezing, approximately 2.5 x 106 cells were re-suspended in FCS containing 10% DMSO, 
transferred to cryogenic vials and frozen down in an isopropanol containing box to -80° C. For 
long-term storage, cells were transferred to liquid nitrogen at -196 °C.  
Frozen cells were thawed in a water bath at 37 °C. To remove the DMSO, cells were spun 
down with a centrifuge and re-suspended in fresh medium.  
2.2.4 Generation of primary keratinocytes 
The skin of the tails from 10 day-old mice was incubated in keratinocyte serum free medium 
(KSFM) supplemented with bovine pituitary extract, epidermal growth factors (Invitrogen) and 
gentamicin (50 µg/mL) containing 2.1 U/mL dispase II (in 50 mM HEPES and 150 mM NaCl, 
pH 7.4) at 4 °C overnight. The following day, the epidermis was separated from the dermis and 
keratinocytes extracted from the epidermis using Tryp LE express Trypsin (Invitrogen) under 
constant agitation using a P1000 pipette at room temperature for 15 min. Subsequently, cells 
were centrifuged for 10 min, keratinocytes re-suspended in growth factor- supplemented KSFM 
and seeded on 12-well. Medium was changed the next day to remove cells that have not 
attached. On day five, keratinocytes were used for the respective experiment. 
2.2.5 Generation of primary bone marrow-derived macrophages 
Femurs of 6 week-old mice were extracted, soaked in 70% Ethanol for 1 minute and excessive 
tissue was removed from the femurs. Femurs were stored in RPMI on ice until bone marrow 
was extracted. Afterwards, head of the femur was snipped off and the other end of the femur 
was cut off with sterilised scissors. Subsequently, femurs were flushed using complete RPMI 
(10% FCS and Pen/Strep), a 2 ml syringe and a 26 5/8 gauge needle. BM was flushed into a 50 
ml conical tube. Bone marrow was dispersed and then strained through a 70 μm nylon cell 
strainer into a new conical 50 ml tube. Cells were counted, centrifuged and cell pellet was 
resuspended in macrophage medium. On day 6 cells were counted again and replated on 12-
well and 96-well plates, respectively. On day seven, BMDMs were used for the respective 
experiment.  
2.2.6 Transfection of adherent cells 
HeLa cells were transfected with FuGene 6 (Roche Applied Science) according to the 
manufacturer’s protocol. 
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HEK293T cells were transfected by the calcium phosphate method. Optimal density is 4 x 106 
cells per 10 cm dish, plated the day before transfection. For transfection of a 10 cm dish, 20 µg 
plasmid DNA and 50 µl CaCl2 (2M) were added to 450 µl H2O. Subsequently, the DNA/CaCl2 
solution was gently mixed with 500 µL 2xHBS. Following 30 min incubation at room 
temperature, the transfection mixture was gently added drop-wise to the cell medium.  
For production of recombinant proteins secreted into the cell culture supernatant, the 
supernatant was harvested 48 hrs and 96 hrs post-transfection.  
2.2.7 Lentiviral infection of eukaryotic cells 
2.2.7.1  Production of recombinant viruses 
HEK293T cells were used for the production of recombinant, lentiviral particles using the 
calcium phosphate method (see chapter 2.2.6). The transfection mixture containing 28 μg of the 
packaging vector pCMV-dR8.91 (HIV_Gag, HIV_Rev), 12 μg of the envelope pMD2G 
(VSVG) and 40 μg of the shRNA plasmid (pLKO.1) to be packed was added drop wise to the 
cells. Following 48 and 96 hrs incubation at 37° C, the lentivirus-containing cell supernatant 
was collected. 
Lentiviral particles were then used to generate cell lines in which the gene of interest was stably 
silenced. Briefly, target cells were spin-infected in the presence of 5 µg/mL polybrene (2000 x 
g, 4 hrs, RT) and infected cells selected with 2 µg/ml puromycin. Knockdown efficiency was 
controlled by western blotting. 
2.2.7.2 Generation of stable knockdown, knockout or overexpressing cells 
HOIL-1-specific shRNAs were obtained from the RNAi consortium (TRC). The sequence for 
stable knockdown of HOIL-1 was 5'-CCACAACACTCATCTGTCAAA-3´ 
(TRCN0000007599), RHS408 was used as control shRNA. To excise HOIL-1 from targeted 
HOIL-1 MEFs, cells were infected with Cre-expressing virus.  
The respective cDNA sequences of HOIL-1, SHARPIN and HOIP were cloned into the 
pCIGW vector in order to stably overexpress the respective proteins.  
2.2.8 siRNA-mediated knock-down 
Transient knock-down of target genes was achieved by siRNA obtained from ThermoScientific 
using Dharmafect as transfection agent. Briefly, per six-well, 1.5 µL Dharmafect were mixed 
with 200 µL FCS-free DMEM for 5 min at RT. Subsequently, 2.2 µL siRNA (20 µM) were 
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added and incubated for 20 min at RT. 1 x 105 cells were transfected with the transfection 
mixture. 
 
2.3 Methods of Molecular Biology 
2.3.1 DNA digestion and restriction analysis 
For the sequence-specific cleavage of DNA molecules samples were incubated with restriction 
endonucleases (Fermentas FastDigest®) for 1 hr at 37 °C.  
2.3.2 Agarose gel electrophoresis of nucleic acids 
Agarose gels in TAE buffer were used to analyse Plasmid DNA and DNA fragments. DNA was 
mixed with 1 x DNA loading buffer, loaded onto 1-2 % (w/v) agarose gels and ran at 130 V for 
40 min in 1 x TAE buffer. To determine the size of the loaded DNA fragments, a marker 
containing DNA fragments of defined molecular sizes (Smart Ladder) was also applied. DNA 
bands were visualised by incubation in a solution containing 0.5 µg/ml ethidium-bromide for 
15 min. UV light with a wavelength of λ = 254 nm enabled visualisation of DNA fragments. 
2.3.3 Gel extraction of DNA fragments 
Isolation of DNA fragments from agarose gels was achieved using the QIAquick Gel 
Extraction kit (Qiagen) according to manufacturer’s instructions. DNA was eluted in 30-50 µl 
water and used in further applications. 
2.3.4 Ligation of DNA fragments 
The optimal ratio for ligation between linearised vector and insert is in the range of 1:3 to 1:5. 
The concentrations of both components were estimated by intensity comparison of the bands in 
agarose gels. Appropriate volumes were mixed with ligase buffer, polyethylenglycol (PEG) and 
2 U T4-ligase (NEB) in a total volume of 20 µl. The reaction was carried over night at room 
temperature. 
2.3.5 Transformation of competent E. coli bacteria and Isolation of Plasmid DNA 
Competent bacteria E.coli TOP 10 F’ (Invitrogen) were thawed on ice and incubated with 1-10 
ng plasmid DNA or the ligation product for 30 min on ice. Heating at 42° C for 60 seconds and 
subsequent cooling on ice for 5 min permeabilised the bacterial membrane and allowed the 
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DNA to enter the cell. 250 µl SOC medium were added, the bacteria were shaken for 30 min at 
37 °C and then plated on LB agar plates containing the respective antibiotic to select for 
positive clones. The next day, single clones were picked, grown in 5 mL LB Amp medium for 
4-8 hrs at 37 °C and the plasmids isolated with the QIAprep Miniprep Kit (Qiagen).  
2.3.6 Polymerase Chain Reaction (PCR) 
All PCRs were done in a volume of 50 μl, containing 1-50 ng plasmid- or cDNA as template. 
The synthetic oligonucleotides were designed with 40-60% GC content, no internal structure or 
complementarities at the 3’-ends. Annealing temperatures were chosen ~5-10°C lower than the 
melting temperature Tm. A typical PCR reaction contained 200 µM dNTP, 2.5 U Polymerase, 1 
x Polymerase Buffer and 0.4 µM Primer.  
 
2.4 Methods of Biochemistry 
2.4.1 Determination of protein content 
To determine the protein concentration of cell lysates, the bicinchoninic acid (BCA)-containing 
protein assay was applied according to the manufacture’s instructions (Pierce). 1-5 μl of the 
lysate were incubated in 100 µl BCA solution at 60 °C for 15 min, followed by measuring light 
absorption at 560 nm in a Multiskan Ascent plate-reader (Thermo Labsystems). 
2.4.2 Precipitation of Receptor Signalling Complexes and HOIP-IRAK1 complexes 
Cells were stimulated with the respective ligand for different time periods. MoTAP-IL-1 
(3xFLAG-Precission-Avi tag; referred to as IL-1) and His-FLAG tagged TNF (HF-TNF, 
referred to as TNF) were used. TNF and IL-1 were produced in bacteria and subsequently 
purified based on standard procedures. Following stimulation, cells were washed twice with 
ice-cold PBS and lysed in 1 mL IP-lysis buffer/cell dish or 5x107 cells at 4 °C for 30 min. The 
detergent-insoluble fraction was then pelleted by centrifugation (13.000 rpm, 30 min) and the 
cell lysates were transferred to a new tube. Equal amounts of protein were subjected to 
precipitation with 10 µL antibody-coupled beads at 4 °C overnight. Briefly, for 
immunoprecipitations of IL-1- and TNF-RSCs anti-FLAG coupled M2 beads (Sigma-Aldrich) 
were used. For HOIP-precipitation, 1 µg HOIP- antibody was pre-coupled to 10 µL Protein G 
beads per sample for 4 hrs at RT. Beads were washed five times the next day in IP-lysis buffer. 
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Subsequently, beads were completely aspirated and dried, re-suspended in 20-40 µL reducing 
2 x SDS buffer and incubated at 75 °C for 10 min. 
2.4.3 Protein interaction studies 
For in-vivo interaction studies, 7.5 x 106 HEK293T cells were seeded on a 10 cm cell culture 
dish the day before tansfection. The next day, cells were transfected with 4-12 μg of the 
respective DNA plasmids by standard calcium phosphate transfection (see chapter 2.2.6). Cells 
were harvested 24 hrs post transfection and lysed in 1 ml IP-lysis buffer supplemented with 1% 
Triton X-100 for 30 min at 4 °C on a rotating wheel. Subsequently, lysates were centrifuged at 
13.000 rpm for 30 min at 4 °C. Immuno-precipitations with the respective antibody-coupled 
beads were performed at 4 °C overnight. Beads were washed five times with IP-lysis buffer and 
the proteins were eluted in 30 μl reducing 2 x SDS sample buffer. Precipitated proteins were 
analysed by western blotting.  
2.4.4 GST pull-down assay for precipitation of ubiquitin chains 
10 μg of purified GST-tagged protein were incubated with glutathione-sepharose resin in 
500 µl IP-lysis buffer at 4 °C for 6 hrs. Beads were washed five times with IP-lysis buffer and 
incubated at 4 °C overnight with 2 μg ubiquitin chains of different linkage and length in 1 ml 
IP-lysis buffer. Beads were washed five times with IP-lysis buffer the next day and binding of 
the respective ubiquitin chains types to the GST-tagged proteins analysed by western blotting. 
2.4.5 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Separation of proteins was performed based on the method by Laemmli (Laemmli, 1970) using 
4-12% Bis-Tris-NuPAGE gels from Invitrogen. Samples were mixed with 2x or 4x reducing 
SDS-Sample buffer and heated for 10 min at 75 °C. The SeeBlueTM Plus2 Pre-Stained marker 
(Novex) was used as a molecular weight standard. The electrophoretic separation was carried 
out at a constant voltage of 100 V for 10 min and subsequently 185 V for 55 min.  
2.4.6 Western blotting 
Western blotting was performed using the Invitrogen gel-system based on the method of 
Towbin (Towbin et al, 1979). Proteins from SDS-PA gels were transferred onto nitrocellulose 
membranes (Amersham Pharmacia), applying a maximum current of 160 mA (30 V) per gel for 
2 hrs. Afterwards, membranes were incubated for at least 15 min with blocking buffer at room 
temperature to occupy non-specific protein binding sites. Subsequently, membranes were 
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subjected to immune-probing with primary antibodies and secondary horseradish-peroxidase 
(HRP)-conjugated antibodies. Proteins were visualised using different ECL solutions (GE 
Healthcare/Pierce). 
2.4.7 Far western blotting 
Protein transfer for far western blotting was performed as described for western blotting (2.4.6). 
Subsequently, membranes were incubated with blocking buffer to occupy non-specific protein 
binding sites. Afterwards, membranes were incubated with GST-1/2xUBAN and -1/2xNZF, 
anti-GST-antibody and secondary horseradish-peroxidase (HRP)-conjugated antibodies. 
Proteins were visualised using different ECL solutions (GE Healthcare/Pierce). 
2.4.8 Stripping of western blot membranes 
If nitrocellulose membranes had to be incubated with alternative antibodies, bound 
immunoglobulins were removed by incubating the nitrocellulose membranes with Stripping 
buffer at RT for 15 min. The acidic pH of the stripping solution (pH 2.4) leads to denaturation 
of the bound antibodies. Subsequently, membranes were washed three times with PBS/Tween, 
followed by incubation with blocking buffer and immuno-probing as described in 2.4.6. 
2.4.9 Enzyme-Linked Immuno Sorbent Assay (ELISA) 
Cells were stimulated for 24 hrs with the respective ligands and cell supernatant was collected 
afterwards. ELISA reactions were performed according to the manufacturer’s protocol. Briefly, 
96-well MaxiSorp plates were coated with 50 μl/well anti-IL-6 or anti-IL-8 antibodies diluted 
in coating buffer and stored at 4 °C overnight. Plates were washed five times with PBS/Tween 
and blocked with 200 μl/well Assay buffer at RT for 1 hr. Plates were washed again and 
standard and supernatants were applied at RT for 2 hrs. Any IL-6 present bound to the 
immobilised antibody. The plates were washed seven times, the detection antibody was applied 
at RT for 1 hr with 50 μl/well. Subsequently, plates were washed again and incubated with 
Streptavidin-HRP solution for 30 min at RT. The wells were again washed and TMB substrate 
solution was added, which produced a blue colour in direct proportion to the amount of IL-6 
present in the initial supernatants. The reaction was stopped with 50 µl 2 N H2SO4 which 
changed the colour from blue to yellow, and the microwell absorbance was read at 450 nm with 
a Multiskan Ascent plate-reader (Thermo Labsystems). 
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2.5 Animal work 
2.5.1 Chronic proliferative dermatitis mice 
The cpdm spontaneous mutation arose in a colony of C57BL/KaLawRij mice in the specific 
pathogen-free-breeding facility of TNO Rijswijk, Netherlands. Cpdm mice were obtained from 
Jackson Laboratory and kept under conventional conditions. The spontaneous mutation of the 
SHARPIN gene is characterised by chronic proliferative dermatitis (cpdm) and was initially 
described by HogenEsch et al. (HogenEsch et al, 1993). SHARPIN deficient cpdm mice of 
both sexes were equally affected. Female cpdm mice do not breed and males become infertile 
with 6-8 weeks of age, thus heterozygous males and females were mated and mutant mice born 
with Mendalian ratio. 
2.5.2 Conditional HOIL-1 mice 
Conditional HOIL-1 knockout mice were generated at the Walter and Eliza Hall Institute 
(WEHI) in Melbourne, Australia. These mice contain a targeted cassette in which exon 1 and 
exon 2 of HOIL-1 are flanked by loxP sites. Hence, HOIL-1 can be excised by crossing these 
mice to tissue-specific Cre-expressing animals (Figure 10). Alternatively, cells isolated from 
conditional HOIL-1 mice can be infected with Cre-expressing lentivirus to generate Hoil-1-/- 
cells. 
 
Figure 10: Schematic representation of the targeted allele used to generate conditional Hoil-1-/- mice. 
 
2.5.3 Enbrel administration 
Ten day old, lesion free cpdm mice were injected twice a week with 125 µg Enbrel 
(Etanercept; Pfizer) in 100 µl saline solution and monitored for skin lesion development. If 
lesions were too severe, mice were culled according to standard procedures. This experiment 
was conducted together with Stefanie Cordier. 
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3. Results  
3.1 Functional analysis of LUBAC’s role in IL-1 signalling 
3.1.1 Stable knockdown of HOIL-1 attenuates IL-1-induced NF-B activation and 
phosphorylation of JNK 
We recently reported on the identification of HOIL-1 and HOIP as novel components of the 
native TNF-RSC. HOIL-1 and HOIP form an E3 ligase complex termed LUBAC whose 
activity is required for proper TNF-induced NF-B and JNK activation and we further showed 
that knockdown of either HOIL-1 or HOIP results in impaired TNF-mediated gene induction 
(Haas et al, 2009). In addition, we identified SHARPIN as a third component of LUBAC and 
showed that all three LUBAC components are recruited to the CD40- and TNF-RSCs (Gerlach 
et al, 2011).  
Activation of MAPKs and NF-B are crucial events in a large variety of immune signalling 
cascades which differ in upstream receptor-specific signalling proteins yet at the same time all 
share a number of downstream signalling components to ensure gene induction. We were able 
to show that one such downstream signalling component namely NEMO is a LUBAC target 
and suggest that absence of linear chains on NEMO and other LUBAC targets has a negative 
effect on TNF-induced NF-B activation (Gerlach et al, 2011). NEMO is a signalling 
component employed by a large number of pro-inflammatory signalling cascades including the 
IL-1 pathway. Stable knockdown of the LUBAC component HOIL-1 in the human cell line 
HEK293RI showed strong attenuation of IL-1-stimulated NF-B and JNK activation as 
assessed by reduced levels of phosphorylated IB, JNK1 and JNK2, respectively (Figure 11). 
A less prominent yet detectable difference could also be observed for phosphorylated p38, 
which was attenuated in HOIL-1 knockdown cells as compared to control cells (Figure 11a). 
This pronounced difference observed on the western blot level was confirmed by IL-8 ELISA 
analyses which showed that IL-8 production and, hence, IL-1-mediated gene induction were 
almost completely abrogated in HEK293RI cells in which HOIL-1 was knocked down 
compared to cells which were stably transfected with an empty control vector (Figure 11b). 
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Figure 11: Stable knockdown of HOIL-1 attenuates IL-1-induced NF-B and MAPK signalling. a) HEK 
293RI cells stably expressing a vector encoding a HOIL-1-specific shRNA sequence were stimulated with 50 
ng/ml IL-1 and signalling responses analysed with the indicated antibodies. Non-targeting shRNA were used as 
control. b) HOIL-1 and control silenced HEK 293RI cells were stimulated with 10 ng/ml IL-1 for 24 hrs and 
supernatants were analysed by IL-8-specific ELISA. n=2 ± STDEV. 
 
 
3.1.2 Overexpression of LUBAC components enhances IL-1-induced NF-B and 
MAPK signalling  
HeLa cells like HEK293RI cells are not only responsive to TNF but also to IL-1 (Figure 12a). 
Overexpression of LUBAC in HeLa cells and other cell lines was shown to enhance activation 
of NF-B upon TNF stimulation (Haas et al, 2009) supporting LUBACs implication in TNF-
signalling. HeLa cells overexpressing LUBAC combinations of either SHARPIN and HOIP or 
HOIL-1 and HOIP show the same activatory effect upon IL-1 stimulation as described for 
TNF. Overexpression of both LUBAC combinations results in enhanced phosphorylation of 
IB and strikingly higher amounts of phosphorylated JNK (Figure 12b). The effect of 
LUBAC overexpression on IL-1-induced JNK activation is even stronger than on NF-B 
activation and implies a prominent role of LUBAC in both MAPK and IKK cascades triggered 
by IL-1 stimulation. 
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Figure 12: LUBAC overexpression enhances IL-1-induced NF-B and MAPK signalling in HeLa cells. a) 
HeLa cells were tested for IL-1 responsiveness and were stimulated with 100 ng/ml IL-1 and 50 ng/ml TNF, 
respectively. b) HeLa cells or HeLa cells stably overexpressing SHARPIN together with HOIP or HOIL-1 
together with HOIP were stimulated with 100 ng/ml IL-1 and signalling responses were analysed with indicated 
antibodies. 
 
3.1.3 SHARPIN deficiency in cpdm MEFs gives contradictory results for IL-1 
signalling, yet primary cells reveal LUBAC contribution to IL-1-induced NF-B 
and JNK activation 
To analyse LUBAC’s role in IL-1-induced signalling under knockout conditions, embryonic 
fibroblasts from chronic proliferative dermatitis (cpdm) mice were isolated and immortalised. 
These mice carry a spontaneous single base pair deletion in the SHARPIN gene on both alleles, 
which leads to the expression of non-functional SHARPIN (see chapter 1.6.1.). The 
macroscopically most prominent phenotypic features observed in cpdm mice include the 
development of inflammatory skin lesions (Figure 13a) and an approximately three-to-four-fold 
increase in spleen weight starting at four to six weeks after birth (Figure 13b and c).  
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Figure 13: SHARPIN-deficient cpdm mice. a) SHARPIN deletion results in the development of severe skin 
lesions and retarded growth. A representative photograph of 6-week-old cpdm and wild-type (wt) mice is shown. 
b) SHARPIN deletion results in splenomegaly. A representative image of spleens from cpdm and wt mice and c) 
the respective spleen weights are depicted (n=4). 
 
Heterozygous cpdm mice harbour the mutation in the SHARPIN gene on only one allele and 
are able to express sufficient amounts of functional SHARPIN proteins. Thus, they do not show 
any signs of physiological disorder or impaired cell signalling and resemble wild-type mice in 
every respect. IL-1 stimulation of heterozygous and homozygous cpdm MEFs which have been 
passaged only two to three times after isolation (thus referred to as short-term cultured 
(ST)-cpdm MEFs) and immortalisation via large T antigen expression, shows that absence of 
functional SHARPIN has a strong negative impact on phosphorylation of IB and, 
consequently also its degradation, two characteristic hallmarks of NF-κB activation (Figure 
14).  
Figure 14: NF-kB activation is strongly 
impaired in ST-cpdm MEFs.   
ST-MEFs from heterozygous and 
homozygous cpdm mice were stimulated 
with 50 ng/ml IL-1 and lysates were 
subjected to western blotting using the 
indicated antibodies. 
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This experiment was performed with two independently generated MEF cell lines and both 
resulted in the same outcome, underscoring the reproducibility of these results. Yet, cpdm 
MEFs cultured for a longer period of time and passaged for more than five times (>p5) after 
immortalisation (thus referred to as long-term cultured (LT)-cpdm MEFs) seem to compensate 
for absence of SHARPIN and showed no differences in either phosphorylation of IBor in its 
degradation (Figure 15a). Also levels of phosphorylated JNK in these LT-cpdm MEFs seemed 
to be similar to those detected in MEFs derived from wild-type mice challenging the hypothesis 
that LUBAC might be involved in IL-1-induced MAPK signalling. This result is in contrast to 
the observation that LUBAC absence or overexpression influences IL-1 signalling in 
HEK293RI and HeLa cells (Figures 11 and 12). Furthermore, IL-1-induced phosphorylation of 
ERK even seemed to be strongly elevated in LT-cpdm MEFs as compared to pERK levels 
detected in wild-type MEFs (Figure 15a). To examine whether the effect observed on the 
protein level via western blot is reflected on the level of gene induction, these cells were used 
in an ELISA testing their capacity for IL-6 production. The results obtained by western blotting 
and IL-6 ELISA corresponded to each other; IL-6 levels were nearly identical in LT-cpdm 
MEFs and wild-type MEFs (Figure 15b).  
 
 
 
Figure 15: cpdm MEFs cultured for a longer period of time exhibit stronger NF-B and MAPK activation.  
Large T antigen transformed wild-type (wt) and cpdm-derived MEFs passaged for more than five times (>p5) were 
stimulated with a) 50 ng/ml IL-1 for different times and lysates were subjected to immunoblotting with the 
indicated antibodies. b) The cells were incubated in the presence or absence of 10 ng/ml IL-1 for 24 hrs and 
subsequent IL-6 ELISA was performed from the cells’supernatant. n=3± STDEV. 
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To exclude the possibility that these contradictory observations were due to cell line-specific 
artefacts, the IL-1 stimulation kinetic was repeated in two other independently generated MEF 
cell lines (termed LT-cpdm2 and LT-cpdm3) which were again passaged for more than five 
times post immortalisation (Figure 16a).  
 
 
 
Figure 16: Different cpdm cell lines give contrary results regarding IL-1- and TNF-stimulated NF-B and 
MAPK signalling. a) MEFs derived from wt and cpdm mice were stimulated with 50 ng/ml IL-1 and signalling 
responses were analysed with the indicated antibodies. b) Signalling responses of wt and cpdm2 MEFs towards 50 
ng/ml IL-1 and TNF were compared by immunoblotting with the indicated antibodies. 
 
 
Interestingly, both LT-cpdm MEF cell lines did not give the same result. While LT-cpdm2 
MEFs basically supported the first hypothesis that SHARPIN absence attenuates IL-1-induced 
NF-κB activation assessed by reduced levels of phosphorylated IκB, LT-cpdm3 MEFs 
showed the exact opposite, hence elevated levels of phosphorylated IκB compared to wild-
type MEFs. However, the strong negative-regulatory effect on IL-1-induced JNK 
phosphorylation observed in HEK293RI cells deficient for HOIL-1 did not apply to either of 
the two LT-cpdm MEF lines used in this experiment. Levels of phosphorylated JNK seemed to 
be the same in all three different MEF lines stimulated with IL-1. In contrast, phosphorylation 
of p38 reflected the observations made for IL-1-induced NF-κB activation in this experiment. 
LT-cpdm2 MEFs, which already showed impaired IκBphosphorylation upon IL-1 
stimulation, also exposed a strong effect on MAPK p38. Phosphorylation of p38 in this MEF 
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cell line was almost completely abolished, whereas LT-cpdm3 MEFs showed equal or even 
slightly elevated levels of p38 phosphorylation compared to levels detected in wild-type MEFs. 
Yet, levels of phosphorylated ERK1 and ERK2 seemed to be slightly increased in both LT-
cpdm MEF lines compared to those detected for wild-type MEFs. Since both LT-cpdm MEF 
lines as well as the wild-type MEFs were cultured under equal conditions it was arguable 
whether the observations and conclusions made for cpdm MEFs were reliable as they did not 
seem to be reproducible once the cells were cultured for a longer period of time. To test 
whether this effect was IL-1-specific or whether other signalling pathways which were shown 
to be LUBAC-dependent such as TNF were also subjected to possible adaption to SHARPIN-
deficiency or immortalisation-induced changes, LT-cpdm3 MEFs and wild-type MEFs were 
stimulated with IL-1 and TNF in parallel and subsequently subjected to western blot analysis 
(Figure 16b). This experiment revealed that the attenuating effect of SHARPIN deficiency on 
TNF signalling was neither lost by immortalisation nor by the number of cell passages, at least 
not TNF-induced NF-κB activation as phosphorylation levels of IκB were significantly 
reduced in LT-cpdm3 MEFs compared to the levels detected in wild-type MEFs. In contrast, 
IL-1 stimulation in LT-cpdm3 MEFs induced increased IκBphosphorylation as it did in the 
previous experiment depicted in Figure 15a.  
Thus, it was necessary to determine the reason for the inconsistent IL-1-induced cellular 
responses obtained from cpdm MEFs. As mentioned above, immortalisation-induced cellular 
changes in combination with SHARPIN-deficiency could be responsible for the different 
signalling outcome. Yet, it is also conceivable that cpdm MEFs deficient for SHARPIN and 
cultured for a longer period of time adapt to the absence of one LUBAC component and could 
be capable of changing their cellular responses as observed in the different experiments. To 
address this question, expression of SHARPIN was transiently silenced in wild-type MEFs and 
their response to IL-1 stimulation was analysed. These wild-type MEFs as well as control 
silenced wild-type MEFs and non-silenced LT-cpdm MEFs were subsequently stimulated with 
IL-1 and subjected to western blot analysis (Figure 17). The result of this experiment revealed 
that silenced SHARPIN expression in immortalised wild-type MEFs resembles the results 
obtained with ST- cpdm MEFs (see Figure 14). As shown in Figure 17, transient knockdown of 
SHARPIN in wild-type MEFs attenuated IL-1-induced NF-κB activation due to impaired 
phosphorylation of IκB. By contrast, in LT-cpdm MEFs deficient for functional SHARPIN 
and cultured for a longer period of time this effect was lost or even reversed, as 
IκBphosphorylation was enhanced when compared to control-silenced wild-type MEFs.  
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However, the issue regarding SHARPIN’s influence in IL-1-induced MAPK signalling does 
not seem to be so clear as levels of IL-1-induced phosphorylation of JNK1 and JNK2 seemed to 
be similar in all three cell lines. Interestingly, the upper band of HOIL-1 was absent in cpdm 
MEFs and total levels of HOIL-1, i.e. upper and lower band, were significantly reduced in 
wild-type MEFs in which SHARPIN expression was silenced, which suggests that SHARPIN 
might be involved in stabilisation of LUBAC (Gerlach et al, 2011). 
To further rule out artefacts or cellular changes caused by either immortalisation of the cells or 
cell culture conditions and to clarify the role of SHARPIN in IL-1-induced JNK and NF-κB 
activation, primary keratinocytes from the tails of ten-day-old wild-type and cpdm mice, i.e. 
mice which have not yet developed any obvious skin lesions, were generated.  
Figure 17: SHARPIN knockdown in wt MEFs attenuates IL-1-induced NF-B activation but does not 
impair phosphorylation of JNK. SHARPIN expression was transiently silenced in wt MEFs. Non-targeting 
siRNA was used as control, cpdm MEFs were left untreated. All cells were stimulated with 50 ng/ml IL-1, lysates 
were subjected to western blotting and signalling responses were analysed using the indicated antibodies. 
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Figure 18: Primary keratinocytes derived from SHARPIN mice show attenuation of IL-1-induced NF-B 
and JNK1/2 activation. a) Primary keratinocytes were tested for their responsiveness towards IL-1 and were 
stimulated for 10 min using different concentrations of IL-1. b) primary keratinocytes from 10-day-old lesion free 
mice were stimulated with 100 ng/mL IL-1 and lysates were subjected to immunoblotting with the indicated 
antibodies. Asterisks indicate unspecific bands. 
 
A titration using IL-1 at different concentrations during a 10-minute stimulation revealed that 
100 ng/ml IL-1 resulted in robust phosphorylation of IκBin primary keratinocytes generated 
from wild-type mice (Figure 18a). This concentration of IL-1 was next used to stimulate 
primary wild-type and cpdm keratinocytes for different times. This experiment revealed that 
primary murine keratinocytes exhibit reduced IL-1-induced IκB phosphorylation and 
degradation as well as reduced phosphorylation of JNK1/2 in the absence of SHARPIN (Figure 
18b), confirming the results obtained from short-term cultured transformed MEF lines (see 
Figure 14). Interestingly, HOIL-1 levels were diminished in cpdm-derived keratinocytes, 
supporting a LUBAC-stabilising function of SHARPIN (Gerlach et al, 2011). This experiment 
was performed with primary keratinocytes from four individual mice, two cpdm and two wild-
type control mice and cells from each genotypic origin resulted in the same outcome, 
underscoring the reproducibility of this result. 
To analyse whether the negative effect on IL-1-induced MAPK and NF-κB signalling was 
restricted to SHARPIN-deficient cells generated form cpdm mice, fibroblasts from embryos in 
which exon 1 and exon 2 of the HOIL-1 gene were flanked by loxP sites were generated and 
analysed. Subsequent infection with a Cre-expressing virus led to efficient excision of HOIL-1 
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by recombination in the antibiotic-selected cells (Figure 19a). These cells will be referred to as 
Hoil-1-/- MEFs in the following paragraphs.  
 
 
 
Figure 19: IL-1-induced NF-B and MAPK activation is strongly impaired in HOIL-1-/- MEFs. a) MEFs of 
indicated genotypes were stimulated with 50 ng/ml IL-1 for the indicated times and lysates were subjected to 
western blot analysis using the indicated antibodies. All MEFs were large T antigen transformed and HOIL-1- 
deficient cells were generated by infection of MEFs obtained from conditionally floxed HOIL-1 embryos. b) 
MEFs were stimulated with 10 ng/ml IL-1 for 24 hrs and supernatants were subjected to IL-6-specific ELISA. 
n=3± STDEV. 
 
 
As shown in Figure 19a, similar to primary cells derived from cpdm mice, Hoil-1-/- fibroblasts 
presented significantly lower levels of phosphorylated IκB than wild-type MEFs, suggesting 
that HOIL-1 deficiency also abrogates IL-1-induced NF-κB activation. Furthermore, 
phosphorylation of p38 was impaired as compared to wild-type and LT-cpdm MEFs, yet 
phosphorylation levels of JNK1 and JNK2 seemed to be similar in all three types of MEFs. 
Interestingly, SHARPIN levels were strongly diminished in Hoil-1-/- fibroblasts. Furthermore, it 
seemed as if SHARPIN expression in Hoil-1-/- MEFs was reduced to a greater degree than 
reduction of HOIL-1 levels in SHARPIN-deficient LT-cpdm MEFs. The fact that 
IκBphosphorylation was hardly detectable in Hoil-1-/- MEFs and that degradation of 
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IκBwas delayed and less efficient when compared to wild-type and LT-cpdm MEFs, raised 
the question whether HOIL-1 could be more important for IL-1 signalling than SHARPIN. This 
hypothesis was supported by the results obtained from an IL-6 ELISA in which wild-type, 
cpdm and Hoil-1-/- MEFs were analysed for their capacity to produce IL-6 upon IL-1 
stimulation (Figure 19b). Although LT-cpdm MEFs also showed less IL-6 production 
compared to wild-type MEFs, the capacity of Hoil-1-/- MEFs to produce IL-6 in response to 
IL-1 was almost completely abrogated.  
In summary, these results revealed that LUBAC is involved in IL-1-induced NF-κB activation 
and that absence of either SHARPIN or HOIL-1 in MEFs which have been cultured for a short 
period of time impairs NF-κB activity and gene induction. Yet, attenuation of IL-1-induced 
MAPK signalling was only observed in primary cells and in HEK293RI cells in which HOIL-1 
was stably silenced. 
3.2 Functional analysis of potential LUBAC contribution to LPS-induced NF-κB 
activation and gene induction 
TLR and IL-1R family members share considerable homology in the cytoplasmic region and in 
the recruitment of downstream signalling molecules. For this reason the members of these 
receptor families are also referred to as the TLR/IL-1R (TIR)-superfamily. TLR4 is probably 
the most extensively studied TLR signalling cascade and regarding its downstream signalling 
molecules it is very similar to the IL-1 pathway. After LPS binding TLR4 dimerises and 
undergoes conformational changes which are required for the recruitment of the adaptor 
molecule MyD88 and further signalling proteins including IRAKs, TRAF6, TAK1 and TAB1/2 
which all also form part of the IL-1 signalling cascade (reviewed by Akira & Takeda, 2004). 
Since the data presented in chapter 3.1 provides strong evidence that LUBAC is involved in 
IL-1 signalling it therefore seemed likely that the TLR4 pathway might also require LUBAC 
activity for the induction of proper NF-κB activation and gene induction. 
3.2.1 Absence of SHARPIN and HOIL-1 has a negative regulatory effect on LPS-
induced NF-κB activation and gene induction 
To investigate a possible implication of LUBAC in TLR4 signalling, wild-type, cpdm and 
Hoil-1-/- MEFs were stimulated with 50 ng/ml LPS for different times. Following stimulation 
and cell lysis, lysates were subjected to western blot analysis to test for NF-κB and MAPK 
activation (Figure 20a). LPS stimulation in LT-cpdm MEFs led to slightly higher levels of 
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IκBphosphorylation and similar levels of IκBdegradation as compared to levels detected in 
wild-type MEFs. Phosphorylation of JNK1 and JNK2 also seemed to be elevated in LT-cpdm 
MEFs, whereas LPS-induced phosphorylation of the NF-κB subunit p65, an important event 
for transcription initiation, seemed to be equal if not slightly diminished in LT-cpdm MEFs as 
compared to wild-type control cells. However, HOIL-1 deficiency seems to have a profound 
negative impact on LPS signalling. Levels of IκBphosphorylation and degradation in Hoil-1-/- 
MEFs were strongly diminished upon LPS stimulation as well as phosphorylation of p65, 
suggesting an important role for HOIL-1-mediated LUBAC activity in TLR4 signalling.  
 
 
Yet, levels of phosphorylated JNK1 and JNK2 in Hoil-1-/- MEFs were not attenuated when 
compared to wt MEFs, which raises the question whether LUBAC might be important for LPS-
induced NF-κB activation but dispensable or less crucial for MAPK activation by LPS. 
Following stimulation with 10 ng/ml LPS for 24 hrs the IL-6 production by these cells was 
determined (Figure 20b).  This analysis led to similar conclusions as the results obtained by 
western blotting; IL-6 production in LT-cpdm MEFs was similar to wild-type cells upon LPS 
stimulation whereas production of IL-6 was almost abrogated in Hoil-1-/- MEFs, underscoring 
Figure 20: HOIL-1 deficiency has a strong negative impact on LPS-induced NF-B and JNK activation. a)
MEFs of indicated genotypes were stimulated with 50 ng/ml LPS, lysates were subjected to immunoblotting and
incubated with the indicated antibodies. b) In addition, these cells were stimulated with 10 ng/ml LPS and
supernatants were analysed via IL-6-specific ELISA. n=3 ± STDEV. 
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the importance of HOIL-1 for LPS-induced gene induction. To rule out that the difference 
between cpdm and Hoil-1-/- MEFs was due to different numbers of cell passages as already 
observed for IL-1 signalling, wild-type and ST-cpdm MEFs (passage 3) were used and 
stimulated with 50 ng/ml LPS for different times. SHARPIN was shown to be crucial for 
proper TNF-induced NF-κB and JNK signalling as well as for gene induction (Gerlach et al, 
2011). The same wild-type and ST-cpdm MEFs used for LPS stimulation were therefore 
stimulated with 50 ng/ml TNF in parallel as a “positive control”. All lysates were subsequently 
subjected to western blot analysis and the effect of SHARPIN-deficiency on TLR4 signalling 
was directly compared with the effect detected by TNF stimulation. As shown in Figure 21 
ST-cpdm MEFs showed strongly impaired levels of LPS-induced IκBphosphorylation and 
degradation, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Levels of phosphorylated IB in ST-cpdm MEFs stimulated with 50 ng/ml LPS were even 
lower than those detected after TNF stimulation which were also diminished compared to wild-
type control levels, albeit to a lesser extent than following LPS stimulation. However, levels of 
Figure 21: Absence of SHARPIN attenuates NF-B activation. LPS- and TNF-induced signalling responses in 
MEFs of indicated genotypes were compared. Cells were stimulated with 50 ng/ml LPS and TNF, respectively, 
subjected to immunoblotting and incubated with the indicated antibodies.
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phosphorylated JNK1 and JNK2 were decreased in ST-cpdm MEFs following TNF treatment 
but not upon LPS stimulation. These results were reproducible with other, independently 
derived ST- (<p5) but not LT- (>p5) cpdm MEF lines. Overall, these results revealed that 
SHARPIN and HOIL-1 are both involved in LPS-induced NF-κB activation and that absence of 
either of the two LUBAC components impairs NF-κB activity and gene induction but does not 
completely abrogate it. In contrast, LPS-induced MAPK activation seems to be largely 
unaffected by absence of either of the two LUBAC components. 
3.3 Functional analysis of LUBAC implication in NOD2 signalling 
NOD2 is a member of the NLR family and its specific ligand MDP derives from cell wall-
components of Gram-positive as well as Gram-negative bacteria, which makes NOD2 a general 
intracellular sensor for most, if not all, bacteria. Its expression is therefore restricted to antigen 
presenting cells such as macrophages and dendritic cells and to primary epithelial cells. Recent 
publications have shown that cIAP1 and cIAP2 interact with NOD2 in an MDP stimulation-
dependent manner and that both E3 ligases are required for RIP2 recruitment to the NOD2 
receptor complex (Bertrand et al, 2009). Work from our laboratory showed that cIAPs are 
responsible for the recruitment of LUBAC to the TNF-RSC and that RIP1 is a target of 
LUBAC (Gerlach et al, 2011; Haas et al, 2009). Due to these findings, we speculated that upon 
MDP-stimulation cIAPs mediate the recruitment of LUBAC to NOD2 and that linear ubiquitin 
chains produced by LUBAC contribute to MDP-induced NF-κB activation. Furthermore, we 
hypothesised that NOD2-expressing cells, deficient for one of the three LUBAC components 
might show impaired NOD2-dependent activation of NF-κB.  
3.3.1 NOD2 signalling requires LUBAC for proper NF-κB activation and MAPK 
signalling  
To test our hypothesis, primary bone marrow-derived macrophages (BMDMs) were isolated 
from wild-type and cpdm mice and, following maturation, the cells were treated with MDP at 
increasing concentrations and for different times. Baseline expression of NOD2 is relatively 
low but can be upregulated by IFN- pre-treatment (Rosenstiel et al, 2003). Thus, cells were 
treated with 10 ng/ml IFN- for two hours prior to stimulation. As shown in Figure 22a, 
treatment with 200 ng/ml L18-MDP, a synthetic derivative of MDP which has been shown to 
display a higher adjuvant activity than MDP (Matsumoto et al, 1981), led to solid 
phosphorylation levels of IκBand ERK1/2 in wild-type BMDMs 60 to 120 minutes after 
stimulation. Strikingly, IκBphosphorylation as well as phosphorylation of ERK1/2 were 
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almost completely abrogated in BMDMs isolated from cpdm mice. Repetition of the 
experiment with BMDMs isolated from additional cohorts of mice led to very similar results, 
showing that phosphorylation of IκB, ERK1/2 and p38 was not completely inhibited in cpdm-
derived BMDMs but profoundly diminished in comparison to the levels in wild-type BMDMs 
(Figure 22b). Furthermore, the experiment shown in Figure 22b revealed that the levels of 
phosphorylation of IκB, ERK1/2 and p38 were highest 30 minutes after onset of stimulation 
by MDP.  
 
Figure 22: LUBAC plays a role in NOD2 signalling. a) Primary BMDMs were tested for L18-MDP 
responsiveness. Cells were stimulated for the indicated times with L18-MDP at the indicated concentrations and 
signalling responses were analysed by immunoblotting using the indicated antibodies. b) Primary BMDMs were 
stimulated with 200 ng/ml and NOD2 signalling output was analysed with the indicated antibodies. 
 
These experiments indicate that SHARPIN deficiency strongly attenuates NF-κB and MAPK 
signalling in response to MDP and suggest that LUBAC plays an important role in NOD2 
signalling. 
3.4 Functional analysis of LUBAC involvement in IL-33 signalling 
IL-33 binds a heterodimeric complex consisting of ST2, a member of the IL-1R family, and IL-
1RAcP. It induces signalling through the TIR domain of IL-RAcP by recruiting the adaptor 
protein MyD88 and IRAK1 and IRAK4 to the receptor complex, thereby inducing the 
activation of numerous signalling proteins including NF-κB, ERK1/2, p38 and JNK. Due to the 
fact that the IL-33 pathway shares many signalling molecules with the IL-1 signalling cascade, 
it was hypothesised that IL-33 signalling might depend on LUBAC activity in a manner similar 
to the one identified for IL-1. 
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3.4.1 IL-33 signalling does not depend on LUBAC activity 
To test the hypothesis that LUBAC is implicated in IL-33 signalling, MEFs derived from wild-
type mice and cpdm mice were stimulated with murine IL-33 at two different concentrations 
(10 ng/ml and 50 ng/ml) for different times before lysis and cell lysates were subsequently 
subjected to western blot analysis. As shown in Figure 23, stimulation with IL-33 at both 
concentrations induced strong phosphorylation of IκBand JNK1/2 in both MEF lines after ten 
minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was no difference detectable regarding phosphorylation levels of these two proteins. 
However, IκBdegradation was slightly different in wild-type and cpdm MEFs. While 
degradation of the inhibitor of NF-κB was rapidly induced in wild-type MEFs and not 
detectable anymore after ten minutes of stimulation, IκBdegradation in cpdm MEFs was 
slightly delayed and disappeared only after 20 minutes of stimulation. In contrast, pJNK levels 
were equal in wild-type and cpdm MEFs and were induced with the same kinetics in both MEF 
Figure 23: SHARPIN deficiency delays IB degradation but does not influence its phosphorylation.
MEFs from wt and cpdm mice were tested for their IL-33 responsiveness using different concentrations of IL-
33. Lysates were subjected to western blot analysis and incubated with the indicated antibodies. 
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lines starting 10 minutes after stimulation and further increased upon 20 minutes of IL-33 
treatment. To check whether absence of HOIL-1 differs from SHARPIN-deficiency, wild-type, 
cpdm and Hoil-1-/- MEFs were stimulated in parallel with 5 ng/ml murine IL-33 for different 
times before lysis and cell lysates were subsequently subjected to western blot analysis. As 
shown in Figure 24, levels of phosphorylated IκBwere similar in cpdm MEFs as compared to 
pIκBlevels detected in wild-type MEFs.  
 
 
 
 
 
 
 
 
 
 
 
 
However, 10 minutes after IL-33 stimulation IκBphosphorylation in Hoil-1-/- MEFs was even 
slightly elevated when compared to the levels detected in cpdm and wild-type MEFs (Figure 
24). This result challenged the hypothesis that LUBAC contributes to IL-33-induced NF-κB 
activation. In addition, IL-33-induced JNK signalling was also not dependent on LUBAC 
activity as pJNK1/2 levels were not reduced in IL-33-stimulated cpdm and Hoil-1-/- MEFs as 
compared to wild-type MEFs.  
In summary, the experiments provided in this thesis do not indicate that LUBAC contributes to 
IL-33 signalling. Yet, to clearly define whether or not LUBAC plays a role in IL-33 signal 
Figure 24: IL-33-induced NF-B and MAPK activation is not impaired in SHARPIN- and HOIL-1-
deficient MEFs. MEFs of the indicated genotypes were stimulated with 5 ng/ml IL-33 for different time points 
and signalling output was analysed via western blotting using the indicated antibodies. Asterisk indicates 
unspecific band. 
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transduction, experiments with primary IL-33-responsive cells, such as primary mast cells, 
need to be performed. 
3.5 LUBAC’s role in noncanonical NF-B signalling and its influence in 
TWEAK-induced canonical NF-B signalling 
One phenotypic feature of cpdm mice are developmental abnormalities regarding lymphoid 
architecture which are very similar to lymphoid organogenesis defects observed in mice with 
defective non-canonical NF-B signalling (Sun, 2011). Due to this similarity, I hypothesised 
that SHARPIN-deficiency and therefore reduction of LUBAC activity might negatively affect 
non-canonical NF-B signalling. TWEAK, also known as TNFSF12, induces two separate 
signalling cascades for NF-B activation, the NEMO/IKK-dependent canonical, also called 
classical, NF-B signalling pathway and the IKK-dependent alternative or non-canonical NF-
B signalling pathway which is characterised by p100 degradation and the release of p52 
fragments which together with RelB form primary NF-B heterodimers in non-canonical 
NF-B signalling. 
3.5.1 TWEAK-induced canonical and non-canonical NF-B signalling is impaired in 
HOIL-1-deficient cells  
To test the influence of SHARPIN- and HOIL-1 deficiency on TWEAK-induced canonical and 
non-canonical NF-B signalling, wild-type, cpdm and Hoil-1-/- MEFs were stimulated with 
100 ng/ml murine TWEAK for different times before lysis and cell lysates were subsequently 
subjected to western blot analysis (Figure 25). 
While p100 degradation and p52 generation were not significantly altered in cpdm MEFs 
compared to levels detected in wild-type MEFs (Figure 25a), absence of HOIL-1 by contrast 
had a negative effect on TWEAK-induced non-canonical NF-B activation (Figure 25b). Total 
levels of p100 were hardly detectable and strongly down-regulated in Hoil-1-/- MEFs, whereas 
basic levels of p52 were slightly higher than in wild-type MEFs, yet did not further increase 
upon TWEAK stimulation. Basal levels of p100 were also lower in cpdm MEFs as compared to 
wild-type levels, yet not to the same extent as in Hoil-1-/- MEFs. In addition, p52 generation 
was readily detectable in cpdm MEFs and induced with the same kinetics as in wild-type 
MEFs.  
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Figure 25: Non-canonical and canonical NF-B activation is affected by SHARPIN and HOIL-1 deficiency. 
a) wt and cpdm MEFs were stimulated with 100 ng/ml murine TWEAK for different time points and signalling 
outputs were analysed with western blotting using the indicated antibodies. b) wt and HOIL-1-/- MEFs were treated 
like wt and cpdm MEFs as described in a). 
 
 
The strong attenuation of p52 generation observed in Hoil-1-/- MEFs indicates that HOIL-1-
dependent LUBAC activity is required for TWEAK-induced non-canonical NF-B signalling. 
In contrast, SHARPIN contribution to TWEAK-induced non-canonical NF-B signalling 
seems to be dispensable. Yet, it cannot be excluded that SHARPIN might be involved in non-
canonical NF-B signalling induced by other stimuli such as RANKL or BAFF. Furthermore, 
SHARPIN-deficiency in cells responsible for proper lymphoid organ development might show 
the same negative effect on non-canonical NF-B activity as it was shown for TWEAK-
stimulated Hoil-1-/- MEFs. 
 TWEAK-induced canonical NF-B activity is negatively affected in cpdm and Hoil-1-/- MEFs 
likewise, yet the effect in Hoil-1-/- MEFs is more pronounced (Figure 25 a and b). Degradation 
of IκBwas strongly impaired in both Hoil-1-/- and cpdm MEF lines as compared to wild-type 
MEFs. Phosphorylation of IκBwas also attenuated in both MEF lines and in the case of 
Hoil-1-/- MEFs phosphorylation was also delayed.  
In summary, while TWEAK-induced non-canonical NF-B signalling seems to require HOIL-1 
but not SHARPIN, canonical NF-B activity induced by TWEAK relies on HOIL-1 and 
SHARPIN likewise. 
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3.6 Analysis of the IL-1 receptor signalling complex and other IL-1-induced 
complexes 
Using a novel modified tandem affinity purification (moTAP) approach, we recently identified 
HOIL-1, SHARPIN and HOIP as functional components of the TNF- and CD40-RSCs (Haas et 
al, 2009; Gerlach et al, 2011). Due to the results presented in chapter 3.1 which strongly 
indicate a contribution of LUBAC to IL-1-induced NF-κB and JNK1/2 activation, it was next 
tested whether IL-1 stimulation induced the recruitment of LUBAC to the membrane-
associated IL-1-RSC, similar to TNF- and CD40-RSCs. 
3.6.1 Production and characterisation of moTAP-IL-1
To analyse whether LUBAC is recruited to the IL-1-RSC, the moTAP technique, which is 
based on a modified TAP tag attached to the ligand, was employed. The advantages of this 
procedure are the small size of the moTAP tag compared to traditional TAP tags and the 
PreScission protease site that allows protein purification at 4°C. The moTAP strategy for IL-1 
included a 3xFLAG-tag as a first tag and a biotinylated Avi-tag as a second tag and a protease 
cleavage site located between the two tags (Figure 26).  
 
 
 
 
Briefly, the strategy includes cell stimulation with the moTAP ligand, followed by the first 
immunoprecipitation (IP) of the receptor signalling complex via the first FLAG-tag, 
PreScission treatment to remove proteins bound unspecifically to anti-FLAG beads and a 
subsequent re-IP utilising the second biotinylated Avi-tag. The benefit of this two-step IP 
comprises higher specificity without loss of sensitivity compared to one-step IPs (Haas et al, 
2009). 
The moTAP-IL-1 was produced in AVB101 bacteria, an E.coli B strain that co-expresses 
biotin ligase and the gene of interest, both inducible with Isopropyl β-D-1-
thiogalactopyranoside (IPTG), allowing the production and purification of the biotinylated 
Figure 26: Schematic illustration of moTAP-IL-1. The sequence of mature IL-1 is fused to two different tags, a 
2 x FLAG- and a biotinylated Avi-tag, which are separated by a protease cleavage site (PS). 
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protein directly from bacterial culture. Purification was obtained by using a Ni-NTA column 
and elution was conducted with elution buffer containing high concentrations of imidazole. As 
Figure 27a shows, moTAP-IL-1 was eluted from the column in fractions two to four as 
assessed by SDS-PAGE and subsequent Coomassie staining. After pooling all fractions which 
contained the protein and dialysis over night against maintainance buffer, moTAP-IL-1 was 
analysed for its two tags. For this purpose, moTAP-IL-1 and FLAG-tagged yet unbiotinylated 
TNF were subjected to SDS-PAGE and subsequent western blot analysis. Figure 27b shows 
that both, the FLAG tag and the biotinylated Avi tag were expressed, as both anti-FLAG 
antibody and streptavidin-HRP, specifically detected moTAP-IL-1 which has an apparent 
molecular weight of approximately 25 kDa. In order to estimate the concentration of 
moTAP-IL-1, different amounts FLAG-TNF of known concentration and moTAP-IL-1 were 
loaded on the same gel and subjected to gel electrophoresis and western blot analysis. 
Incubation of the western blot membrane with anti-FLAG antibody and its respective 
secondary antibody allowed for estimation of the concentration of moTAP-IL-1 to be about 
40 ng/μl (Figure 27c).   
 
 
 
Figure 27: Production and characterisation of moTAP IL-1. a) Coomassie gel and b) western blot analysis 
with anti-FLAG antibody and streptavidin-HRP. c) Protein concentration estimation via western blot analysis 
using different known concentrations of TNF and constant IL-1 amounts of unknown concentration. d) Biological 
activity of moTAP-IL-1 was tested. IL-1-responsive HEK293RI, EL-4 and IL-1 non-responding D6/76 cells were 
stimulated with 100 ng/ml moTAP-IL-1 and signalling output was analysed via western blot. 
FT: Flow-through, F: Fraction. 
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Next it was analysed whether the ligand produced in this thesis was biologically active. IL-1 
responsive HEK293RI and EL-4 cells as well as IL-1 non-responsive D6/76 cells which served 
as negative control, were stimulated with 100 ng/ml moTAP-IL-1 for 10 and 120 minutes. Via 
western blot analysis the lysates were analysed for phosphorylation and degradation of IB.  
As shown in Figure 27d, moTAP-IL-1 was biologically active as it induced NF-B activation 
in HEK293RI and EL-4 cells yet not in IL-1-non-responders D6/76, assessed by detection of 
IBphosphorylation and degradation. Since neither HEK293 cells nor EL-4 and D6/76 cells 
express TLR4 and are therefore not responsive to LPS, it can be excluded that the observed 
NF-B activation detected in EL-4 and HEK293RI cells was induced by potential LPS 
contamination of moTAP-IL-1 which was produced in E.coli.  
3.6.2 HOIP forms part of the IL-1-RSC and interacts with IRAK1
To analyse the IL-1-RSC and to investigate whether LUBAC might be recruited to it, EL-4 
cells were stimulated with moTAP-IL-1 for different times, subjected to cell lysis using 
different  lysis buffer conditions and a one-step FLAG-immunoprecipitation was performed.  
Brikos et al. performed mass-spectrometric analyses of the endogenous IL-1-RSC precipitated 
from EL-4 cells and showed that IL-1RAcP, MyD88 and IRAK4 were stably associated with 
the IL-1-RSC and that IRAK1 was only transiently associated (Brikos et al, 2007). Taking 
these data into account, western blot analysis was conducted and immunoblotting for different 
proteins known to be involved in IL-1 signalling was performed (Figure 28).  
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Immunoblotting with IL-1RI antibody, shown in the first panel of Figure 28, confirmed 
successful binding and precipitation of moTAP-IL-1 to IL-1RI if cells were lysed with a Tris-
based lysis buffer. No IL-1RI was detected in immunoprecipitations of unstimulated cells, 
indicating that IL-1RI does not bind unspecifically to anti-FLAG-coupled agarose beads which 
were used for the IPs shown in Figure 28. Furthermore and in line with Brikos et al., IRAK4 
was recruited to the IL-1-RSC after 5 minutes of stimulation and was retained in the complex 
precipitated 10 minutes after stimulation, without showing any changes regarding molecular 
weight or band intensity. In contrast to the report by Brikos et al., which showed that IRAK1 
was only transiently associated with IL-1-RSC reaching its maximal recruitment after 2 
minutes before declining again, IRAK1 recruitment kinetics were different for the RSC 
presented in this thesis. This RSC analysis showed co-precipitation of IRAK1 after 5 minutes 
of stimulation and IRAK1 recruitment was further increased following 10 minutes of 
stimulation with moTAP-IL-1. Interestingly, modification of recruited IRAK1 was already 
detectable 5 minutes after onset of stimulation, yet it was significantly enhanced after 10 
minutes of stimulation as shown by a strong shift of the band spanning approximately 20 kDa. 
Presence of MyD88 was also tested, yet detection was not successful (data not shown). The 
major aim of this experiment was to investigate a potential recruitment of LUBAC to the IL-1-
Figure 28: Purification of the IL-1-RSC. EL-4 cells were stimulated with 100 ng/ml moTAP IL-1, treated 
with different lysis buffer conditions and subjected to immuno-precipitation via FLAG-antibody. IL-1RSC was 
analysed via western blot. LB: Lysis buffer. 
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RSC. Thus, immunoblotting with a HOIP-specific antibody was accomplished. Intriguingly, 
immunoblotting revealed that HOIP was recruited to the IL-1-RSC in a stimulation-dependent 
manner. Although the signal was not very strong, as compared to HOIP-levels detected in input 
lysates, the band was specific and not detected in any of the lanes in which lysates obtained 
from untreated cells were subjected to immunoprecipitation. 
Regarding the different lysis buffer conditions tested in this experiment, it appeared that use of 
Tris-based lysis-buffers generated significantly better results and stronger signals than a Hepes-
based lysis-buffer. Yet, no significant difference was observed regarding the tested detergents. 
IPs accomplished with lysis-buffer complemented with Triton-X 100 did not show any 
difference to IPs performed with NP-40-containing lysis-buffer. Considering that NP-40 is a 
milder detergent, NP-40-containing Tris-based lysis-buffer was used for all following IPs. 
Recruitment of HOIP to the native IL-1-RSC as shown in Figure 28 has not been reported so 
far and supports the notion that LUBAC exerts its function in IL-1 signalling in an IL-1-RSC-
associated manner rather than in further downstream sub-complexes.  
To investigate IL-1-induced HOIP interaction with IL-1 signalling proteins in more detail, 
IL-1-responsive EL-4 and IL-1-non-responsive D6/76 cells were stimulated with moTAP-IL-
1 for different times and lysates were immunoprecipitated with anti-HOIP serum. Following 
protein transfer, the immunoblot was incubated with anti-IRAK1 antibody. As shown in Figure 
29a, strong interaction between HOIP and modified IRAK1 can be detected in EL-4 but not in 
D6/76 cells. This result clearly shows that the interaction between IRAK1 and HOIP is 
IL-1-stimulation-dependent and that this type of interaction is not a matter of unspecific 
binding but only occurs in IL-1-responsive cells upon stimulation with IL-1. Furthermore, 
levels of interaction increase with stimulation-time, reaching its maximum at ten minutes after 
stimulation and declining afterwards. 
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Figure 29: IL-1-induced HOIP interaction with endogenous IRAK1. a) EL-4 and D6/76 were stimulated with 
100 ng/ml moTAP IL-1, subjected to HOIP-immuno-precipitation and incubated with IRAK1 antibody. b) 
HEK293RI cells were treated accordingly. 
 
 
To exclude the possibility that this interaction was unspecific and IRAK1 was non-specifically 
binding to either serum-proteins or protein G beads, lysates generated from cells stimulated for 
10 minutes, the time point when levels of interaction were maximal, were subjected to IP with 
anti-Caspase 3 serum (Iso.ctr). This control was loaded in lane seven of the depicted western 
blot (Figure 29a) and only weak interaction with IRAK1 was detected as compared to lysates 
incubated with anti-HOIP serum, underscoring the specificity of the observed HOIP-IRAK1-
interaction.  
To verify this result, the experiment was repeated in IL-1-responsive HEK293RI cells. As can 
be seen in Figure 29b, HOIP exclusively interacted with modified IRAK1. In contrast to EL-4 
cells, IRAK1-HOIP-interaction levels were generally weaker and strongest after 5 minutes of 
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stimulation in HEK293RI cells as compared to EL-4 cells in which levels were most 
pronounced 10 minutes after stimulation. Furthermore, interaction levels in HEK293RI cells 
were declining after 5 minutes of stimulation and were hardly detectable after 30 and 60 
minutes of stimulation.    
To further examine interaction of IRAK1 with HOIP and HOIL-1 and SHARPIN as well, 
overexpression studies were accomplished. Figure 30 shows overexpression of IRAK1 alone 
(lane 1) and co-overexpression with each LUBAC component alone (lane 2-4) or in 
combination with all LUBAC combinations (lane 5-8), respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One day after transfection with the respective plasmids, lysates were immunoprecipitated with 
anti-IRAK1 antibody and subjected to western blot analysis. The depicted input control shows 
that all proteins were successfully overexpressed, yet HOIP overexpression appeared weakest. 
This fact is very interesting, because although overall HOIP expression was quite low, IRAK1 
Figure 30: IRAK1 binds to LUBAC via HOIP interaction. HEK293RI cells over-expressed IRAK1 together 
with different LUBAC components and different LUBAC combinations. Lysates were subjected to FLAG-
immuno-precipitation and subsequent western blot analysis.
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interaction seemed to be strongest with HOIP alone (lane 4) or with LUBAC combinations in 
which HOIP was co-expressed (lanes 6-8). HOIL-1 overexpression which was very strong, as 
can be seen in input western blot (lanes 9, 12 and 13), resulted in only weak interaction with 
IRAK1 when expressed alone (lane 2) or in combination with SHARPIN (lane 5), yet 
interaction was strongly increased when co-overexpressed with HOIP (lanes 6 and 8). Due to 
these results, it cannot be excluded that weak interaction of HOIL-1 with IRAK1 in the absence 
of HOIP overexpression, as observed in lanes 2 and 5, was facilitated by and possibly 
dependent on endogenous HOIP. To verify this hypothesis, the experiment would need to be 
repeated in either HOIP-deficient cells or in cells in which HOIP expression was silenced by 
RNAi. The HOIP-dependent interaction of SHARPIN and IRAK1 was even more pronounced 
as overexpression of SHARPIN and IRAK1 alone did not result in any detectable interaction-
levels of these two proteins (lane 3). And also co-overexpression of SHARPIN, HOIL-1 and 
IRAK1 did not result in co-immunoprecipitation of SHARPIN (lane 5), consistent with the idea 
that SHARPIN and HOIL-1 interaction with IRAK1 is HOIP-dependent. Only when HOIP was 
co-expressed, SHARPIN could be co-immunoprecipitated, albeit at a very low level (lane 7 and 
8) when compared to its overall expression (lane 12). These results suggest that direct 
interaction between IRAK1 and SHARPIN is rather unlikely and that SHARPIN requires HOIP 
presence to interact with IRAK1 in a potentially indirect, HOIP-mediated manner. In contrast, 
interaction of HOIP with IRAK1 was always detected with the same intensity (lanes 4 and 6-8), 
and did not seem to depend on co-expression of either SHARPIN or HOIL-1. Furthermore, 
HOIP expression rather increased HOIL-1 (lanes 6 and 8) and facilitated SHARPIN (lanes 7 
and 8) interaction with IRAK1. In summary, these results imply that LUBAC interaction with 
IRAK1 is mediated by HOIP. 
This prompted the question as to which domain of HOIP is required for this interaction.   
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To approach this question, different forms of truncated HOIP (Figure 31a) were co-expressed 
with IRAK1 and their capacity to interact with FLAG-tagged IRAK1 was investigated via 
FLAG-IP (Figure 31b).  
 
 
 
Figure 31: IRAK1 interacts with C- and N-terminal domains of HOIP. a) Different HOIP mutants b) were
over-expressed in HEK293RI cells together with IRAK1. Lysates were subjected to FLAG-immuno-precipitation
and subsequent western blot analysis. 
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As shown before, a strong interaction between wt HOIP and IRAK1 was detected (lane 2). An 
interaction was also observed between IRAK1 and HOIP which lacked its C-terminal (ΔC-
term) portion (lane 3). However, although overexpression of ΔC-term HOIP was much stronger 
than expression of wt HOIP (lane 10), the level of ΔC-term HOIP interacting with IRAK1 was 
not higher than the level of wt HOIP interacting with IRAK1. This result indicates that only a 
relatively small proportion of total ΔC-term HOIP interacted with IRAK1, potentially because 
a domain located in the C-terminus of HOIP may not be essential for interaction with IRAK1 
but may enhance it. A very similar result was  
 
obtained with a truncated form of HOIP which only represents the N-terminal part of HOIP (N-
term). Again overexpression of N-term HOIP was very strong (lane 11), yet interaction with 
IRAK1 did not exceed the amounts of wt HOIP binding IRAK1 (lane 4), suggesting a similar 
hypothesis as for ΔC-term HOIP, that a domain located in the C-terminal region or the UBA 
domain might be required for increased IRAK1 interaction.  
Mutated forms of HOIP which lack all domains but the RING domains located in the C-
terminal region of HOIP (C-term) were expressed at a much lower intensity than ΔC-term or 
N-term HOIP (lane 12) even though same amounts of plasmid DNA were transfected. Despite 
low expression of C-term HOIP, interaction with IRAK1 was detectable (lane 5). Expression of 
a mutated form of HOIP in which the UBA domain is excised (ΔUBA) was unfortunately not 
expressed and therefore no conclusions can be drawn regarding a potential contribution of the 
UBA domain of HOIP to IRAK1 binding (lanes 6 and 13). However, since C-term and N-term 
HOIP were capable of binding IRAK1, the UBA domain does not seem to be required for this 
kind of interaction, yet might increase interaction levels. Finally, N-terminus-lacking HOIP 
mutants (ΔN-term) were expressed (lane 14) and interaction with IRAK1 was detectable, 
indicating that the N-terminal region of HOIP, similar to the C-terminus, is not required for 
IRAK1 interaction. In summary, all truncated forms of HOIP which were expressed were 
capable of interacting with IRAK1, yet with different intensities. However, the mutants used in 
this overexpression study did not help in determining the domains of HOIP essential for 
interaction with IRAK1. 
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3.7 Generation, characterisation and administration of tools specifically 
interacting with linear or K63-linked poly-ubiquitin chains 
Ubiquitination is a fundamental post-translational modification that controls stability, 
localisation and activation of myriad proteins implicated in cellular signalling processes. A 
number of recent publications have revealed linkage-type specificity for different UBDs of 
proteins involved in NF-B and MAPK signalling. NEMO, ABINs and optineurin for instance 
all share the UBAN domain which has been shown to specifically bind M1-linked ubiquitin 
chains (Ivins et al, 2009; Komander et al, 2009; Lo et al, 2009; Rahighi et al, 2009). The NZF 
domain of TAB2 in contrast has been shown to specifically interact with K63-linked poly-
ubiquitin chains (Ivins et al, 2009; Komander et al, 2009; Lo et al, 2009; Rahighi et al, 2009). 
Due to the fact that commercially available antibodies specifically recognising linearly linked 
poly-ubiquitin chains do not exist to date, an antibody-independent approach for specific 
detection and pull-down assays of linear and K63-ubiquitinated proteins was developed in this 
thesis. Taking the knowledge of UBD-linkage specificity into account, it was hypothesised that 
recombinant GST-tagged proteins containing the NEMO-UBAN- or TAB2-NZF-motif should 
be suitable tools to accomplish pull-down assays with linear ubiquitin chains and K63-linked 
chains, respectively. It was further assumed that these proteins might also qualify for detection 
of accordingly modified proteins in western blot analysis. Thus, recombinant proteins 
containing the UBAN domain from NEMO (1xUBAN) and NZF-motif from TAB2 (1xNZF) 
fused to a GST-tag were produced in E.coli. To potentially increase the yield of interaction, we 
additionally developed a cloning strategy for two UBAN or NZF domains separated by a short 
linker of 8 amino acids and marked with a GST-tag (2xUBAN and 2xNZF).  
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3.7.1 Generation, purification and characterisation of GST-tagged 1x/2x UBAN- and 
1x/2x NZF domains 
The UBAN motif described for NEMO consists of 71 amino acids (291-361) and the NZF of 
TAB2 comprises 31 amino acids (663-693). Taking into account that GST has an apparent 
molecular weight of approximately 26 kDa, GST-1x and 2xUBAN should exhibit molecular 
weights of about 34 and 43 kDa, respectively. Furthermore, GST-1x and 2xNZF should have a 
molecular weights of approximately 29 and 33 kDa, respectively. Purification of the proteins 
from lysates of TOP 10 competent E.coli cells was accomplished by GST-HiTrap columns and 
elution was performed with Glutathion-containing buffer. Figure 32 shows the Coomassie-
stained gels of the fractions collected after elution.  
 
Figure 32: Purification of GST-tagged UBAN and NZF domains. a) Coomassie gels of the different fractions 
obtained from GST-1xUBAN and -2xUBAN purification via Ni-NTA column. b) Coomassie gels of the different 
fractions obtained from GST-1xNZF and -2xNZF purification via Ni-NTA column. FT: Flow-through, F: Fraction. 
 
 
According to these results, the following fractions were pooled, dialysed and protein 
concentration was determined: For GST-2xUBAN and GST-1xUBAN fractions 2-4 were 
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pooled (Figure 32 a). For GST-2xNZF fractions 2 and 3 were pooled and for GST-1xNZF 
fractions 2 to 4 (Figure 32 b). Molecular weights of all GST-proteins correlated with the 
calculated and predicted molecular masses. After purification of the different proteins, 
characterisation studies were accomplished. If the protein structure of the different GST-tagged 
UBDs was intact, they should be able to detect the respective ubiquitin chains on immunoblots. 
The technique in which non-antibody proteins are employed to probe proteins of interest on a 
blot is called far western blotting.  
The concept of this strategy which can be employed to detect protein-protein interactions is 
illustrated in Figure 33 using GST-2xUBAN as an example.  
 
Proteins of interest are transferred to western blot membranes which are subsequently 
incubated with the probe, in this case GST-2xUBAN. After extensive washing, the 
immunoblots are incubated with an antibody which recognises the probe, which is an anti-GST-
antibody in the illustrated example. In theory, anti-GST-antibody binds to the GST-tag of the 
2xUBAN protein. Following a number of washing steps, incubation with an HRP-coupled 
secondary antibody recognising the constant region of the anti-GST antibody is conducted.  
Figure 33: Flow-chart of far western 
blotting strategy.  
Step 1. Separate proteins after cell lysis 
via SDS-PAGE. Linearly ubiquitinated 
protein X represents the “prey protein” 
for GST-2xUBAN. 
Step 2. Probe membrane with the “bait 
protein” GST-2xUBAN. Bait protein
interacts with prey protein on membrane.
Step 3. Wash membrane thoroughly with 
PBS/T. 
Step 4. Incubate membrane with primary 
antibody directed against GST-tag of bait 
protein. 
Step 5. Wash membrane thoroughly with 
PBS/T. 
Step 6. Incubate membrane with HRP-
coupled secondary antibody directed 
against primary antibody. 
Step 7. Wash membrane thoroughly with 
PBS/T. 
Step 8. Expose membrane to X-ray film. 
Band represents linearly ubiquitinated 
prey protein in lysate that bound GST-
labeled bait 2xUBAN. 
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Another intensive washing step is followed by ECL-development. If UBAN-domains interact 
specifically with linear chains and NZF-domains only with K63-linked ubiquitin chains, 
detection of proteins with only the respective chain type should be accomplished.  
3.7.1.1 The UBAN motif specifically detects linear tetra-ubiquitin chains in far western 
analyses whereas the NZF domain shows no preference for K63-linked tetra-ubiquitin 
chains  
In order to test GST-tagged 1x- and 2xUBAN proteins for their capacity to specifically detect 
linear ubiquitin chains in far western blotting, K48-, K63- and M1-linked tetra-ubiquitin chains 
were loaded on a polyacrylamide gel and subjected to SDS-PAGE. Following protein transfer, 
the immunoblot was stained with Ponceau-red, visualising the loaded types of ubiquitin chains. 
As shown in Figure 34a, concentrations of the different chain types were approximately equal.  
 
 
Figure 34: GST-2xUBAN specifically binds linear ubiquitin chains in far western blotting. a) Ponceau-red 
staining of tetra-ubiquitin chains (2 μg/lane) of different linkages. b) Far western blot analysis with GST-2xUBAN 
and -1xUBAN and the membrane depicted in a). c) Incubation of the immunoblot with the indicated antibodies.
Membranes were first incubated with anti- K48-specific antibody, following anti-Ubi- and K63-specific 
antibodies. For detection of total ubiquitin, the antibody from Millipore (clone #07-375) was used. 
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After Ponceau-staining, the western blot was cut into three pieces, each piece containing one 
lane loaded with K48-, K63- and M1-linked tetra-ubiquitin chains, respectively. All pieces 
were subjected to far western blotting (Figure 34b). One piece was incubated with GST-only 
protein, this probe was used as a control to exclude that potential detection of ubiquitin chains 
via 1x- and 2xUBAN was not due to their GST-tag. The second piece was incubated with GST-
1xUBAN and the third piece with GST-2xUBAN. Following the far western blotting protocol, 
ECL-development revealed that GST-only protein did not interact with any of the loaded 
chains (Figure 34b, left panel). However, incubation with GST-2xUBAN resulted in interaction 
with linearly-linked tetra-ubiquitin chains. This interaction was specific because no interaction 
was observed with K48- or K63-linked tetra-ubiquitin chains (Figure 34b, middle panel). 
Incubation with GST-1xUBAN also revealed specific interaction with M1-linked but not with 
K48- or K63-linked tetra-ubiquitin chains, yet the interaction was considerably weaker than 
with GST-2xUBAN (Figure 34b, right panel). After far western blot analyses all three 
immunoblot pieces were stripped and re-probed with anti-K48- and anti-K63-specific 
antibodies (Figure 34c, left and middle blot) as well as with anti-total Ubiquitin antibody (anti-
Ubi) (Figure 34c, right blot). Incubation with anti-Ubi antibody verified the Ponceau-red 
staining showing that all proteins were loaded at almost equal amounts. Incubation of the 
immunoblots with anti-K48- and anti-K63-recognising antibodies confirmed their specificity 
and showed that K48-linked chains were loaded in the first lane and K63-linked chains in the 
second lane of each immunoblot piece. 
 
This far western blotting procedure shown in Figure 34 was repeated in the same manner for 
incubation with GST-2xNZF and GST-1xNZF and the results are depicted in Figure 35. 
Ponceau-red staining showed again approximately equal loading of all chain types, although 
K63-linked chains appeared slightly weaker in this blot (Figure 35a). Again, the GST-only 
probe did not reveal any interaction capacity with ubiquitin chains (Figure 35b, left panel), and 
GST-1xNZF did not show any binding capacity either (Figure 35b, right panel). Even long 
exposure times did not reveal any protein band. In contrast, incubation with GST-2xNZF 
showed, that all three chain types were recognised by this probe with almost similar intensities 
(Figure 35b, middle panel), suggesting that GST-2xNZF lacks specificity for K63-linked 
ubiquitin chains and cannot be used as a specific tool in far western blotting. Stripping and re-
incubation of the immunoblots with anti-Ubiquitin antibody once again verified the Ponceau-
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red staining results, that similar amounts of the different chain types were loaded (Figure 35c, 
right blot).   
 
 
 
Figure 35: GST-2xNZF of TAB2 binds to K48-, K63- and linearly-linked ubiquitin chains in far western 
blotting. a) Ponceau S- staining of ubiquitin chains of different linkages. b) Far western blot analysis with GST-
2xNZF and -1xNZF and the membrane depicted in a). c) Incubation of the immunoblot with the indicated 
antibodies. Membranes were first incubated with anti-Ubi antibody, following anti-K48- and K63-specific 
antibodies.  
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3.7.1.2 The UBAN domain shows specific interaction with linear chains in pull-down assays 
whereas the NZF domain is not capable of precipitating ubiquitin chains  
To investigate whether GST-UBAN and -NZF proteins are suitable for specifically 
precipitating linearly- and K63-linked chains, pull-down assays were performed. GST-
1xUBAN and -2xUBAN as well as GST-1xNZF and 2xNZF proteins were pre-coupled to 
glutathione-sepharose beads and were incubated with differently linked tetra-ubiquitin chains 
over night at 4°C. Precipitates were subjected to SDS-PAGE and western blot analysis 
(Figure 36).  
 
 
 
Figure 36: GST-2xUBAN specifically binds linearly-linked ubiquitin chains in pull-down assays. Tetrameric 
ubiquitin chains of different linkages were incubated with GST-only, GST-2xUBAN and GST-1xUBAN, 
respectively. Subsequently, GST-precipitation and western blot analysis were performed. Lowest panel represents 
Pnceau s-stained input control of GST-proteins b) Tetrameric ubiquitin chains of different linkages were incubated 
with GST-2xNZF and GST-1xNZF, respectively. Subsequently, GST-precipitation and western blot analysis were 
performed. 
 
Similar to the results observed in far western blotting experiments, immobilised GST-2xUBAN 
interacted selectively with linearly-linked ubiquitin chains, yet not with ubiquitin chains of 
other linkages (Figure 36a). The GST-tag of 2xUBAN was not involved in the specific 
interaction as immobilised GST-only did not interact with any of the three differently linked 
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tetra-ubiquitin chains (Figure 36a), underscoring the specificity of GST-2xUBAN for linear 
ubiquitin chains. However, GST-1xUBAN was not capable of binding any of the applied tetra-
ubiquitin chains, suggesting that this tool would not be suitable for pull-down assays with 
proteins modified with M1-linked ubiquitin chains (Figure 36a). The Ponceau-staining shown 
in Figure 36a (lowest panel) shows that similar amounts of GST-only, -2xUBAN and 1xUBAN 
were used in this pull-down assay. Different to GST-2xUBAN, neither immobilised GST-2x- 
nor 1xNZF were capable of interacting with any of the provided ubiquitin chains (Figure 36b) 
whose presence was demonstrated with anti-K48-, anti-K63 and anti-total-Ubiquitin antibodies 
in input control.  
Taken together, these experiments showed no specificity regarding interaction of GST-1x- and 
2xNZF proteins for K63-linked ubiquitin chains, yet they revealed strong specificity of GST-
2xUBAN for linear tetra-ubiquitin chains in both, far western blotting and pull-down assays. 
3.7.2 The GST-2xUBAN shows differences in its affinity for M1-linked ubiquitin 
chains of different lengths in far western analyses and pull-down assays 
All experiments shown in 3.7.1 were performed using tetra-ubiquitin chains and GST-2xUBAN 
proved to be a specific tool for the interaction with linearly-linked tetra-ubiquitin chains. 
Taking the results described in Figures 34-36 into account, GST-2xUBAN was then examined 
for its capacity to interact with linear ubiquitin chains of different lengths apart from tetra-
ubiquitin chains. To do this, ubiquitin chains consisting of 2 up to 11 ubiquitin molecules 
attached to each other via linear linkages (Ub2-Ub11) were loaded on a gel, protein transfer 
was preformed and the immunoblot was subjected to far western blotting with GST-2xUBAN 
and GST-only as control (Figure 37a). Protein-staining with Ponceau-red revealed that the 
concentrations loaded for each chain type were not equal. It turned out that the amount of 
chains consisting of six ubiquitin molecules was considerably lower compared to amounts of 
all other chains, except Ub4 (i.e. tetra-ubiquitin) chains which were not detectable at all with 
Ponceau-staining.  Taking these facts into account, far western blotting with GST-2xUBAN 
revealed that chains of all lengths tested were detected by GST-2xUBAN protein with the 
exception of di-ubiquitins (Ub2). Chains consisting of only two ubiquitin molecules which are 
fused via a head-to-tail-linkage were not detected by GST-2xUBAN although the loaded 
concentration was high (Figure 37a). Stripping of the immunoblot and re-probing it with GST-
only exhibited a weak unspecific binding of GST only to linear chains Ub7-11. However, given 
that the same anti-GST and secondary antibody had to be used, it cannot be excluded that this 
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detection was due to prior incubation with GST-2xUBAN which showed very strong 
interaction with longer chains including Ub7-11.  
 
 
 
Figure 37: GST-2xUBAN binds to linearly-linked ubiquitin chains of different length. a) Linearly linked 
ubiquitin chains of different lengths were loaded on a gel, subjected to SDS-PAGE and immunoblotted on a 
nitrocellulose membrane. Ponceau S-staining serves as input control. Far western blot analyses with prey proteins 
GST-2xUBAN (upper panel) and GST-only (lower panel) were performed. b) Incubation of linearly linked 
ubiquitin chains of different lengths with GST-2xUBAN and subsequent GST-2xUBAN pull-down with 
glutathione-sepharose beads was performed for proof of in-vitro interaction. 
 
Linear ubiquitin chains of the same lengths were then used to check the capacity of GST-
2xUBAN to interact with non-reduced Ub2 to Ub11 in a pull-down assay. In contrast to the 
results obtained from far western blotting non-reduced Ub3 and Ub5 were less strongly bound 
by immobilised GST-2xUBAN than the reduced forms of Ub3 and Ub5 in the far western 
(Figure 37b).  
However, no significant difference was observed regarding the binding capacity of GST-
2xUBAN for non-reduced chain types Ub6-Ub11. Interaction with Ub4 was very strong as 
compared to the far western, yet this was due to the fact that three times of the amount of Ub4 
was added to this assay. Additional Ub4 was added to this assay because the Ponceau-staining 
in Figure 37a showed that the concentration of Ub4 chains must have been much lower than 
that of the other chain types. Intriguingly, non-reduced Ub2 was not precipitated at all by GST-
2xUBAN. This observation was in line with the result obtained from the far western blot shown 
in Figure 37a. This suggests that di-ubiquitin chains in general cannot interact with GST-
2xUBAN with the affinity or avidity required to take advantage of the reported interaction 
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between linearly linked di-ubiquitin and the UBAN domain of NEMO for the purpose of 
specific molecular recognition in affinity precipitation. 
Pull-down with immobilised GST only showed that the observed interaction of GST-2xUBAN 
with linear ubiquitin chains of different lengths are not mediated by its GST-tag, underscoring 
the specificity of the generated tool. 
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3.8 Employment of the GST-2xUBAN for the identification of new LUBAC 
targets 
Having identified GST-2xUBAN as a suitable tool for specifically detecting synthetic linear 
ubiquitin chains of different lengths, it was hypothesised that GST-2xUBAN should not only 
interact with synthetic linear chains but also with linearly ubiquitinated target proteins modified 
by LUBAC. To test this hypothesis different potential LUBAC target proteins were over-
expressed together with different LUBAC combinations followed by UBAN-pull-down.  
3.8.1 Identification of IRAK1 as a potential LUBAC target 
Recent work from our laboratory identified RIP1 and NEMO as LUBAC targets and showed 
that they are linearly ubiquitinated in the native TNF-RSC (Gerlach et al, 2011). To test the 
efficiency of the strategy described in chapter 3.8, we overexpressed myc-tagged RIP1 together 
with V5-tagged LUBAC components in HEK293 cells and subjected the lysates to UBAN-pull-
down (Figure 38a).  
 
 
 
Figure 38: GST-2xUBAN pull-down of RIP1 and NEMO in the presence of different LUBAC complexes. a) 
Over-expression of myc-tagged RIP1 together with different V5-tagged LUBAC combinations in HEK293RI. 
Following GST-2xUBAN pull-down, lysates were subjected to western blot analysis and incubated with the 
indicated antibodies. b) Over-expression of FLAG-tagged NEMO together with different V5-tagged LUBAC 
combinations in HEK293RI. Following GST-2xUBAN pull-down, lysates were subjected to western blot analysis 
and incubated with the indicated antibodies.   
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Simultaneous overexpression of RIP1 and wt HOIP together with HOIL-1 and/or SHARPIN 
resulted in interaction of immobilised GST-2xUBAN with RIP1 (Figure 38a, lanes 2, 4 and 6), 
suggesting that this interaction is due to LUBAC-mediated linearly linked chains on RIP1. In 
contrast, overexpression of RIP1 and catalytically inactive HOIP (HOIP mutR) in combination 
with HOIL-1 and/or SHARPIN, did not result in interaction of GST-2xUBAN with RIP1, 
indicating that lack of linear ubiquitin chains on RIP1 abrogates its interaction with GST-
2xUBAN (Figure 38a, lanes 3, 5 and 7). This experiment was repeated with FLAG-tagged 
NEMO instead of RIP1 and the results are depicted in Figure 38b. Interestingly, overexpression 
of NEMO alone (Figure 38b, first lane) already resulted in its interaction with GST-2xUBAN 
calling the specificity of this experiment in question. Furthermore, overexpression of HOIP 
mutR together with HOIL-1 and/or SHARPIN also led to interaction between GST-2xUBAN 
and NEMO (Figure 38b, lanes 3, 5 and 7). Interaction between NEMO and immobilised GST-
2xUBAN upon overexpression of HOIP mutR together with HOIL-1 (Figure 38b, lane 3) 
seemed to be even stronger than interaction levels upon overexpression of wt HOIP and HOIL-
1 (Figure 38b, lane 2). However, in-vitro-ubiquitination assays with NEMO performed in our 
laboratory showed that expression of NEMO alone without co-expression of E1 and E2 or 
LUBAC components already results in different forms of ubiquitinated NEMO which could 
possibly also include linearly modified NEMO proteins. This could explain the interaction of 
NEMO with GST-2xUBAN detected in all lanes independently from the pattern of the 
overexpressed proteins.   
Taking into account that LUBAC is required for full IL-1- and LPS-induced NF-B and MAPK 
activation (chapters 3.1 and 3.2) several proteins employed by both signalling pathways were 
checked for their potential to function as LUBAC targets. 
TAK1 complexes with TAB2 and TAB3 in both, IL-1 and LPS signalling pathway and exerts 
its function rather downstream, activating the IKK complex for NF-B activation on the one 
hand and MAP2Ks on the other. GST-2xUBAN was unable to pull-down FLAG-tagged TAK1, 
neither with co-overexpressed wt HOIP in combination with HOIL-1 and/or SHARPIN (Figure 
39a, lanes 2, 4 and 6) nor with HOIP mutR and HOIL-1 and/or SHARPIN (Figure 39a, lanes 3, 
5 and 7). However, overexpression of all proteins was successful as verified by input control 
(Figure 39a, lanes 8-14). Absence of an interaction between TAK1 and GST-2xUBAN in lanes 
2, 4 and 6 suggests that TAK1 is not linearly ubiquitinated, at least not with a linear ubiquitin 
chain of at least three ubiquitin molecules. This result suggests that TAK1 is not likely to be a 
target of LUBAC.  
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MyD88 functions as receptor-associated adaptor molecule in the IL-1 and LPS signalling 
pathways, respectively. It was therefore tested whether MyD88 could possibly function as a 
LUBAC target. However, overexpression of FLAG-tagged MyD88 together with wt HOIP in 
combination with HOIL-1 and/or SHARPIN did not lead to GST-2xUBAN-mediated pull-
down of MyD88 (Figure 39b, lanes 2, 4 and 6), implying that MyD88 was also not modified by 
LUBAC. It was therefore not surprising that co-overexpression of catalytically inactive HOIP 
mutR in combination with HOIL-1 and/or SHARPIN did not induce GST-2xUBAN-MyD88 
interaction either (Figure 39b, lanes 3, 5 and 7). Overexpression of all proteins was checked 
and is presented in input control (Figure 39b, lanes 8-14). 
 
 
Figure 39: Analysis of GST-2xUBAN pull-down of TAK1 and MyD88 in the presence of different LUBAC 
complexes. a) Over-expression of FLAG-labeled TAK1 together with different V5-tagged LUBAC combinations 
in HEK293RI cells. GST-2xUBAN pull-down was performed. Lysates were subjected to western blot analysis and 
incubated with the indicated antibodies. b) FLAG-tagged MyD88 and different V5-tagged LUBAC combinations 
were over-expressed in HEK293RI cells. Following GST-2xUBAN pull-down, lysates were subjected to western 
blot analysis and incubated with the indicated antibodies.   
 
 
Taking the results presented in 3.6.2 into account in which IL-1 stimulation-dependent IRAK1 
interaction with HOIP was shown, overexpression of FLAG-tagged IRAK1 together with 
different LUBAC combinations was performed. Intriguingly, IRAK1 pull-down with 
immobilised GST-2xUBAN was achieved only in the presence of catalytically active wt HOIP 
together with HOIL-1 and/or SHARPIN (Figure 40a, lanes 5, 7 and 9), yet no interaction was 
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observed when HOIP mutR was overexpressed in combination with HOIL-1 and/or SHARPIN. 
These results strongly suggest that the interaction between IRAK1 and GST-2xUBAN was 
mediated by linearly linked ubiquitin chains which were attached to IRAK1 by catalytically 
active co-expressed LUBAC. The strongest interaction was achieved when all three LUBAC 
components were overexpressed at the same time (lane 9), suggesting that this LUBAC 
combination is most efficient in ubiquitinating IRAK1. Furthermore, abrogation of LUBAC 
activity via HOIP mutR overexpression prevented linear ubiquitination of IRAK1 and therefore 
prevented the interaction between IRAK1 and GST-2xUBAN (Figure 40a, lanes 6, 8 and 10).  
 
 
 
 
Figure 40: GST-2xUBAN precipitates IRAK1 but not TRAF6 in the presence of catalytically active 
LUBAC. a) FLAG-tagged IRAK1 was over-expressed together with different V5-tagged LUBAC combinations in 
HEK293RI cells. GST-2xUBAN pull-down was performed. Lysates were subjected to western blot analysis and 
incubated with the indicated antibodies. b) Over-expression of myc-tagged TRAF6 together with different V5-
tagged LUBAC combinations were over-expressed in HEK293RI cells. Following GST-2xUBAN pull-down, 
lysates were subjected to western blot analysis and incubated with the indicated antibodies.   
 
 
A pull-down assay with GST-only proteins did not result in interaction with IRAK1 (Figure 
40a, lanes 1-3). This shows that the observed interaction of IRAK1 with GST-2xUBAN in 
lanes 5, 7 and 9 was not due to unspecific GST-mediated interaction. 
TRAF6 is another signalling protein employed by both, IL-1 and LPS pathways. However, 
overexpression of myc-tagged TRAF6 with LUBAC components did not lead to similar results 
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as for IRAK1. Neither co-expression of wt HOIP together with HOIL-1 and/or SHARPIN 
(Figure 40b, lanes 2, 4 and 6), nor overexpression of HOIP mutR in combination with HOIL-1 
and/or SHARPIN (Figure 40b, lanes 3, 5 and 7) resulted in interaction between immobilised 
GST-2xUBAN and TRAF6, yet expression of all proteins was verified (Figure 40b, lanes 8-
14). This result indicates that TRAF6 is not a direct LUBAC target.  
In summary, these experiments provided strong indication that IRAK1 is a LUBAC target, 
whereas TAK1, MyD88 and TRAF6 are most likely not linearly ubiquitinated by LUBAC, thus 
do not serve as LUBAC targets.  
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3.9 GST-2xUBAN precipitates the endogenous TNF-RSC 
Pull-down experiments described in 3.7.1.2 and 3.8 have identified GST-2xUBAN as a suitable 
tool to precipitate specifically synthetic linear tetra-ubiquitin chains as well as overexpressed 
proteins modified by catalytically active LUBAC complexes. We therefore hypothesised that 
GST-2xUBAN might also be capable of precipitating the endogenous TNF-RSC which 
contains linearly ubiquitinated proteins such as RIP1 and NEMO, but possibly also other 
LUBAC target proteins. 
3.9.1 GST-2xUBAN is capable of precipitating the native TNF-RSC 
To test whether the GST-2xUBAN is suitable for precipitating the endogenous TNF-RSC via 
its interaction with linear components of the latter, U937 cells were stimulated with TNF for 
different times and lysates were subjected to different pull-downs. Figure 41a illustrates the 
work-flow of this experiment.  
 
 
 
Figure 41: Comparison of TNFR pull-down with M2-agarose beads versus GST-2xUBAN. a) Flow chart of 
the experimental strategy. b) U937 cells were stimulated with TNF for different times, lysed and subjected to 
TNFR-, GST-2xUBAN and GST-only-IP. Subsequently, western blot analysis was performed and incubation with 
the indicated antibodies was accomplished. 
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Following FLAG-TNF stimulation U937 cells were lysed and each lysate was divided into 
three sets of samples. Each set was subjected to a different pull-down assay. One third of the 
lysate was subjected to FLAG-IP (i.e. TNFR-IP), one third to GST-2xUBAN-IP and one third 
to GST only-IP as control. Following immunoprecipitation, all samples were subjected to 
western blot analysis. For the GST only-IP only two samples of the GST only-IP were loaded 
(non-stimulated and 30 min stimulation) whereas all samples of TNFR- and GST-2xUBAN-IP 
were loaded. The result of this experiment is depicted in Figure 41b. Whereas the TNFR-IP 
gave strong signals for known components such as RIP1, TNFR1, cIAP1/2, HOIP and HOIL-1, 
detection of these proteins in GST-2xUBAN-IP was considerably weaker and in the case of 
TNFR1 not detectable at all. However, modified RIP1 was clearly detectable in GST-2xUBAN 
pull-down as compared to GST only pull-down in which detection of modified RIP1 was 
absent, suggesting that GST-2xUBAN interaction with modified RIP1 was mediated by 
linearly-linked ubiquitin chains on RIP1 recognised by the 2xUBAN motif. Detection of 
cIAP1/2 and HOIP 15 and 30 minutes after stimulation was very weak, yet still not detected at 
all in GST only control pull-down. Detection of HOIL-1 in GST-2xUBAN pull-down was 
detected only after 5 minutes of stimulation, whereas very strong signals for HOIL-1 could be 
detected in TNFR pull-down. In summary, a pull-down of the endogenous TNF-RSC via GST-
2xUBAN is possible due to the presence of proteins modified by linear ubiquitin chains. Yet, as 
compared to TNF-RSC pull-down via anti-FLAG antibody this technique provides much 
weaker detection signals and seems to be less suitable for such an approach. However, higher 
cell numbers and separation of the TNF-RSC components by isoelectric focussing and 
molecular mass in two-dimensional gels (2D gels) might enhance the outcome of GST-
2xUBAN pull-down assays. Furthermore, this technique might enable the identification of 
linear ubiquitin chains on components of signalling complexes other than the TNF-RSC. 
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3.10 Summary 
The E3 ubiquitin ligase LUBAC has been shown to generate a new type of poly-ubiquitin chain 
which is characterised by head-to-tail linkages and exerts a crucial function in TNF and CD40 
signalling by contributing to NF-B and MAPK activation, respectively. Absence of functional 
SHARPIN, one of three LUBAC components results in the development of a severe 
inflammatory phenotype, underlining the importance and physiological relevance of linear 
ubiquitin chains in immune signalling. Deregulation of immune signalling pathways is very 
often causative for a number of auto-immune diseases. It is therefore of great importance to 
precisely study the different signalling pathways and proteins implicated as well as the different 
kinds of modifications relevant for their proper functioning. 
The focus of this study was to investigate LUBAC’s role in different immune signalling 
pathways and to possibly identify LUBAC target proteins involved in these cascades. The 
results obtained and presented in this thesis show an important contribution of LUBAC in IL-1, 
LPS and NOD2-induced canonical NF-B signalling, yet its role in MAPK signalling could not 
be clearly determined. Furthermore, an important role of HOIL-1 was defined for TWEAK-
induced canonical as well as non-canonical NF-activation.  
Studies regarding the IL-1-RSC revealed for the first time an IL-1-stimulation-dependent 
recruitment of HOIP to the native receptor complex, possibly via IRAK1 as strong interaction 
with modified forms of this kinase were observed at endogenous protein expression levels.  
Generating a tool which is capable of specifically interacting with linear ubiquitin chains of 
different lengths allowed for pull-down assays to identify potential LUBAC target proteins. 
This approach revealed IRAK1 as a likely target of linear ubiquitination by LUBAC, whilst 
other proteins employed by the IL-1 signalling cascade, including the adaptor protein MyD88, 
TRAF6 and TAK1 turned out to be unlikely targets of LUBAC. 
Furthermore this linear-ubiquitin chain-sensing binding tool was shown to be capable of 
precipitating the native TNF-RSC by linear ubiquitinated complex components, albeit to a 
much lower degree than the ligand-mediated pull-down. However, separation of the TNF-RSC 
components by isoelectric focussing and molecular mass in 2D gels and subsequent far western 
blotting with this linear chain-specific tool generated in this thesis might lead to identification 
of further LUBAC targets and to a better understanding of the ubiquitin network present in the 
TNF-RSC. 
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4. Discussion 
Ubiquitination is a highly versatile form of protein modification which controls localisation, 
stabilisation and activity of numerous cellular components. Numerous experimental 
approaches in the past few years have extended our knowledge about this type of protein 
modification, its regulation, including formation of ubiquitin chains, its recognition and 
removal, as well as its physiological functions. Extensive research on unconventional 
ubiquitin chains, i.e. the ubiquitin chain-linkage types other than K48- and K63-linked chains, 
has provided extensive information and new insight on the role of ubiquitination in cell 
signalling.  It was shown that K11- and linearly linked ubiquitin chains are involved in TNF-
signalling (Dynek et al, 2010; Haas et al, 2009; Kirisako et al, 2006; Tokunaga et al, 2009). 
Furthermore, LUBAC, an E3 ubiquitin ligase that conjugates linearly linked ubiquitin chains 
on target proteins, was identified as a component of the native TNF- and CD40-RSCs and was 
shown to be critical for TNF- and CD40-induced MAPK signalling and NF-B activation by 
targeting NEMO for linear ubiquitination (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et 
al, 2011). Cpdm mice which lack a functional form of the LUBAC component SHARPIN 
exhibit a prominent immunological phenotype and further develop a psoriasis-like skin 
phenotype of auto-inflammatory character, which can be rescued by ablation of TNF (Gerlach 
et al, 2011). It was therefore of great interest to study a potential LUBAC contribution to 
other immune signalling pathways, whose deregulation was shown to be involved in auto-
inflammatory diseases. In this thesis, a variety of other immune signalling pathways were thus 
analysed for their requirement of LUBAC and linearly linked ubiquitin chains for the 
induction of NF-B and MAPK signalling. Furthermore, components of the IL-1 and LPS 
signalling pathways and the membrane-associated IL-1-RSC were studied for their capacity to 
interact with LUBAC and to function as targets of the latter.  
 
4.1 LUBAC’s implication in different innate immune signalling pathways 
Deregulation of innate immune signalling pathways can contribute to the development of 
chronic inflammatory diseases. In the case of pro-inflammatory cytokines, such as IL-1 and 
TNF, or innate-immune mediators like IL-33, excessive production or uncontrolled release 
enhances the immune response and can cause manifestation of chronic inflammation 
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(Dinarello, 2011a; Dinarello, 2011b; Feldmann & Maini, 1999). Furthermore, mutations in 
certain PRRs, such as NOD2, have been shown to exert similar outcomes, causing the 
development of chronic inflammatory diseases (Hugot et al, 2001; Ogura et al, 2001). For 
these reasons and to check for a potential contribution to the inflammatory phenotype 
developed by cpdm mice, the implication of LUBAC in various innate immune signalling 
pathways was studied in this thesis. 
4.1.1 LUBAC contributes to IL-1-, LPS- and MDP-induced NF-B activation 
IL-1 functions as a major mediator in innate immunity and its deregulation has been shown to 
contribute to different chronic inflammatory diseases. Considering the inflammatory cpdm 
phenotype, it was therefore immanent to investigate LUBAC’s role in IL-1 signalling. Stable 
HOIL-1 knockdown in HEK293RI cells resulted in strong attenuation of IL-1-induced NF-
B, JNK and p38 activation and almost completely abrogated IL-1-stimulated IL-8 release 
(Figure 11). In line with this result, overexpression of different LUBAC components in HeLa 
cells enhanced IL-1-induced phosphorylation of IB and JNK (Figure 12). Thus, it was not 
surprising that IL-1-induced NF-B activation was also impaired in different freshly isolated 
MEF lines derived from SHARPIN-deficient cpdm mice as compared to cells generated from 
heterozygous cpdm mice, which do not develop the disease, as depicted in Figure 14. 
However, after immortalisation of the cells via infection with SV40 large T antigen-
expressing lentivirus and long-term culturing, the effect observed in freshly isolated cpdm 
MEFs seemed to be reverted. IL-1 stimulation of immortalised cpdm MEFs kept in culture for 
a longer period of time showed strongly enhanced levels of phosphorylated ERK1/2, slightly 
elevated levels of phosphorylated  and same levels of phosphorylated JNK1/2 (Figure 
15a). In addition, basal levels of ERK1/2 were also slightly enhanced. In line with this 
observation, IL-1-induced IL-6 production in these cpdm MEFs was higher than in wt MEFs 
(Figure 15b), suggesting that the process of immortalisation and/or high passage numbers 
caused a change in IL-1-induced cell responses. To exclude the possibility of a cell line-
dependent artefact, the experiment was repeated with two other immortalised cpdm MEF lines 
which had been passaged for more than five times and were thus termed LT (long-term 
cultured) -cpdm MEFs (Figure 16a). However, the result was not consistent as one MEF line 
(LT-cpdm1) reflected the results obtained with the freshly isolated cpdm MEFs depicted in 
Figure 14a, i.e. lower levels of phosphorylated  and almost complete abrogation of p38 
phosphorylation upon IL-1 stimulation, whereas the other cpdm MEF line (LT-cpdm2) 
reproduced the results observed with the previously studied LT-cpdm MEF line (Figure 15a), 
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showing elevated levels of IL-1-induced pand additionally higher levels of pp38. 
Interestingly, both LT-cpdm MEF cell lines (LT-cpdm1 and LT-cpdm2) exhibited higher 
levels of pJNK1/2, basal ERK1/2 and pERK1/2 than the wt MEFs.  
Comparison of IL-1-induced versus TNF-induced levels of p in LT-cpdm2 cells should 
elucidate whether reversion from impaired to enhanced NF-B activation observed in 
immortalised LT-cpdm MEFs was restricted to IL-1 stimulation or whether it also applied to 
other stimuli such as TNF. The experiment revealed that NF-B activation was impaired in 
TNF-stimulated LT-cpdm2 cells compared to wt MEFs. Thus, attenuation of TNF-induced 
NF-B activation as a consequence of SHARPIN-deficiency appears to be independent of 
SV40 large T antigen-expressing lentiviral infection and cell passage number in contrast to 
impaired IL-1-induced NF-B activation (Figure 16b).  
As the SV40 gene is integrated randomly into chromosomal DNA, this may cause some 
functional changes in the resulting infected cells. In fact, SV40 large T antigen-induced 
alterations in cellular responses to IL-1 have been reported earlier (Asamitsu et al, 1999; 
Muthukkumar et al, 1996). To exclude a specific effect of SV40 large-T antigen on 
IL-1-induced NF-B activation in SHARPIN-deficient MEFs, SHARPIN expression was 
transiently silenced in immortalised wt MEFs and IL-1-induced levels of pwere 
compared to those detected in non-silenced wt MEFs and LT-cpdm2 MEFs (Figure 17). If the 
presence of SV40 large T antigen in combination with the absence of SHARPIN were 
responsible for elevated NF-B activation, wt MEFs, which were also infected with large T 
antigen and transiently silenced for SHARPIN expression should also exhibit elevated IL-1-
induced levels of p. However, the opposite was the case, wt MEFs with SHARPIN 
knock-down showed impaired phosphorylation as compared to control silenced wt and 
non-silenced LT-cpdm2 MEFs. This observation reflected the effects seen in freshly isolated 
cpdm MEFs (Figure 14) and LT-cpdm1 MEFs (Figure 16a). These results indicated that SV40 
transfection and gene integration had negligible effects on IL-1-induced NF-B activation in 
SHARPIN-deficient cpdm MEFs. This finding implies that some LT-cpdm MEF lines might 
adapt to SHARPIN-deficiency, possibly by up-regulating HOIL-1 and/or HOIP. Thus LT-
cpdm MEFs might compensate for attenuated IL-1-induced NF-B activation by inducing 
high levels of HOIL-1 which substitutes non-functional SHARPIN. This theory is supported 
by the fact that HOIL-1 levels in LT-cpdm MEFs are similar to HOIL-1 levels observed in wt 
MEFs, whereas HOIL-1 levels in both wt MEFs silenced for SHARPIN and freshly isolated 
cpdm MEFs (< p6) are decreased (Figure 17) (Gerlach et al, 2011).  
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IL-1-induced pJNK1/2 levels were similar in all three cell lines, control silenced wt, 
SHARPIN-silenced wt and LT-cpdm2 MEFs, challenging a role for LUBAC in IL-1-induced 
MAPK signalling. However, primary keratinocytes isolated from mice 10 days of age which 
have not yet developed any obvious skin lesions showed strong attenuation of both NF-B 
and JNK1/2 activation and supplied evidence for LUBAC contribution to IL-1-induced 
MAPK signalling (Figure 18b). At first sight, LUBAC contribution to IL-1-induced NF-B 
and MAPK signalling seems contradictory as cpdm mice suffer from multi-organ 
inflammation which is indicative of elevated cytokine levels and enhanced gene-induction 
rather than of impaired cytokine signalling. However, analysis of cpdm-derived keratinocytes 
and cpdm MEFs revealed increased sensitivity to TNF-induced cell death, which was shown 
to be partially apoptotic and partially necroptotic (Gerlach et al, 2011). This finding was in 
line with a publication reporting on increased levels of keratinocyte cell death in the skin of 
cpdm mice (HogenEsch et al, 1999). We therefore established the hypothesis that absence of 
SHARPIN impairs TNF-induced NF-B and MAPK signalling due to lack of linear ubiquitin 
chains, thus resulting in TNF-induced cell death favouring signalling promoting necroptosis 
and apoptosis which may also lead to secondary necrosis. Necroptosis is a pro-inflammatory 
form of cell death which creates an inflammatory milieu by uncontrolled release of active 
IL-1, IL-33 and other alarmins into the surrounding tissue, thus inducing the production of 
more pro-inflammatory cytokines and sustaining inflammatory stimuli (Challa & Chan, 2010; 
Van Herreweghe et al, 2010; Vandenabeele et al, 2010). Since IL-1-induced NF-B and 
MAPK signalling is only attenuated in cpdm-derived cells but not completely abrogated, it 
would be conceivable that elevated IL-1 levels are involved in the development of the 
inflammatory phenotype of cpdm mice. To test this hypothesis, it would be necessary to 
analyse tissue samples of diseased cpdm mice for IL-1 levels. In line with this hypothesis, 
genetic ablation of IL-1RAcP reduced, but did not completely prevent skin lesions in cpdm 
mice (Liang et al, 2011). This suggests that elevated levels of IL-1 and/or other ligands which 
require IL-1RAcP for their signal transduction could contribute to the inflammation in cpdm 
mice but that they are neither causative nor the only mediators, as some other alarmins, e.g. 
HMGB1 (high-mobility group protein B1), do not require IL-1RAcP for signalling (Rauvala 
& Rouhiainen, 2010). In contrast, genetic ablation of TNF completely resolved skin lesions in 
cpdm mice. According to our hypothesis this is due to the fact that in the absence of TNF 
necroptotic cell death is prevented and thereby the trigger of the inflammatory response is 
removed (Gerlach et al, 2011). However, treatment of skin lesion-free cpdm mice 15 days of 
age with the TNFR2-Fc fusion protein Enbrel, known to block the binding of endogenous 
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TNF to TNF-Receptors, did not prevent or even delay the development of skin lesions (data 
not shown). In these mice, dermatitis occurred with similar kinetics as compared to untreated 
cpdm mice. Thus, the cpdm inflammatory phenotype is TNF-driven and results from 
accumulating defects due to a deregulated TNF signalling output, most likely as a 
consequence of necrotic cell death in the skin and possibly other inflamed tissues which might 
already start during embryogenesis or the first days following birth. This explains why the 
condition of cpdm mice progressively worsens over time. Accumulation of diverse 
inflammatory mediators as a consequence of progressively increased TNF-induced 
necroptotic cell death might induce the inflammatory phenotype of cpdm mice which starts to 
develop when a certain threshold of such mediators is exceeded. Hence, onset of treatment of 
cpdm mice with a TNF inhibitor 15 days after birth is too late to interfere with the 
development of skin lesions because by this time the inflammatory process has become 
independent of its initiator TNF.  
Unlike SHARPIN-deficient cpdm mice which develop a severe inflammatory phenotype and 
exhibit immunological disorders (HogenEsch et al, 1993; HogenEsch et al, 1999), Hoil-1 
knockout mice do not develop any prominent inflammatory lesions (Tokunaga et al, 2011; 
Tokunaga et al, 2009). One reason for this might be that MEFs derived from Hoil-1-/- mice 
show a much stronger attenuation of NF-B activation and p38 phosphorylation upon 
treatment with IL-1 and other pro-inflammatory stimuli than cpdm MEFs (Figure 19). This 
suggests that reduction in the absolute signalling capacity of IL-1 and other pro-inflammatory 
stimuli in Hoil-1-/- mice is too strong to allow for the development of a cpdm-like phenotype. 
Another hypothesis based on the data generated in our lab considers the type of TNF-induced 
cell death as being decisive for the development of an auto-inflammatory phenotype. Studies 
from our lab identified a clear difference regarding the type of TNF-induced cell death 
observed in cpdm and Hoil-1-/- MEFs. While SHARPIN-deficient cells were prone to both, 
TNF-induced necroptosis and apoptosis, Hoil-1-/- MEFs almost exclusively died by apoptosis, 
a non-immunogenic form of cell death, thus preventing the uncontrolled release of IL-1 and 
other pro-inflammatory mediators. Taken together, these observations and the different 
extents of IL-1 signalling attenuation in cpdm and Hoil-1-/- MEFs shown in this thesis imply 
that HOIL-1 and SHARPIN cannot functionally compensate for each other but indeed serve 
non-redundant roles at least with regard to prevention of TNF-induced cell death, which 
would explain the observed phenotypic differences in cpdm and Hoil-1-/- mice.  
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Thus, the data generated in this thesis on LUBAC’s role in IL-1 signalling provided evidence 
for contribution to NF-B activation, whereas the implication of linear ubiquitination in 
IL-1-induced MAPK signalling seems to be less clear. Whilst primary cells generated from 
cpdm mice showed impaired JNK1/2 activation, HOIL-1 deficiency in non-primary, 
transformed MEFs did not seem to affect JNK1/2 activity but attenuated phosphorylation of 
p38. Hence, further experiments with primary cells of both, cpdm and Hoil-1-/- mice have to 
be performed to elucidate the precise function of LUBAC in the complex networks of IL-1-
induced MAPK signalling cascades. 
The IL-1 signalling cascade and LPS-induced TLR4 signalling pathway share various 
signalling features and a number of signalling proteins for the induction of NF-B and MAPK 
activation (Keating & Bowie, 2009; Verstrepen et al, 2008), thus this pathway was also 
examined for potential LUBAC contribution. The results showed a clear defect in NF-B 
signalling of both ST-cpdm MEFs and Hoil-1-/- MEFs by exhibiting low levels of pIB and 
phosphorylated p65 (Figures 20 and 21). In contrast, LPS-induced JNK1/2 signalling was not 
affected. These results are in line with the observations made by Ikeda et al., who showed that 
primary cpdm macrophages exhibited attenuated levels of LPS-induced pIB as well as 
reduced secretion of TNF and MCP-1, yet no impaired MAPK signalling (Ikeda et al, 2011). 
Recently, Zak et al. reported on SHARPIN contribution to TLR2 signalling in macrophages 
derived from cpdm mice, thus expanding LUBAC’s role in innate immune signalling. The 
authors observed impaired IL-12 production in cpdm macrophages as a consequence of 
attenuated TLR2-induced NEMO-dependent signalling, including impaired p105 
phosphorylation and p65 nuclear localisation. However, the authors also reported on reduced 
phosphorylation of ERK due to SHARPIN deficiency (Zak et al, 2011). Hence, MAPK-
dependency on LUBAC might vary depending on cell type and the specific TLR studied. 
Homozygous mutations in the NOD2 encoding gene have been shown to impair NOD2 
signalling and to predispose patients to the development of CD (Hugot et al, 2001; Ogura et 
al, 2001). As cpdm mice also exhibit inflammation of the forestomach and oesophagus it 
seemed interesting to investigate whether LUBAC is involved in NOD2 signalling and 
whether absence of SHARPIN might contribute to the observed inflammation of the intestinal 
tract in cpdm mice. Intriguingly, primary BMDMs from cpdm mice exhibited very strong 
attenuation of MDP-induced IB phosphorylation and less strong impairment of MAPK 
signalling (Figure 22), suggesting that impaired NOD2 signalling as a consequence of 
SHARPIN deficiency could be responsible for inflammation of the intestinal tract in cpdm 
 4. Discussion 
126 
 
mice. Furthermore, this finding strengthens the hypothesis that, besides polymorphisms of 
NOD2, deregulated expression, somatic mutation, germ-line polymorphisms or mutations in 
genes encoding LUBAC components could also drive susceptibility to CD in man. 
In contrast to the results on LUBAC-dependent PRR signalling presented in this thesis and 
published by Zak et al. earlier this year, Inn and colleagues suggested a negative-regulatory 
effect of LUBAC in RIG-I and TRIM25 (tripartite motif-containing protein 25) -mediated 
type I interferon induction (Inn et al, 2011). In this study, LUBAC was suggested to inhibit 
RIG-I-induced type-I interferon production by targeting TRIM25 for proteasomal degradation 
and by competing with TRIM25 for RIG-I binding, hence potently inhibiting RIG-I 
ubiquitination and antiviral activity in a mechanistically separate manner. In line with these 
data, different reports on LUBAC and linear ubiquitin chains suggested a function as 
degradation signal for the latter (Kirisako et al, 2006; Prakash et al, 2009; Thrower et al, 
2000; Zhao & Ulrich, 2010). Yet, it remains to be seen whether proteasomal degradation of 
TRIM25 is directly mediated via LUBAC-generated linear chains or whether LUBAC is 
involved in the regulation of another E3 ubiquitin ligase which is responsible for TRIM25-
degradation upon LUBAC overexpression.  
 
4.1.2 LUBAC is dispensable for IL-33 signalling 
IL-33 is a potent activator of eosinophils and mast cells and has been shown to drive 
maturation of the latter from bone marrow precursors in vitro (Ali et al, 2007; Allakhverdi et 
al, 2007). IL-33 has also been linked to T helper 2 (Th2) cell maturation, thus promoting a 
Th2 cytokine profile (Meisel et al, 2001; Xu et al, 1998). Furthermore, in vivo administration 
of an artificially truncated but biologically active form of IL-33 resulted in elevated Th2 cell 
cytokine levels, including IL-4, IL-5 and IL-13 and also induced eosinophilia and 
splenomegaly (Chackerian et al, 2007; Schmitz et al, 2005). SHARPIN-deficient cpdm mice 
are characterised by increased mast cell numbers, elevated IL-5 and IL-13 levels in 
homogenates generated from inflamed skin lesions, and by the development of eosinophilia 
and splenomegaly (Renninger et al, 2010; Seymour et al, 2007). These hallmarks strongly 
indicate an IL-33 contribution to the development of the cpdm phenotype. Hence, LUBAC 
implication in IL-33 signalling was studied in cpdm and Hoil-1-/- MEFs. However, in contrast 
to IL-1 signalling, neither IL-33-induced NF-B activation nor MAPK signalling were 
markedly attenuated in cpdm and      Hoil-1-/- MEFs as compared to wt MEFs (Figures 23 and 
24).  
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Yet, to provide clear evidence for LUBAC-independence of IL-33 signalling, primary mast 
cells isolated from cpdm and Hoil-1-/- mice should be analysed. In contrast to IL-1 and IL-
18, IL-33 has been shown not to require proteolysis for activation. In fact the contrary is the 
case as IL-33 bioactivity is diminished by caspase-dependent proteolysis in apoptotic cells 
(Ali et al, 2010; Luthi et al, 2009). Consequently, IL-33 is active when released by necrotic 
cells but inactive when released by apoptotic cells. Hence, active IL-33 could drive the 
inflammatory phenotype in cpdm mice in which keratinocytes die partially via TNF-induced 
cell death in a necroptotic manner, whereas Hoil-1-/- mice do not exhibit this phenotype as 
TNF-induced cell death is apoptotic, leading to inactivation of IL-33. 
4.1.3 Different roles for HOIL-1 and SHARPIN in TWEAK-induced non-canonical 
NF-B signalling 
TWEAK and its cognate receptor Fn14 (fibroblast growth factor-inducible 14) are members 
of the TNF and TNFR superfamilies, respectively (Winkles, 2008). TWEAK is a multi-
functional cytokine, yet recent studies have attributed distinct pro-inflammatory functions to 
TWEAK as it is a strong activator of NF-B and regulates cell proliferation and angiogenesis, 
thus controlling tissue regeneration and repair in vivo following traumatic, infectious, toxic or 
autoimmune injury (Campbell et al, 2006; Jin et al, 2004; Luster et al, 2005). A number of 
reports have supported the postulated pro-inflammatory role of TWEAK and have shown 
in-vivo contribution to the clinical severity of the auto-immune, inflammatory diseases RA, 
systemic lupus erythematosus (SLE) and multiple sclerosis (Kamata et al, 2006; McInnes & 
Schett, 2007; Paleolog, 2002; Perper et al, 2006). Activation of the NF-B pathway is a 
universal cellular response upon TWEAK stimulation. Due to TWEAK’s contribution to auto-
inflammatory diseases and due to the fact that LUBAC plays an important role in induction of 
NF-B activation by various stimuli, a potential implication of LUBAC in TWEAK-induced 
signalling was investigated (Figure 25). As TWEAK activates both the canonical and non-
canonical NF-B pathway (Saitoh et al, 2003), cpdm and Hoil-1-/- MEFs were analysed for 
hallmarks of both NF-B pathways (Figure 25). Intriguingly, the results showed different 
outcomes for TWEAK-induced non-canonical NF-B signalling. While p100 levels were 
considerably down-regulated in Hoil-1-/- MEFs and p52 activation was not induced in these 
cells, non-canonical NF-B signalling was seemingly unaffected in cpdm MEFs. These results 
were obtained in ST-MEFs and have been repeated several times, thus the obtained results 
indicate different functions for SHARPIN and HOIL-1 in non-canonical NF-B signalling. In 
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contrast, canonical NF-B signalling was attenuated in both cpdm and Hoil-1-/- MEF lines, 
respectively, exhibiting attenuated phosphorylation and almost completely abrogated 
degradation of IB.  
Briefly, the observed different outcomes in HOIL-1- and SHARPIN-deficient cells regarding 
TWEAK-induced non-canonical NF-B signalling are a further indication that HOIL-1 and 
SHARPIN cannot functionally compensate for each other.  
4.2 HOIP is recruited to the IL-1-RSC possibly via interaction with IRAK1 
Several studies and data presented in this thesis have provided conclusive evidence for 
LUBAC’s implication in a variety of signalling pathways (Gerlach et al, 2011; Haas et al, 
2009; Ikeda et al, 2011; Inn et al, 2011; Tokunaga et al, 2011; Tokunaga et al, 2009; Zak et al, 
2011). Yet, LUBAC association with endogenous receptor complexes has so far only been 
shown for TNF- and CD40-RSCs (Gerlach et al, 2011; Haas et al, 2009). The data presented 
in chapter 3.1 showed a clear contribution of LUBAC to IL-1-induced NF-B activation. 
Thus, one aim of this thesis was to analyse at which level of the IL-1 signalling cascade 
LUBAC comes into play, which IL-1 signalling components might interact with LUBAC and 
whether LUBAC recruitment to the IL-1-RSC takes place.  
4.2.1  HOIP forms part of the IL-1-RSC 
Binding of IL-1 to its receptor, IL-1R1, results in signalling complex formation. Several 
proteins have been shown to associate with IL-1R1 upon stimulation, including IL-1RAcP 
(Greenfeder et al, 1995; Korherr et al, 1997; Radons et al, 2002; Wesche et al, 1998), MyD88 
(Medzhitov et al, 1998; Wesche et al, 1997a), and IRAKs (Cao et al, 1996a; Li et al, 2002; 
Muzio et al, 1997). Recruitment of the IL-1 signal transducer TRAF6 to the IL-1-RSC has 
been discussed controversially (Jiang et al, 2002; Qian et al, 2001), and mass spectrometric 
analysis of the IL-1-RSC excluded TRAF6 as a stable component thereof (Brikos et al, 2007). 
However, in contrast to Brikos et al., who suggests a transient complex-association of IRAK1 
reaching its maximal recruitment levels after two minutes of stimulation before declining, 
receptor analyses accomplished during this thesis with different lysis buffer conditions 
showed stimulation-dependent IRAK1 recruitment to the IL-1-RSC five and ten minutes after 
IL-1 treatment and no decrease of IRAK1 but rather an accumulation of modified IRAK1 
within this stimulation period (Figure 28). This difference is quite surprising, as the 
experiments shown in this thesis were performed with the same cell line as the studies by 
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Brikos et al.. The reason for this discrepancy is unclear, yet Brikos et al. used 20 ng/ml 
untagged IL-1to stimulate 1x107 cells, whereas in this thesis 100 ng/ml moTAP-tagged IL-1 
were employed to stimulate the same number of cells.  
In addition, IRAK4 recruitment was observed as well, yet modification of this kinase as seen 
for IRAK1 was not detected, supporting the presumption that IRAK4 exerts its kinase 
function predominantly on other receptor complex components such as IRAK1 rather than on 
itself by multiple auto-phosphorylation events (Li et al, 2002).  
Strikingly, stimulation-dependent HOIP recruitment to the IL-1-RSC occurred with the same 
kinetics as IRAK1 recruitment (Figure 28). This result suggests that K63-linked ubiquitin 
chains, reported to be attached to IRAK1 by the E3 ubiquitin ligase Pellino (Ordureau et al, 
2008; Windheim et al, 2008b), may form a recruitment platform for HOIP and, consequently 
LUBAC. This platform is similar to the TNF-RSC which requires cIAP1/2-generated 
ubiquitin chains for the recruitment of LUBAC (Haas et al, 2009). HOIP-pull down assays 
performed upon IL-1 stimulation in different cell lines verified this observation, as modified 
IRAK1 was co-precipitated in a strictly stimulation-dependent manner with HOIP (Figure 
29). The EL-4 sub-cell line D6/76 which lacks IL-1RAcP, is incapable of transmitting IL-1 
signals into the cell, thus resulting in IL-1 non-responsiveness (Wesche et al, 1997b). IL-1 
stimulation of these cells and subsequent HOIP-pull-down failed to co-precipitate IRAK1, 
emphasising the specificity of the HOIP-IRAK1 interaction, its requirement of IL-1 
stimulation and of modifications of IL-1 signalling components (Figure 29a). 
4.2.2 IRAK1 and HOIP interact with each other possibly via N-and C-terminal 
domains of the latter 
Pull-down assays with overexpressed FLAG-tagged IRAK1 and single LUBAC components 
as well as different LUBAC combinations, revealed varying affinities of the different LUBAC 
components for IRAK1. While HOIP was co-precipitated with same intensities regardless of 
whether expressed alone or in combination with HOIL-1 and/or SHARPIN, co-precipitation 
of the other two LUBAC components seemed to either depend on HOIP presence in the case 
of SHARPIN, or was strongly increased in the presence of HOIP as observed for HOIL-1 
(Figure 30). This result suggests that LUBAC interaction with IRAK1 is HOIP-mediated. 
Overexpression of IRAK1 results in activation of downstream signalling (Knop et al, 1998) 
possibly due to modification of abundantly expressed IRAK1, including phosphorylation and 
K63-linked poly-ubiquitination. We previously showed that HOIP preferentially binds 
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K63-linked over linearly and K48-linked ubiquitin chains and that HOIP was responsible for 
LUBAC recruitment to the TNF-RSC (Haas et al, 2009). Taking these findings into account, 
it is conceivable that HOIP directs HOIL-1 and SHARPIN to the IL-1-RSC by binding to 
Pellino-generated K63-linked ubiquitin chains on IRAK1 and possibly to other ubiquitinated 
components of the IL-1-RSC. Analysis of the IL-1-RSC in Pellino-depleted cells should 
reveal whether HOIP is still recruited to the receptor complex and will help testing this 
hypothesis. When HOIP is not overexpressed, HOIL-1 and/or SHARPIN interaction with 
IRAK1 relies on endogenous HOIP levels. However, whereas SHARPIN-IRAK1 interaction 
was not detactable in the absence of over-expressed HOIP, HOIL-1-IRAK1 interaction could 
be detected in the absence of over-expressed HOIP, albeit to a low extend (Figure 30). There 
are two possible explanations why HOIL-1 interaction with IRAK1 was detected but 
interaction of IRAK1 with SHARPIN was not detectable. The first explanation is that HOIL-1 
over-expression was much stronger than SHARPIN overexpression as can be seen in the input 
control. Levels of SHARPIN interacting with IRAK1 via endogenous HOIP might be too low 
to be detected. The second possibility considers the stoichiometry of the tripartite complex. 
To date, the stoichiometry of LUBAC is not known, thus if SHARPIN molecules constituted 
the smallest proportion of all three LUBAC components, endogenous HOIP levels might be 
too low to allow for SHARPIN detection in the experiment depicted in Figure 30.  
Interaction studies of IRAK1 with truncated forms of HOIP revealed that domains on the C- 
and N-termini of HOIP are involved in interaction with IRAK1 (Figure 31). Deletion of either 
of the two termini does not abrogate IRAK1 interaction, yet in relation to input levels only a 
relatively small portion of N- and C-terminus-lacking HOIP molecules interacted with 
IRAK1, whereas input levels of HOIP wt approximated levels of co-precipitated HOIP wt. 
IRAK1 has been shown to be modified with K63-linked poly-ubiquitin chains upon IL-1 and 
LPS-stimulation (Ordureau et al, 2008). Pellino and TRAF6 have been suggested to be the 
physiologically relevant E3s for IRAK1 (Conze et al, 2008; Windheim et al, 2008b). 
Furthermore, Lys134 and Lys180 of IRAK1 were identified to be critical for downstream 
signalling as arginine substitution of these residues impaired IL-1R/TLR-mediated IRAK1 
ubiquitination, NEMO binding and NF-B activation (Windheim et al, 2008b). Thus, it would 
be interesting to generate Lys134 and Lys180 IRAK1 mutants to investigate whether LUBAC 
requires K63-linked ubiquitin chains on these residues for interaction with IRAK1 or whether 
the observed binding of HOIP to IRAK1 is independent of K63-linked poly-ubiquitin chains. 
In addition, silencing of Pellino should also help answer this question. 
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4.3 Linkage-specific Ubiquitin binding domains: Novel tools for detecting 
protein interactions and modifications 
Numerous recent studies on crystal structures have revealed that certain UBDs provide the 
capability of linkage-specific ubiquitin chain recognition (Komander et al, 2008; Komander et 
al, 2009; Kulathu et al, 2009; Laplantine et al, 2009; Lo et al, 2009; Rahighi et al, 2009; Sato 
et al, 2011; Wu et al, 2006). Utilising this knowledge, linkage-specific tools were generated 
which could be used to detect proteins specifically modified with distinct ubiquitin chain 
linkages in different assays. 
4.3.1  GST-2xUBAN is a specific tool for the detection of linear ubiquitin chains  
NEMO, Optineurin and ABIN1-3 all share the highly conserved UBAN motif (Wagner et al, 
2008; Wu et al, 2006) which was shown to bind to tandem linear di-ubiquitins or longer 
chains of K63-linked ubiquitins with higher affinity as compared to mono-ubiquitin or K48-
linked poly-ubiquitin chains which exhibited only low affinities for UBAN (Lo et al, 2009; 
Rahighi et al, 2009; Wu et al, 2006). Naturally occurring point mutations of NEMO in this 
region have been shown to cause immunodeficiency and ectodermal hyperplasia in human 
patients due to impaired NF-B signalling (Courtois & Gilmore, 2006; Filipe-Santos et al, 
2006; Sebban-Benin et al, 2007). While initial UBAN-binding studies concentrated only on 
K63-linked poly-ubiquitin chains, recent work provided strong structural, biochemical and 
functional evidence for UBAN-binding capacity to linear ubiquitin chains. Moreover, 
quantitative isothermal titration measurements using the UBAN domain of NEMO detected 
nearly 100-fold higher affinity towards linear di-ubiquitins than K63-linked di-ubiquitins, 
underlining NEMO’s specificity towards linear ubiquitin chains (Komander et al, 2009; Lo et 
al, 2009; Rahighi et al, 2009). Furthermore, certain amino acids of UBAN have been 
identified to be crucial for the interaction with linear ubiquitin chains but have been shown to 
be dispensable for binding to K63-linked ubiquitin chains. Reconstitution of these mutants in 
NEMO-/- MEFs failed to restore NF-B activity or to prevent those cells from TNF-induced 
cell death, thus emphasising the physiological relevance of linear ubiquitination in cell 
signalling (Rahighi et al, 2009). Hence, the UBAN domain of NEMO was considered as a 
qualified tool for the detection and interaction of linearly-linked ubiquitin chains and proteins 
modified in this manner. 
Therefore, in this thesis GST fusion proteins containing either one or two NEMO-derived 
UBAN domains were constructed and tested for their suitability as tools to specifically 
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recognise linear ubiquitin linkages. The characterisation of these GST-1xUBAN and -
2xUBAN revealed a highly specific binding capacity of both proteins towards synthetic 
linearly-linked tetra-ubiquitin chains and no interaction with K48- or K63-linked tetra-
ubiquitin chains in far western blot analyses (Figure 34). However, the detection of linear 
tetra-ubiquitin by GST-2xUBAN was much stronger than by GST-1xUBAN, suggesting that 
two consecutive UBAN domains enhance the avidity to linearly linked ubiquitin chains. 
Crystallisation of the NEMO CoZi region, which comprises the coiled-coil 2 and the leucine 
zipper region of NEMO including the UBAN domain, forms a parallel coiled-coil 
homodimer, capable of binding M1-linked chains over K63- and K48-linked chains (Lo et al, 
2009; Rahighi et al, 2009). It is possible that the protein conformation of GST-2xUBAN more 
closely resembles the UBAN region of naturally occurring NEMO homo-dimers than the 
GST-1xUBAN, thus enabling a higher affinity to M1-linked ubiquitin chains. Pull-down 
assays with M1-, K48- and K63-linked tetra-ubiquitin chains and GST-1xUBAN and -
2xUBAN, respectively, led to similar results. Pull-down with GST-2xUBAN resulted in 
precipitation of M1-linked tetra-ubiquitin chains in vitro yet not to precipitation of K63- or 
K48-linked tetra-ubiquitin chains. This result indicates that GST-2xUBAN is capable of 
interacting specifically with non-reduced M1-linked ubiquitin chains used in the pull-down 
assay as well as with M1-linked ubiquitin chains which have been reduced prior to SDS-
PAGE and far western blot analysis. In contrast, GST-1xUBAN which was capable of binding 
M1-linked tetra-ubiquitin chains in far western blotting did not precipitate ubiquitin chains of 
this linkage type in the pull-down assay (Figure 36a). One possible explanation for this 
difference could be that in far western blotting all tetra-ubiquitin chains are concentrated in 
one band and detection of these chains by GST-1xNZF is more likely than in pull-down assay 
in which the tetra-ubiquitin chains are diluted in a total volume of 1 ml.  
Subsequent far western blot analyses of GST-2xUBAN with linearly-linked chains of 
different lengths showed high specificity of GST-2xUBAN towards chains consisting of three  
(Ub3) up to eleven ubiquitin molecules (Ub11) (Figure 37a). Similar results were obtained with 
pull-down assays using GST-2xUBAN to precipitate linearly-linked chains of different 
lengths (Figure 37b). Whereas GST-2xUBAN precipitation efficacies towards Ub6 to Ub11 
were similar to detection efficacies in far western blot analyses, affinities towards Ub5 and 
especially Ub3 were markedly reduced in the pull-down assay as compared to the far western 
blot analyses. Strikingly, linearly-linked di-ubiquitins (Ub2) were not detected at all by GST-
2xUBAN, neither by western blot analyses nor by pull-down assays. Interestingly, Rahighi et 
al. suggested that the specificity towards linearly linked ubiquitin chains of the NEMO CoZi 
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region is restricted to linear di-ubiquitins only, whereas K63-linked tetra-ubiquitin chains 
were capable of binding to their NEMO CoZi construct. In contrast, the characterisation 
studies of GST-1xUBAN and -2xUBAN presented in this thesis showed high specificity of 
the generated constructs towards linearly linked tetra-ubiquitin chains and in the case of GST-
2xUBAN towards Ub3-Ub11 but not towards linear di-ubiquitins. One reason for the observed 
differences could be that Rahighi et al. used the NEMO CoZi region for their studies which 
includes N- and C-terminal regions beyond the UBAN domain and comprises amino acids 
(aa) 250-369, whereas the constructs used in the analyses presented in this thesis contain the 
UBAN motif only which is encoded by aa 289-339. The additional parts of the CoZi region 
might influence the overall domain structure and conformation which might lead to the 
varying binding affinities towards ubiquitin chains of different linkages and lengths. A just 
recently published study on the crystal structure of the HOIL-1-NZF domain has shown 
specific binding activity to linear di-ubiquitins (Sato et al, 2011). The study showed that the 
C-terminal part of the NZF comprising aa 221-250 and referred to as NZF-tail considerably 
enhances the affinity towards linear di-ubiquitins. This study exemplifies that even very short 
protein regions consisting of only a few amino acids can exert significant influence on 
binding affinities and can appreciably alter specificity, supporting the latter explanation for 
different interaction capabilities of the NEMO CoZi region as compared to the NEMO-UBAN 
only.  
In summary, despite the fact that GST tag-induced dimerisation was recently shown to affect 
UBA-domain specificity in favour of K63-linkage binding (Sims et al, 2009), characterisation 
of the GST-tagged constructs used in this thesis revealed GST-2xUBAN to be a specific tool 
for the detection of synthetic linearly linked ubiquitin chains consisting of three up to eleven 
ubiquitin chains in far western blot analyses and pull-down assays, respectively. 
4.3.2  GST-2xNZF lacks binding of linkage-specific ubiquitin chains 
Alam et al. and Meyer et al. were the first to describe ubiquitin interactions of NZF zinc 
fingers, yet due to the restricted knowledge at that time they did not check for linkage-specific 
ubiquitin binding of NZFs (Alam et al, 2004; Meyer et al, 2002). More recent studies 
suggested specificity of TAB2- and TAB3-NZFs towards K63-linked ubiquitin chains over 
linearly and K48-linked ubiquitin chains (Komander et al, 2009; Kulathu et al, 2009; Sato et 
al, 2009). Thus, GST-tagged 1xNZF and 2xNZF proteins of TAB2 were generated and 
characterised in the same manner as described earlier for GST-1x/2xUBAN proteins. 
However, GST-1xNZF did not show any affinity towards the applied different tetra-ubiquitin 
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chains linked via M1, K63 and K48, neither in far western blot analyses (Figure 35b) nor in 
pull-down assays, respectively (Figure 36b). In contrast, GST-2xNZF detected all three 
ubiquitin chain types with approximately the same signal strength in far western blot analyses 
(Figure 35b), whereas pull-down assays with GST-2xNZF did not reveal binding capacity to 
any of the three tetra-ubiquitin chains tested (Figure 36b). It might be that the GST-tag 
influences the overall protein conformation and affects the ubiquitin binding surfaces of 
1xNZF and 2xNZF, thus inhibiting 1xNZF interaction with ubiquitin and altering linkage-
specific binding of 2xNZF. As linkage-specificity for GST-2xNZF was not guaranteed, it 
could not be used for detection of K63-linked ubiquitin chains or for ubiquitin-mediated 
protein-interaction studies.  
It remains to be tested whether GST-2xNZF may be able to differentiate between K48-, K63-, 
M1-linked ubiquitin chains and any of the other linkage types. Competition assays with GST-
2xNZF and ubiquitin chains of all possible linkage types should be suitable to adress this 
question.  
4.4 Identification of potential LUBAC targets in immune signalling pathways by 
means of linear-linkage specific GST-2xUBAN 
Having identified GST-2xUBAN as a suitable tool for detection and pull-down of linearly-
linked ubiquitin chains, co-overexpression of LUBAC, IL-1 and LPS signalling pathway 
components and subsequent pull-down assays with GST-2xUBAN should help to identify 
potential LUBAC targets implicated in IL-1 and LPS signalling. 
4.4.1  IRAK1 is a potential LUBAC target 
We identified RIP1, a central kinase of the TNFR signalling pathway, as a LUBAC target that 
is simultaneously ubiquitinated with M1-, K11-, K48- and K63-linked ubiquitin chains 
(Gerlach et al, 2011). Apart from RIP1, we also identified NEMO as another LUBAC target 
as mass-spectrometric analysis revealed exclusively M1-linked ubiquitin chains on NEMO 
when present in the native TNF-RSC (Gerlach et al, 2011).  Thus, RIP1 and NEMO were 
utilised as positive controls in the GST-2xUBAN-mediated LUBAC target search. Co-
overexpression of RIP1 with different LUBAC versions and subsequent GST-2xUBAN pull-
down showed co- precipitation of RIP1 only when catalytically active versions of LUBAC 
were expressed, i.e. HOIL-1/HOIP wt, SHARPIN/HOIP wt and HOIL-1/SHARPIN/HOIP wt. 
Co-overexpression with catalytically inactive or HOIP-deficient LUBAC versions did not 
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allow for GST-2xUBAN pull-down of RIP1, suggesting that these LUBAC versions were 
unable to conjugate linearly-linked ubiquitin chains on RIP1 (Figure 38a). This experiment 
indicated that GST-2xUBAN was not only capable of precipitating synthetic linearly linked 
chains but also M1-linked chains conjugated by overexpressed catalytically active LUBAC 
versions. Furthermore, it revealed that the pull-down strategy was working for RIP1 
representing the positive control. In contrast, repeating this experiment with NEMO, co-
precipitation of NEMO with GST-2xUBAN occurred with both catalytically active as well as 
inactive LUBAC versions (Figure 38b). Data from our laboratory and studies by others 
(Zhang et al, 2000) showed that overexpression of NEMO alone resulted in strong NF-B 
activation, suggesting that high levels of NEMO are sufficient to induce endogenous LUBAC 
activity, resulting in linear ubiquitination of NEMO and subsequent NF-B activation even in 
the absence of a signal-inducing receptor ligand. According to this hypothesis, overexpression 
of NEMO alone leads to its modification with linearly-linked ubiquitin chains and to co-
precipitation with GST-2xUBAN independent of LUBAC co-overexpression. If this 
hypothesis were correct, overexpressed NEMO should no longer co-precipitate with GST-
2xUBAN in LUBAC-depleted cells.  
Co-overexpression of different LUBAC versions with the IL-1 signalling pathway 
components TAK1 and MyD88 and subsequent GST-2xUBAN pull-down did not allow for 
co-precipitation of neither of the two proteins (Figure 39a and b). These results suggest it to 
be unlikely that TAK1 or MyD88 would serve as LUBAC targets and be linearly 
ubiquitinated.  
TRAF6, a central E3 ubiquitin ligase of the TIR-superfamily signal transduction pathways 
(Carpenter & O'Neill, 2009; Chung et al, 2007), was also co-overexpressed with catalytically 
active and inactive LUBAC versions and subsequently analysed for co-precipitation with 
GST-2xUBAN in a GST-pull-down. However, as seen for TAK1 and MyD88 before, pull-
down with GST-2xUBAN did not result in co-precipitation of TRAF6, implying that also 
TRAF6 does not serve as a LUBAC target and, hence, lacks linearly linked ubiquitination 
(Figure 40b). 
In contrast, GST-pull-down with GST-2xUBAN following overexpression of different 
LUBAC versions and IRAK1 resulted in strong co-precipitation of the latter, yet only when 
catalytically active LUBAC versions were co-expressed. Similar to the results obtained with 
RIP1, co-overexpression of catalytically inactive or HOIP-deficient LUBAC versions 
inhibited IRAK1 co-precipitation with GST-2xUBAN (Figure 40a). This result strongly 
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suggests IRAK1 as a LUBAC target. However, as discussed in chapter 4.2.2, IRAK1 was 
shown to interact with HOIP and HOIP-containing LUBAC versions. Hence, this result does 
not exclude the possibility that IRAK1 co-precipitation with GST-2xUBAN is HOIP-
mediated as HOIP-containing LUBAC versions are also precipitated with GST-2xUBAN 
possibly either due to auto-ubiquitination in an M1-linked manner or because of the affinity of 
one of the LUBAC components to M1-linked chains as already shown for HOIL-1 (Sato et al, 
2011). Thus, this result cannot be regarded as evidence for linear ubiquitin chains on IRAK1 
but provides further indication for LUBAC interaction with IRAK1. In order to 
unambiguously demonstrate whether IRAK1 is linearly ubiquitinated upon IL-1 stimulation, 
EL-4 cells should be stimulated with IL-1 and these cell lysates subsequently subjected to 
HOIP pull-down. This should lead to the precipitation of HOIP-IRAK1 complexes as shown 
in Figure 29. Subsequent denaturation of these complexes should disrupt the HOIP-IRAK1 
interaction, thus dissolving the complex without affecting the ubiquitin chains attached to 
IRAK1. Renaturation of the proteins, followed by re-immunoprecipitation of IRAK1, SDS-
PAGE and far western blotting with GST-2xUBAN should reveal whether IRAK1 is linearly 
ubiquitinated or not. 
Different studies showed that IRAK1 undergoes K63-linked poly-ubiquitination in response 
to IL-1 (Conze et al, 2008; Ordureau et al, 2008; Windheim et al, 2008b), but the possibility 
that it is also modified with linearly-linked poly-ubiquitin chains has not been excluded in any 
of these studies. In this context it is interesting to note that ABINs were shown to function as 
important regulators of immunity and tissue homeostasis as they disrupt signalling complexes 
such as TNF-RSCs, IL-1-RSCs or TLR signalling complexes by competing with other 
ubiquitin-binding proteins for the binding to specific ubiquitinated targets (Heyninck et al, 
2003; Verstrepen et al, 2009). ABIN-1 was originally identified in a yeast-two hybrid screen 
as an A20-interactor (Heyninck et al, 1999) and was only later shown to specifically interact 
with linearly-linked ubiquitin chains (Rahighi et al, 2009). Oshima et al. showed that ABIN-1 
knockout mice die during embryogenesis due to TNF-dependent fatal liver apoptosis (Oshima 
et al, 2009). Yet, replacing endogenous wild-type ABIN-1 by a mutant lacking the UBAN 
domain led to auto-immunity in mutant knock-in mice which could be prevented by crossing 
to MyD88-deficient mice (Nanda et al, 2011). Thus, Nanda et al. suggested that interaction of 
ABIN-1 with poly-ubiquitin chains, possibly linearly linked chains, limits the strength of 
signalling downstream of TLR/IL-1-MyD88 and that this is critical to prevent auto-immunity. 
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Based on the findings presented in this thesis and other recent reports, I propose a working 
model for activation of IL-1 signalling (Figure 42), whereby IRAKs are recruited to the IL-1R 
complex via MyD88. IRAK4 subsequently activates IRAK1 and IRAK2 and, together with 
IRAK1, the E3 ligase Pellino. Pellino in turn attaches K63-linked poly-ubiquitin chains to 
IRAK1, thereby enabling the recruitment of LUBAC to the IL-1RSC via K63-linked ubiquitin 
chains on IRAK1. LUBAC attaches linearly linked ubiquitin chains to IRAK1, thus enabling 
IKK complex-recruitment via binding of NEMO to M1-linked ubiquitin chains on IRAK1. 
Once the IKK complex is recruited to IRAK1, LUBAC adds linear ubiquitin chains to NEMO 
and possibly to other targets in its proximity, serving as an optimised scaffold for the 
recruitment of further NEMO proteins and IKK complexes, respectively, thus activating the 
IKK complex and enabling a potent immune response (Figure 42a).  
 
 
Figure 42: Schematic depiction of a Working Model for Recruitment of LUBAC into the IL-1-RSC. 
 
 
NF-B activation leads to the transcription of different genes and the expression of a variety 
of proteins, including regulatory components such as ABIN-1 which are responsible for 
terminating the IL-1 signalling cascade to prevent excessive production of pro-inflammatory 
mediators and chronic inflammation. ABIN-1 then competes with NEMO for binding to M1-
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linked chains on IRAK1, limiting the extent of activation of NEMO, thus terminating IL-1-
induced NF-B activation (Figure 42b). 
Some of the recently identified proteins shown to bind linearly-linked ubiquitin chains are 
known to be involved in the IL-1 pathway and form part of IL-1 signalling complexes 
(Komander et al, 2009; Kulathu et al, 2009; Lo et al, 2009; Rahighi et al, 2009). It is therefore 
conceivable that their ability to interact with proteins ubiquitinated with M1-linked chains 
might induce IL-1 signalling complex stabilisation, thus not only enhancing IL-1-induced NF-
B activation but also affecting MAPK signalling. 
4.5 Precipitation of the TNF-RSC utilising the GST-2xUBAN 
TNF stimulation induces the formation of a stable membrane-associated receptor signalling 
complex which has been shown to be further stabilised by the recruitment of catalytically 
active LUBAC. LUBAC in turn is important for sustained interaction of the IKK complex 
with TNF-RSC, thus enhancing TNF-induced gene induction and prevention of cell death 
(Haas et al, 2009).  Characterisation studies presented in chapter 3.7 showed that GST-
2xUBAN is capable of selectively binding to synthetic linearly-linked ubiquitin chains in far 
western blot analyses as well as in pull-down assays. Pull-down experiments with 
overexpressed proteins (chapter 3.8) revealed that GST-2xUBAN does not only bind to free 
synthetic M1-linked chains but also to M1-linked chains when these are attached to proteins. 
However, these results were obtained with overexpression and overexpression of proteins 
could result in excessive, non-physiological amounts of linearly linked ubiquitin chains, 
thereby facilitating a potentially artefactual GST-2xUBAN interaction with LUBAC targets. 
Thus, to investigate whether GST-2xUBAN was also able to interact with endogenous levels 
of linearly linked ubiquitin chains, it was employed in pull-down assays of the TNF-RSC in 
U937 cells. This complex is known to contain at least two components modified with M1-
linked chains, namely RIP1 and NEMO (Gerlach et al, 2011). Strikingly, the GST-2xUBAN 
pull-down was successful as components such as RIP1, HOIP, HOIL-1 and cIAP1/2 were 
successfully precipitated, revealing GST-2xUBAN as a useful tool for the detection of 
endogenous levels of linearly linked ubiquitin chains and for target protein search (Figure 41). 
However, pull-down of TNF-RSC components via GST-2xUBAN was far weaker than 
immunoprecipitation with FLAG-tagged TNF. This could be due to restricted accessibility of 
linearly linked ubiquitin chains in the TNF-RSC. Due to our concept of TNFR signalling, 
linearly linked ubiquitin chains enhance the stability of the complex as more complex 
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components capable of binding to linearly-linked chains are recruited to the complex binding 
to LUBAC generated chains, thereby “occupying” binding sites for GST-2xUBAN.  
Independently of these considerations, this experiment revealed that GST-2xUBAN is capable 
of binding to endogenously generated M1-linked ubiquitin chains but is less suitable for pull-
down of the whole TNF-RSC.  
Apart from GST-2xUBAN application in pull-down assays, expression of 2xUBAN proteins 
in cells might be a useful tool for inhibition of NF-B and possibly MAPK activation in 
signalling pathways which require LUBAC. The idea is that high amounts of 2xUBAN 
proteins expressed in cells compete with other signalling pathway components for binding to 
LUBAC-generated M1-linked chains upon stimulation, thereby blocking further downstream 
M1-linked ubiquitin-dependent events which would lead to NF-B and/or MAPK activation 
and gene induction. Due to the findings presented in chapters 3.1-3.3 and 3.5, this inhibitory 
effect would not be restricted to TNF and CD40 signalling but should also be applicable to 
IL-1, LPS, NOD2 and TWEAK signalling. 
Furthermore, 2xUBAN-containing proteins could be powerful tools for the detection of 
unknown LUBAC targets in far western blot analyses of a variety of RSCs. This approach 
involves single step FLAG- or two step moTAP pull-down of the respective RSC, its 
separation by isoelectric focussing and molecular mass in 2D gels and subsequent far western 
blot analysis. Molecular mass and isoelectric point (pI) of each RSC component should reveal 
which protein of the RSC was detected by the 2xUBAN-containing M1-linkage sensor in far 
western blot analysis as a consequence of serving as a LUBAC target.  
This approach might provide insight into the complexity of ubiquitin modifications in general 
and linearly linked ubiquitination in particular as it might reveal so far unknown protein 
interactions not only in immune signalling pathways known to date to involve LUBAC and 
linear ubiquitination. 
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4.6 Summary and outlook 
In this thesis, it was shown that deficiency of SHARPIN, a factor that forms the linear 
ubiquitin chain assembly complex (LUBAC) together with HOIL-1 and HOIP, has a negative 
impact on a variety of immune signalling pathways. The data provided in this thesis 
demonstrated that absence of functional SHARPIN impaired canonical NF-B activation in 
IL-1, LPS, NOD2 and TWEAK signalling, whereas TWEAK-induced non-canonical NF-B 
signalling as well as IL-33 signalling were not affected by SHARPIN deficiency. 
Furthermore, SHARPIN contribution to MAPK signalling was only detected in primary cells 
following stimulation by IL-1 or with the NOD2 ligand MDP. Similar results were obtained 
in cells deficient for HOIL-1 as IL-1, LPS and TWEAK-induced activation of canonical NF-
B were strongly impaired whereas IL-33 signalling was not affected by HOIL-1 deficiency. 
However, in contrast to SHARPIN deficiency, absence of HOIL-1 also impaired TWEAK-
induced non-canonical NF-B signalling, thus providing evidence for functional differences 
between SHARPIN and HOIL-1 and demonstrating that both proteins cannot compensate 
each other. More studies and the use of primary cells will be required to investigate further 
functional differences and to potentially differentiate between SHARPIN-mediated and 
HOIL-1-mediated LUBAC functions. Furthermore, in vivo models for auto-inflammatory 
diseases and immunological challenge with different pathogens in SHARPIN- and HOIL-1-
deficient mice will be required to analyse LUBAC contribution to these diseases and to 
possibly identify a divergence in the impact of SHARPIN- versus HOIL-1-deficiency on these 
diseases.  
Moreover, this thesis identified HOIP as a novel component of the IL-1-RSC and suggests 
that recruitment of HOIP, and as a consequence thereof of the tripartite LUBAC, is mediated 
by HOIP’s interaction with IRAK1. Furthermore, generation and application of a novel linear-
linkage specific tool identified IRAK1 as a potential LUBAC target. This tool, a GST-tagged 
2xUBAN domain of NEMO, was shown to specifically interact with synthetic linearly-linked 
ubiquitin chains of different lengths and to precipitate the native TNF-RSC by binding to 
linearly-linked chains attached to components of the latter. Due to its specificity and its 
capability to recognise M1-linked ubiquitin chains present in endogenous RSCs, the GST-
2xUBAN represents a useful tool for the specific detection of M1-linked ubiquitin chains in 
other signalling complexes and potentially also for the identification of further, as of yet 
unknown LUBAC targets. The combination of different techniques such as RSC-
immunoprecipitation, denaturation of the precipitated complexes to dissolve protein 
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interactions, followed by renaturation and subsequent UBAN-pull-down will enable the 
exclusive extraction of proteins modified with M1-linked ubiquitin chains which can then be 
analysed by mass spectrometry. An alternative strategy for the identification of new LUBAC 
targets is the combination of RSC-pull-down, isoelectric focussing, subsequent SDS-PAGE 
and far western blot analysis with GST-2xUBAN. The identification of other LUBAC 
substrates, together with the determination of the physiological roles of each one of the linear 
ubiquitination events catalysed by LUBAC, will be crucial to gain a better understanding of 
signal transduction and molecular mechanisms induced by different immunological stimuli. 
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5. Appendix 
5.1 Abbreviations 
A   Alanine 
aa   Amino acid 
ABIN   A20 binding inhibitor of NF-kappaB 
AMP   Adenosin-monophosphate 
AP-1   Activator protein 1 
APC   Antigen precenting cell 
APF-1   ATP-dependent proteolysis factor  
ASK   Apoptosis signal-regulating kinase  
ATP   Adenosin-triphosphate 
BAFF   B cell-activating factor 
BARD   BRCA1-associated RING domain protein 
ax   Bcl2-associated X protein
Bcl-2   B cell lymphoma 2 
BIR   Baculoviral IAP repeat 
bp   base pair 
BRCA   Breast cancer 
C   Cystein 
CARD  Caspase recruitment domain 
Caspase  Cysteinyl-aspartate specific proteases 
CD   Crohn’s disease 
CD40L  CD40 ligand 
Cezanne  Cellular Zn finger anti-NF-κB 
cIAP   Cellular inhibitor of apoptosis protein 
CLR   C-type lectin receptor 
COX   Cyclo-oxygenase 
cpdm   Chronic proliferative dermatitis 
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CYLD   Familial Cylindromatosis Protein 
D   Aspartic acid 
Da   Dalton 
DAMP  Danger-associated molecular pattern 
DC   Dendritic cell 
DCIR   DC-immuno receptor 
DD   Death domain 
DMEM  Dulbecco’s modified Eagle’s medium 
dsRNA  Double stranded ribonuclease acid 
DUB   Deubiquitinases 
E   Glutamic acid 
ELISA  Enzyme-linked immunosorbent assay 
ELK   ETS-like transcription factor 
ER   Endoplasmic reticulum 
ERK   Extracellular signal related kinase 
F   Phenylalanine 
FCS   Fetal calf serum 
Foxp3   Forkhead box P3 
G   Glycine 
GM-CSF  Granulocyte macrophage colony-stimulating factor  
GST   Glutathion-S-Transferase 
GTP   Guanosine-triphosphate  
H   Histidine 
HA   Hemaglutinin 
HBS   Hepes buffered saline 
HECT   Homologous with E6-associated protein C-terminus 
HEK   Human embryonic kidney 
HOIL-1  Haeme-oxidized IRP2 ubiquitin ligase 1 
HOIP   HOIL-1-interacting protein 
HRP   Horseradish-peroxidase 
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I   Isoleucine 
IBR   In Between RING 
ICE   Interleukin-1 Converting Enzyme 
iE-DAP  -D-glutamyl-meso-diaminopimelic acid 
IFN   Interferon 
Ig   Immunoglobuline 
IB   Inhibitor of kappaB 
IKK   Inhibitor of kappaB kinase 
IL   Interleukin 
IL-1RA  IL-1 receptor antagonist 
IL-1RAcP  IL-1 receptor accessory protein 
IP   Immunoprecipitation 
IPS   IFN--promotor stimulator 1 
IPTG   Isopropyl -D-1-thiogalactopyranoside 
IRAK   IL-1R-associated kinase 
IRF   Interferon regulatory factor 
ITAM   Immunoreceptor tyrosine-based activation motif 
JAK   Janus kinase 
JAMM  JAB1/MPN/MOV34 metalloprotease 
JNK   c-Jun N-terminal kinase 
K   Lysine 
KD   Dissociation constant 
kDa   kilo Dalton 
L   Leucine 
LB   Lysogeny Broth 
LGP   Laboratory of genetics and physiology 
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LPS   Lipopolysaccharide 
LRR   Leucine-rich repeat 
LT   Lymphotoxin  
LUBAC  Linear ubiquitin chain assembly complex 
M   Methionine 
MAPK  Mitogen-activated protein kinase 
MCP   Monocyte chemotactic protein 
MDA   Melanoma differentiated-associated gene 
MDP   Muramyl dipeptide 
MEF   Mouse embryonic fibroblasts  
MEKK  MAP/ERK kinase kinase  
MKP   MAPK phosphatise 
MLK   Mixed-lineage kinase 
MMP   Mitochondrial membrane permeabilisation  
moTAP  Modified tandem affinity purification 
MS   Mass spectrometry 
MW   Molecular weight 
Myc   Myelocytomatosis viral oncogene homolog 
N   Asparagine 
NALP   NACHT-, LRR- and PYD-Containing Protein 
NBD   Nucleotide binding domain 
NEMO  NF-B essential modulator 
NF-AT  Nuclear factor of activated T-cells 
NF-B  Nuclear factor kappaB 
NIK   NF-B inducing kinase 
NK   Natural Killer 
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NLK   Nemo-like kinase 
NLR   NOD-like receptor 
NOD   Nucleotide-binding oligomerisation domain 
NZF   Npl4-type zinc finger 
OPD   o-Phenylene-diaminedihydrochloride 
OTU   Ovarian tumour proteases  
P   Proline 
PAGE   Polyacrylamid gel electrophoresis 
PAMP  Pathogen-associated molecular pattern 
PBMC  Peripheral blood mononuclear cells 
PBS   Phosphate buffered saline 
PDB   Pull-down buffer 
PE   Phycoerythrin 
PGN   Peptidoglycan 
PH   Pleckstrin homology  
PI3K   Phosphatidylinositol-3-kinase 
PKC   Protein kinase C 
Poly (I:C)  Polyinosinic:polycytidylic acid   
PRR   Pattern recognition receptor 
PS   Protease cleavage site 
Q   Glutamine 
R   Arginine 
RA   Rheumatoid Arthritis 
RANK  Receptor activator of NF-B 
RBCK1  RBCC protein interacting with PKC 1 
RBR   RING-IBR-RING 
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RHD   Rel homology domain 
RIG   Retinoic acid-inducible gene 
RING   Really Interesting New Gene 
RIP   Receptor interacting protein  
RLR   RIG-I-like receptor 
RNF   RING finger protein  
RPMI   Roswell Park Memorial Institute medium 
RSC   Receptor signalling complex 
RTKs   Receptor tyrosine kinases 
S   Serine 
SCF   Stem-cell factor 
SCF-TrCP  Skp1, Cul1, Roc1 and the F-box protein -TrCP 
SHARPIN  SHANK-associated RH-domain-interacting protein 
SIGIRR  Single immunoglobulin IL-1R-related molecule 
siRNA   Small interfering RNA 
SLE   Systemic lupus erythematosus  
Stdev   Standard deviation 
T   Threonine 
TAB   TAK1 binding protein 
TAD   Transactivation domain  
TAK1   TGF-β-activated kinase 1 
TAP   Tandem-affinity purification 
TCR   T cell receptor 
TGF   Transforming growth factor 
TH   T helper cells 
TICAM  TIR domain-containing adapter molecule 
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TIEG   TGF-inducible early gene 
TIRAP  TIR-domain-containing adapter protein 
TIR   Toll-IL-1 receptor 
Tpl2   Tumour progression locus 2 
TLR   Toll-like receptor 
TNF   Tumour necrosis factor 
TNFR   Tumour necrosis factor receptor 
TRADD  TNF-R1-associated death domain 
TRAF   TNF-receptor associated factor 
TRAM  TRIF–related adaptor molecule 
TrCp   Transducin repeat-containing protein 
TRIF   TIR-domain-containing adapter-inducing interferon-β 
TWEAK  TNF-like weak inducer of apoptosis 
UBA   Ubiquitin-associated 
UBAN   Ubiquitin-binding domains found in ABINs and NEMO 
UBC   Ubiquitin conjugating enzyme 
UBD   Ubiquitin-binding domain 
UBL   Ubiquitin-like 
UCH   Ubiquitin C-terminal hydrolase 
UEV   Ubiquitin-conjugating enzyme variant 
USP   Ubiquitin-specific proteases  
v/v   Volume/volume 
wt   wild-type 
w/v   Weight/volume 
ZF   Zinc finger 
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